|Drug, bio-affecting and body treating compositions patents - Monitor Patents|
USPTO Class 424 | Browse by Industry: Previous - Next | All
03/2012 | Recent | 13: May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Drug, bio-affecting and body treating compositions March listing by industry category 03/12Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 03/29/2012 > 157 patent applications in 97 patent subcategories. listing by industry category
20120076722 - Methods for treating cancers and diseases associated with 4-1bb (cd137) expression: The present invention relates to the role of 4-1BB (CD137) ligand and anti-4-1BB (CD137) antibody in the treatment of cancers and diseases associated with 4-1BB (CD137) expression. More particularly, the present invention relates to the use of (i) 4-1BB (CD137) ligand for inducing proliferation and activation and promoting survival of... Agent: University Of Maryland, Baltimore
20120076723 - Devices and methods for the treatment of cancer: The invention relates to the treatment of cancer. In particular the invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive... Agent: Psimedica Limited
20120076725 - Lung cancer markers, and uses thereof: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness... Agent: Celera Corporation
20120076726 - Protofibril selective antibodies and the use thereof: The invention relates to an isolated antibody, or fragment thereof, having high affinity for human Aβ protofibrils. The invention further relates to compositions that include the antibody, or a fragment thereof, and a pharmaceutically acceptable buffer. The invention further relates to a method of preventing or treating Alzheimer's disease, which... Agent: Bioarctic Neuroscience Ab
20120076724 - Novel serpentine transmembrane antigens expressed in human cancers and uses thereof: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four... Agent:
20120076727 - In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents: The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for 18F imaging, while the therapeutic complex is of use for targeted delivery of chemotherapeutic drugs... Agent: Immunomedics, Inc.
20120076728 - Human protein scaffold with controlled serum pharmacokinetics: This invention provides constructs comprising a protein scaffold, wherein the scaffold comprises Domain III, Domain IIIa, or Domain IIIb of human serum albumin or a polypeptide having substantial sequence identity to the Domain III, the Domain IIIa, or the Domain IIIb; and a targeting moiety in covalent linkage to the... Agent: The Regents Of The University Of California
20120076729 - Methods of treating cancers: The present application describes methods for treating and/or preventing cancer or a cancer symptom, e.g., AMPK-related cancers, in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an FGF, e.g., FGF21, or an FGF agonist, or a pharmaceutical composition comprising the same.... Agent:
20120076730 - Peptides for transport of therapeutics and their carriers in mouse models and humans: A system for targeted delivery of agents (e.g., molecular probes, diagnostic agents, therapeutic agents, imaging agents, research or analytical compounds, enzymes, peptides, proteins, lipids, lipoproteins, sugars, hormones, vitamins, nucleic acids, viruses, bacteria, and/or cells) including use of a composition containing the agent and a targeting moiety, specific for a determinant... Agent: University Of Maryland College Park
20120076731 - Lymphedema associated genes and model: The present invention identifies genes whose gene products are differentially expressed in lymphedema tissues, particularly cutaneous tissue involved in whole organ response to lymphedema. The invention provides methods for diagnosing or assessing an individual's susceptibility to lymphedema. Also provided are therapeutic methods for treating a patient or methods for prophylactically... Agent:
20120076732 - Phosphodiesterase inhibitors and uses thereof: The invention provides for compounds that are phosphodiesterase inhibitors. The invention further provides for a method for screening compounds that bind to and modulate a phosphosdiesterase protein. The invention also provides methods for treating conditions associated with accumulated amyloid-beta peptide deposit accumulations by administering a phosphodiesterase-binding compound to a subject.... Agent:
20120076733 - Post-biopsy cavity treatment implants and methods: A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second... Agent:
20120076737 - Method of using ct/mri dual modality contrast agent: Nanoparticles are used as a contrast agent for magnetic resonance imaging and computed tomography. Each of the nanoparticles includes a metal alloy core and a plurality of hydrophilic molecules covalently bound to the surface of the metal alloy core. Also disclosed is a method for using the contrast agent.... Agent: National Taiwan Normal University
20120076734 - Radiopaque antibiotic dental paste and uses thereof: Compositions useful for disinfecting a dental wound are described. The compositions include an active ingredient comprising one or more antibiotics, a radiopaque substance, and optionally a pharmaceutically acceptable excipient. Methods for treating dental wound sites with the compositions are also described.... Agent:
20120076736 - Host supported genetic biosensors: The present invention relates to an in vivo method of monitoring an analyte in a subject. This method involves providing an expression vector that encodes a biosensor molecule, the biosensor molecule comprising an analyte binding domain and a signal domain. The biosensor molecule produces a signal from the signal domain... Agent: Rochester Institute Of Technology
20120076735 - Nanoparticles for extravascular administration: Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and/or diagnostic agents, for use in research and medical applications.... Agent: Genesegues, Inc.
20120076738 - Combination treatment for dermatological conditions: The invention relates to a method of treating dermatological conditions or symptoms associated therewith in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the affected area of... Agent:
20120076739 - Novel combination of anticholinergics-b2-adrenoceptor agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids and/or phosphodiesterase 4 inhibitors for the treatment of inflammatory diseases: The invention relates to novel combinations based on anticholinergics, β2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases.... Agent: Meda Pharma Gmbh & Co., Kg
20120076740 - Water soluble pharmaceutical compositions of hops resins: The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions... Agent:
20120076743 - Novel aryl c-xyloside compounds, and cosmetic use: e
20120076741 - Sunscreen composite particles for uva and uvb protection: Sunscreen composite particles for UVA and UVB protection are described. The particles are substantially free of supplied UVB sunscreen and are prepared with a UVA sunscreen suitable to undergo keto-enol tautomerization.... Agent: Conopco, Inc., D/b/a Unilever
20120076742 - Topical drug delivery system with dual carriers: A topical drug delivery system for use as a self-medication delivery system, formed as a multi-functional hygroscopic solution comprising a non-hygroscopic first chemical penetration enhancer, a hygroscopic second chemical penetration enhancer and an anti-oxidizing dispersant mixable in solution with the first and second chemical penetration enhancers and an active pharmaceutical... Agent:
20120076744 - Unsaturated fatty acid monoesters and diesters on ascorbic acid and cosmetic uses thereof: in which: R1 is a hydrocarbon chain of an unsaturated fatty acid from C12 to C24 including at least one unsaturation; and R2 and R3 are, independently or simultaneously: a hydrogen or a C1-C3 alkyl or a phenyl; and R4: a hydrogen atom or COR1′, where R1′ is a hydrocarbon... Agent: Pierre Fabre Dermo-cosmetique
20120076745 - Hair cosmetic product: A hair cosmetic product has a two agent type hair cosmetic which comprises a first agent containing an alkali agent and a second agent containing hydrogen peroxide, wherein at least one of the first and second agents contains a surfactant; and a foamer vessel which discharges a mixed liquid comprising... Agent: Kao Corporation
20120076747 - Cationic synthetic polymers with improved solubility and performance in phosphate surfactant-based systems and use in personal care and household applications: The present invention is related to surfactant-based formulations comprising the polyelectrolytes and blends of such polyelectrolytes with non-cellulosic cationic polysaccharide polymers wherein the surfactant is a phosphate ester. The surfactant-based formulations exhibit improved clarity of the resulting formulations, their improved conditioning of keratin substrates, textile substrates, and hard-surface substrates, their... Agent: Hercules Incorporated
20120076746 - Hairspray: e
20120076748 - Odor conjugater for chemically neutralizing odors: An odor conjugater for chemically neutralizing odors.... Agent:
20120076749 - Modified blood factors comprising a low degree of water soluble polymer: The present invention relates, in general, to materials and methods for the preparation of modified blood factors which have low levels of water soluble polymer molecules conjugated to the blood factor but exhibit biological activity similar to or better than molecules having a higher number of water soluble polymer moieties.... Agent: Baxter International Inc.
20120076750 - Fibrin based glue with functionalized hydrophilic polymer protein binding agent: The present invention provides a non-liquid biomaterial that may be used as a surgical sealant, a suture support, a blood flow controller, an adhesion reducing agent, an adhesion preventing agent, a tissue support, a tissue filler, a wound dressing or a combination thereof. The non-liquid biomaterial may comprise a blood... Agent:
20120076751 - Plant volatiles: The present invention provides compounds and compositions for attracting or repelling sap-sucking insects, such as whitefly, as well as methods for using such compositions.... Agent: Keygene N.v.
20120076752 - Mesothelin vaccines and model systems: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and... Agent: The Johns Hopkins University
20120076754 - Use of il-17 polypeptides for use in the prevention or treatment of atherosclerosis: The present invention relates to the prevention or treatment of atherosclerosis, using an IL-17 polypeptide and pharmaceutical compositions thereof.... Agent:
20120076753 - Use of nkp46 for preventing diabetes: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.... Agent:
20120076757 - Composition for transmucosal delivery of polypeptides: The invention described herein provides an oral solid transmucosal dosage form that enhances transmucosal permeation of biologically active polypeptides across oral mucosal tissue and provides relatively rapid efficacious therapeutic onset thereof. Dosage forms prepared according to the invention can enhance transmucosal absorption of polypeptides in therapeutic serum concentrations to the... Agent: Cephalon, Inc.
20120076755 - Hepatitis c virus inhibitors: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent: Enanta Pharmaceuticals, Inc.
20120076756 - Novel benzimidazole derivatives: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent: Enanta Pharmaceuticals, Inc.
20120076758 - Antibodies against west nile virus and therapeutic and prophylactic uses thereof: The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV), infection utilizing said compositions.... Agent: Washington University
20120076761 - Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease: Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment... Agent: University Of Massachusetts
20120076763 - Combination anti-hiv vectors, targeting vectors, and methods of use: Recombinant lentiviral vectors containing at least: a lentiviral backbone comprising essential lentiviral sequences for integration into a target cell genome; a nucleic acid encoding a CCR5 RNAi; and an expression control element that regulates expression of the nucleic acid encoding the CCR5 RNAi element, are provided by this invention. In... Agent: The Regents Of The University Of California
20120076762 - Induced pluripotent stem cell generation using two factors and p53 inactivation: Methods and compositions are provided for, inter alia, the generation of induced pluripotent stem cells. Induced pluripotent stem cells may be generated by reprogramming and inhibition of p53. Further, useful intermediates for the generation of induced pluripotent stem cells are also provided.... Agent: The Salk Institute For Biological Studies
20120076764 - Methods and pharmaceutical compositions for healing wounds: A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected... Agent: Bar Iian University
20120076765 - Use of novel strains for biological control of pink rot infections in potato tubers: Six bacterial strains: Bacillus simplex strain 03WN13, Bacillus simplex strain 03WN23, Bacillus simplex strain 03WN25, Pseudomonas koreensis strain 10IL21, Pantoea agglomerans strain 10IL31, and Pseudomonas lini strain 13IL01, are superior antagonists of Phytophthora erythroseptica Pethybr., the causative agent of pink rot on potatoes. These bacterial strains are effective for suppression... Agent:
20120076760 - Compositions and methods of vascular injury repair cross-reference to related applications: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.... Agent:
20120076759 - Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases: The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS).... Agent: Henry Ford Health System
20120076766 - Topical drug delivery system with dual carriers: A method of selecting the constituent elements of a therapeutic composition for application to wounds having a pathogen load is disclosed. The method includes selecting a pharmaceutical active agent selected from a list of pharmaceutical active agents approved for over the counter non-prescription use, and said pharmaceutical active agent having... Agent:
20120076767 - Process for concentration of a polypeptide: The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such a concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.... Agent:
20120076768 - Digestive/laxative compositions: Described are digestive/laxative compositions and methods of manufacture and use of same. In a preferred embodiment, the invention provides for a digestive/laxative composition including actinidin. The actinidin is preferably contributed by inclusion of fruit of genus actinidia, or a product thereof. Preferably, the process for forming the composition includes a... Agent:
20120076769 - Herbal composition for cancer treatment: A therapeutic herbal composition comprising Saw Palmetto, Bromelain, Willow Herb, Grape Seed Complex, Wild Rosella, Liquorice, Passionfruit Seed and Selenium Yeast is claimed. The composition may be used as a general health promotant but is also useful as a treatment of cancer and inflammation. Prostate cancer and hyperplasia may be... Agent: Interhealth Biosciences Pty Ltd.
20120076770 - Modulation of autophagy and and serotonin for treatment of multiple myeloma related diseases: THE INVENTION RELATES TO compounds, proteins and methods of treatment therewith. Aspects of embodiments of the invention further relates to compounds and methods of treatment for bone, bone marrow, and bone tissue.... Agent:
20120076773 - Novel drug delivery devices: Compositions provided by contacting a biotin-containing component and an avidin-containing component are useful as drug delivery devices. Bioactive agents may be covalently bound to the biotin-containing component, the avidin-containing component, or both, mixed therewith, or combinations of the foregoing.... Agent:
20120076772 - Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph: The present invention provides, among other aspects, storage stabile aqueous formulations of immunoglobulins with histidine at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing immunoglobulin compositions by formulating with histidine at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein... Agent: Baxter International Inc.
20120076771 - Surface modification of silk fibroin matrices with poly(ethylene glycol) useful as anti-adhesion barriers and anti-thrombotic materials: The present invention provides compositions and methods for the production of silk fibroin matrices surface-PEGylated on one or more surfaces. Such surface-PEGylated silk fibroin matrices can be used in biomedical applications, such as anti-adhesive and anti-thrombosis materials. Silk matrices may be surface-PEGylated, for example, by a reaction with a functional... Agent: Trustees Of Tufts College
20120076774 - Detection and/or treatment of diseases associated with autoantibodies: The present invention provides a method for detecting autoantibodies to osteoprotegerin (OPG). The method comprises the step of providing a biological sample from a subject with, or at risk of osteoporosis and detecting whether or not any antibodies against osteoprotegerin (OPG) are present in said sample. In addition the invention... Agent:
20120076777 - Anti-fibroblastic fluorochemical emulsion therapies: The present invention is directed to compositions and methods targeting tissue resident cells, such as fibroblasts, in a subject harboring conditions or at risk for conditions that would benefit from anti-fibroblastic therapy. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention... Agent: Mtm Research LLC
20120076778 - Antibodies against insulin-like growth factor i receptor and uses thereof: An antibody binding to IGF-IR and being glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is between 20% and 50%, has improved properties in antitumor therapy.... Agent:
20120076775 - Combination of hgf inhibitor and egf inhibitor to treat cancer: The present invention is directed toward a method of treating cancer by administering to a patient an inhibitor of Hepatocyte Growth Factor and an inhibitor of, e.g., Epidermal Growth Factor.... Agent:
20120076782 - Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38: The present invention provides novel methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such... Agent: Morphosys Ag
20120076784 - Highly concentrated, liquid formulations of anti-egfr antibodies: The invention relates to processes for the preparation of highly concentrated, liquid formulations comprising at least one anti-EGFR antibody and/or one of its variants and/or fragments, in particular monoclonal antibodies against the EGF receptor, particularly preferably of Mab C225 (cetuximab) and Mab h425 (EMD 72000), by ultrafiltration. The invention furthermore... Agent:
20120076776 - Method for treating inflamation by lymphocyte depletion or sequestering: A method for preventing inflammation, comprising administering to a subject a lymphocyte sequestrating or depletion agent before the onset of inflammation. A method for treating inflammation caused by an injury or an infection, comprising depleting immune lymphocyte of a subject by administering to said subject a lymphocyte sequestrating or depletion... Agent:
20120076781 - Methods of treating cancers with her3 antisense oligonucleotides: One aspect of the invention provides methods for treating cancers which are resistant to treatment with a protein tyrosine kinase inhibitor by co-treatment with the protein tyrosine kinase inhibitor and one or more antisense oligomers that reduce the expression of HER3 and/or HER2 and/or EGFR. Another aspect of the invention... Agent: Enzon Pharmaceuticals, Inc.
20120076780 - Recombinant fusion protein and polynucleotide construct for immunotoxin production: The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of... Agent:
20120076783 - Reduced-viscosity concentrated protein formulations: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.... Agent: Genentech, Inc.
20120076779 - Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral ph: The present invention provides, among other aspects, storage stabile aqueous formulations of labile proteins at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing a labile therapeutic protein composition at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stabile... Agent: Baxter International Inc.
20120076785 - Method for inhibiting neurodegeneration: Methods for screening for compounds that inhibit neurodegeneration are presented. Shedding of APP can be a useful marker for neurodegeneration and compounds that inhibit shedding of APP are useful as inhibitors of neurodegeneration. Such compounds may be useful in treatment and/or prevention of various neurological diseases, disorders and neuronal damage... Agent: Genentech, Inc.
20120076786 - Bispecific antibodies: The present invention provides compositions and methods for targeting stem cells to injured cardiac tissue.... Agent:
20120076787 - Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye: The invention relates to combinations of TNFα antagonists with VEGF antagonists for use in treating diseases of the eye, and provides antigen-binding proteins which bind to TNFα or a TNFα receptor and/or VEGF or a VEGF receptor.... Agent:
20120076788 - C-cbl and antagonists thereof for the treatment and diagnosis of cancer: The present invention relates to the treatment of cancer. More specifically, the present invention relates to the use of c-cbl as a marker for the diagnosis and/or prognosis of cancer, and to the use of a c-cbl antagonist for the treatment of a cancer associated with resistance to apoptosis.... Agent: Universite Claude Bernard Lyon 1
20120076790 - Anti-cd48 antibodies and uses thereof: The present invention provides antibodies that bind to CD48 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human CD48. In certain embodiments, the antibodies of the present invention block the binding of CD48 to one or more... Agent: Regeneron Pharmaceuticals, Inc.
20120076789 - Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer: A novel gene (designated 121P1F1) and its encoded protein, and variants thereof, are described wherein 121P1F1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 121P1F1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 121P1F1 gene... Agent: Agensys, Inc.
20120076791 - Methods of treating chronic prostatitis/chronic pelvic pain syndrome: The present invention relates to the use of TNF-α for the treatment of a pain and/or a urinary tract symptom(s) associated with Cronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS).... Agent:
20120076792 - Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of o the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have... Agent: The Uab Research Foundation
20120076793 - Agent for promoting hepatic cell replication and agent for improving insulin resistance: An effective amount of a neutralizing agent for CXCL10 belonging to a subfamily of chemokines which are heparin-binding proteins is administered to the hepatocytes to promote the replication of the hepatocytes. As the neutralizing agent for CXCL10, a factor which is specifically bound to CXCL10 and inhibits an activity of... Agent: Stelic Institute Of Regenerative Medicine
20120076794 - Host cell specific binding molecules capable of neutralizing viruses and uses thereof: Provided are human binding molecules that specifically bind to a host cell protein and have virus neutralizing activity, nucleic acid molecules encoding such human binding molecules, compositions comprising the human binding molecules, and methods of identifying or producing the human binding molecules. The human binding molecules can be used in... Agent: Crucell Holland B.v.
20120076795 - Anti-pecam therapy, compositions, methods, and uses: The disclosure relates to the discovery that systemic administration of an antibody that binds to PECAM-1 increases body weight while suppressing the metastatic spread of a wide variety of different tumor types which are typically fatal in humans. This discovery provides a basis for the generation of novel treatments and... Agent: Sutter West Bay Hospitals D/b/a California Pacific Medical Center
20120076796 - Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis: The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl12, Angptl13, Angptl14, Angptl15, Angptl16, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or... Agent: Ablynx N.v.
20120076798 - Antagonistic human light-specific human monoclonal antibodies: Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies.... Agent: Kyowa Hakko Kirin Co., Limited
20120076799 - Antagonists of pcsk9: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors,... Agent: Merck Sharp & Dohme Corp.
20120076797 - Modulation of kit signaling and hematopoietic cell development by il-4 receptor modulation: Methods and compositions are provided for modulating Kit/stem cell factor receptor (SCFR)/CD117 and interleukin 4 receptor (IL-4R) signaling in a cell in vitro and in vivo, and for identifying candidate agents with activity in modulating Kit and IL-4R signaling. These methods find particular use in treating disorders of the hematopoietic... Agent:
20120076800 - Non-aqueous high concentration reduced viscosity suspension formulations of antibodies: The present invention relates to non-aqueous high concentration reduced viscosity suspension formulations of antibodies and methods of making and using them.... Agent:
20120076801 - Human cytomegalovirus neutralising antibodies and use thereof: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B... Agent: Humabs, LLC
20120076802 - Human cytomegalovirus neutralising antibodies and use thereof: The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes... Agent: Humabs, LLC
20120076803 - Antibodies to troponin i and methods of use thereof: The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.... Agent: Abbott Laboratories
20120076804 - Cancer targeted innate immunity: Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of... Agent: University Of Southern California
20120076805 - Methods and compositions for the generation and maintenance of regulatory t cells: Methods and compositions for generating and maintaining induced regulatory T cells (iTregs) are provided. Methods and compositions for treating an autoimmune disorder, organ transplant rejection, graft versus host disease or allergic or hypersensitivity and inflammation are also provided.... Agent: Presidents And Fellows Of Harvard College
20120076806 - Chloramphenicol acetyl transferase (cat)-defective somatostatin fusion protein and uses thereof: Chimeric somatostatin-based polypeptides, polynucleotides used to encode the polypeptides, the methods for isolating and producing the polypeptides and the uses thereof are provided. In addition, low cost adjuvants for enhanced immunogenic response are provided. Vaccinations that include both chimeric somatostatin-based polypeptides and novel adjuvants are included, useful in facilitating farm... Agent: Braasch Biotech LLC
20120076808 - Combined antigen and dna vaccine for preventing and treating autoimmune diseases: The present invention relates to treating and preventing symptoms of an allergy, asthma, an autoimmune disease, and transplant rejection using a combination vaccine containing an antigen and a DNA encoding the antigen.... Agent: China Agricultural University
20120076809 - Method to inhibit the biological activity of calcineurin with selective peptides: The invention relates to the biotechnology sector involving the area of human health. More specifically, the invention is based on the surprising usefulness of peptides LxVPc1, c3 and c4 as efficient selective inhibitors of the calcineurin signalling pathway (CN)-NFAT and the phosphate activity of CN. Said compounds are useful immunosuppressors... Agent: Consejo Superior De Investigaciones Cientificas
20120076807 - Plasmids with immunological action: e
20120076811 - Immunodominant compositions and methods of use therefor: The present invention relates to immunodominant compositions, including immunodominant peptides of HA1 of influenza H5 hemagglutinin, polynucleotides encoding such peptides, and their methods of use. Such peptides are useful, for example, for the prevention, treatment and diagnosis of influenza.... Agent: The Johns Hopkins University
20120076810 - Vaccinia virus polypeptides: This document provides methods and materials related to polypeptides present in a vaccinia virus (e.g., polypeptides that can be isolated from naturally processed and presented class I polypeptides originating from vaccinia virus, a member of the Orthopoxvirus family). For example, methods for generating a vaccine comprising one or more of... Agent:
20120076812 - Antiviral vaccines with improved cellular immunogenicity: The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.... Agent:
20120076814 - Combinations of pneumococcal rrgb clades: Pneumococcal pilus subunit RrgB has at least three clades. Serum raised against a given clade is active against pneumococci which express that RrgB clade, but is not active against strains which express one of the other two clades i.e. there is intra-clade cross-protection, but not inter-clade cross-protection. Thus an immunogenic... Agent: Novartis Ag
20120076813 - Uses of glutamyl trna synthetase (gts) fragments: The present invention relates to polypeptide fragments, including variants and analogs, of Streptococcus pneumonia (S. pneumoniae) glutamyl tRNA synthetase (GtS) protein and compositions comprising the same for use in preventing adhesion of S. pneumoniae to respiratory tract cells, cell-to-cell spread and bacteremia. In particular, the present invention relates to the... Agent: Ben Gurion University Of The Negev Research And De Velopment Authority
20120076815 - Identification and characterization of racemases, definition of protein signatures, and a test for detecting d-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase: This invention provides identification and characterization of racemases and definition of protein signatures of these racemases. This invention also provides identification of nucleic acid molecules encoding a peptide consisting of a motif characteristic of the protein signatures, and to the peptides consisting of these motifs. Antibodies specific for the peptides... Agent: Institut Pasteur
20120076816 - Novel malaria vaccine: (In the formula, X1 represents the 1st to 7th amino acid residues in a polypeptide set forth in SEQ ID NO: 1; X2 represents the 73th to 177th amino acid residues; X3 represents the 178th to 258th amino acid residues; X4 represents the 259th to 289th amino acid residues; X5... Agent:
20120076817 - Polysaccharide-protein conjugate vaccines: Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification... Agent: The United States Of America, As Represented By The Secretary Of The Department Of Health And
20120076818 - Immunogenic composition and use thereof: The invention relates to an immunogenic composition comprising an adenoviral vector and a pox viral vector, or two different adenoviral vectors, wherein one or more of the vectors encodes one or more target antigens; and related methods, uses and kits.... Agent: Isis Innovation Limited
20120076819 - Compositions and methods for treating of microbial infections: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to... Agent: Immunology Labs, Inc.
20120076821 - Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses: Disclosed herein are chimeric TBEV/DEN4 flaviviruses including a first nucleic acid molecule including a 5′ non-coding region (NCR) from a DEN4 virus, a nucleic acid encoding a C protein and non-structural proteins from a DEN4 virus, and a 3′ NCR from a DEN4 virus, wherein nonstructural protein NS4B includes a... Agent:
20120076820 - Cd40l vaccines, compositions, and methods related thereto: The disclosure relates to vaccinating a subject against a viral infection, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the use of CD40L expressed on viral like particle as an adjuvant, in combination with a viral antigen, to vaccinate a subject.... Agent: Emory University
20120076822 - Influenza vaccines with reduced amounts of squalene: Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 μg/ml per strain. In some embodiments the squalene concentration... Agent: Novartis Ag
20120076823 - Vector: The present invention relates to a herpes virus vector which comprises a modified genomic sequence encoding a microRNA (miRNA) against a target sequence. The herpes virus vector may be used as or in a vaccine to prevent and/or treat a disease.... Agent: Institute For Animal Health
20120076824 - Novel edwardsiella ictaluri e-ict-vl33 strain, vaccines thereof, and a method for protecting fishes using said vaccines: A novel Edwardsiella ictaluri E-ict-VL33 strain, a vaccine derived from the novel Edwardsiella ictaluri E-ict-VL33 strain, especially in immersion form and oral form, and a method for protecting fishes from the infection of Edwardsiella ictaluri, especially catfish, the method including a primary immersion immunization using immersion vaccine, and after an... Agent:
20120076825 - Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of... Agent: Alk-abello A/s
20120076826 - Recombinantly produced allergens: The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d... Agent:
20120076827 - Compositions and methods for generating an immune response in a subject: The invention relates to a method for providing an activated antigen-presenting cell or a composition that comprises at least one activated antigen-presenting cell, which method at last comprises the steps of providing a composition that comprises at least one antigen-presenting cell and contacting said composition with a vaccine. Suitably, the... Agent: Stichting Katholieke Universiteit Radboud University Nijmegen Medical Centre
20120076828 - Kanamycin antisense nucleic acid for the treatment of cancer: The invention relates to a nucleic acid comprising a sequence complementary to a fragment of the sequence coding for the kanamycin resistance protein. This nucleic acid is useful as a DNA vaccine adjuvant, and can be used e.g. for treating cancer, for example in combination with a non-immunosuppressive inducer of... Agent:
20120076829 - Isolation, identification and characterisation of strains with probiotic activity, from faeces of infants fed exclusively with breast milk: The invention relates to probiotic micro-organisms isolated from faeces of children exclusively fed with breast milk. Said microorganisms are used in the food or pharmaceutical industry, especially for use in infant formula milk, due to their probiotic properties which have beneficial effects on the health of those ingesting them. Said... Agent: Hero Espana S.a.
20120076831 - Compositions and methods for induction of antigen-specific tolerance: The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect. The invention is useful for treatment of immune related disorders such... Agent:
20120076830 - Differentiation of stem cells with nanoparticles: A method for differentiating mesenchymal stem cells (MSCs) towards osteoblasts and other connective tissue using nanoparticles and electromagnetic stimulation Osteoinductive materials produced using said method may be useful for bone regeneration and reconstruction in treatment of bone trauma and bone related diseases, and to correct birth defects.... Agent:
20120076835 - Hiv inhibiting pyrimidines derivatives: m
20120076836 - Polyion complex of double-stranded ribonucleic acid:
20120076838 - Poorly soluble drug containing microsphere with improved bioavailabilty and method of preparing the same: A poorly soluble drug containing microsphere with improved bioavailability, an oral formulation comprising the same, and a method of preparing the same are provided, wherein the poorly soluble drug containing microsphere is a solid dispersion wherein the poorly soluble drug is dispersed in the water-soluble polymer carrier in a noncrystalline... Agent: Samyang Biopharmaceuticals Corporation
20120076834 - Protective coatings for acidic active ingredients: Dosage forms provided with protective coatings in which a core comprising at least one acidic active ingredient is provided with at least one inner and one outer coating layer, where the outer layer comprises, as component A, a cationic polymer which is an emulsion polymer of N,N-diethylaminoethyl methacrylate and further... Agent: Basf Se
20120076837 - Surface engineering of tissue graft materials for enhanced porosity and cell adhesion: In one aspect, the invention relates to providing enhanced application tissue graft materials in regenerative medicine through improved cellular interactions. Biocompatible implant materials, methods for preparing biocompatible implant materials, methods for using same, and methods for treating tissue injury are disclosed. This abstract is intended as a scanning tool for... Agent:
20120076833 - Surface-oriented antibody coating for the reduction of post-stent restenosis: A coating for a surface of a surgical implant, the coating including a binding protein for capturing cells to the surface via a bi-functional linker molecule. The linker can have a first functional group (such as a trichlorosilyl group) for covalently linking to the surface, and a second functional group... Agent: Econous Systems Inc.
20120076832 - Synthesis and use of therapeutic metal ion containing polymeric particles: Therapeutic particles contain metal ions and are characterized by the use of unique ligand sets capable of making the metal ion complex soluble in biological media to induce selective toxicity in diseased cells. The particles may comprise a polymeric base particle, at least one pharmaceutically active metal ion, including metal... Agent: University Of North Texas
20120076840 - Alkoxysilane derivatives of n-acyl amino acids, n-acyl dipeptides, and n-acyl tripeptides, and particles and stable oil-in-water formulations using the same: Hydrophilic N-acylamino acid, N-acyl dipeptide, and N-acyl tripeptide substituted silanes are prepared which can be utilized as reactive surface treatments for particles of pigments, minerals, and fillers. These treated particles form stable dispersions in the aqueous phase of oil-in-water mixtures that are suitable for cosmetic applications. The treated particles may... Agent: Gelest Technologies, Inc.
20120076839 - Antiperspirant compositions: Anhydrous antiperspirant compositions containing an encapsulated fragrance, in which the encapsulate shell comprises an aminoplast resin, and preferably a melamine/formaldehyde resin. The encapsulates have a weight average particle diameter in the range of 25 to 60 μm, a shell having a measured thickness in the range of from 1 to... Agent:
20120076842 - Cosmetic use of tyr-arg dipeptide to combat cutaneous sagging: h
20120076841 - Porous particles loaded with cosmetically or pharmaceutically active compounds: Individualized porous particles having a volume-average diameter of less than or equal to 10 μm and a specific surface area of greater than or equal to 1 m2/g, and that include at least one cosmetically or pharmaceutically active compound present at least inside the particles.... Agent: L'oreal
20120076844 - Sheet-like cosmetic: d
20120076845 - Saline nose wipe and methods of manufacture and use: The present invention generally relates to a wet wipe or sheet that is suitable for contacting the skin and removing mucus from the skin. More specifically, the present invention relates to a wet wipe having an aqueous saline component suitable for dissolving and removing mucus in combination with the fabric... Agent: Little Busy Bodies, Inc.
20120076846 - Pyrethroid compound, preparation process and use thereof: Disclosed are a pyrethroid compound, a preparation process and the use thereof, wherein the compound is a stereoisomer of 2,3,5,6-tetrafluoro-4-methoxymethylbenzyl-3-(3,3,3-trifluoro-1-propenyl)-2,2-dimeth ylcyclopropanecarboxylate. The structure of the compound is represented by formula (A), in which the carbon-carbon double bond in carboxylic acid section is Z configuration, and the absolute stereo configuration at... Agent:
20120076847 - Medical instrument and method of manufacturing the same: A medical instrument and a manufacturing method thereof are provided. The medical instrument includes a biomedical metal layer and a polymer film. The polymer film is a biodegradable polymer material. The manufacturing method includes the following steps: providing the biomedical metal layer, immersing the biomedical metal layer in a polymer... Agent: Metal Industries Research&development Centre
20120076848 - Method and system for effecting changes in pigmented tissue: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease.... Agent:
20120076849 - Plant composition for the treatment or prevention of viral blood-borne diseases such as diseases caused by the human immunodeficiency virus (hiv) or hepatitis c: A composition based on plants for treating or preventing viral diseases of the blood, such as the diseases caused by the virus of human immunodeficiency (HIV) or hepatitis C. The composition comprises flower of sulfur, a plant containing catechin and a tannin agent, and a pharmaceutically acceptable carrier. The plant... Agent:
20120076850 - Topical patch for pain relief using cooling agent: Topical patch preparations that contain an odorless physiological cooling agent, and methods for using the same are provided. The subject topical patch preparations are made up of an adhesive gel composition that is present on a support, where the adhesive gel composition includes the odorless physiological cooling agent, a water-soluble... Agent:
20120076851 - Chromosome 3p21.3 genes are tumor suppressors: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90%... Agent:
20120076853 - Composition for use in gene therapy: A composition useful in gene therapy and a method of treatment to effect gene therapy is provided. In particular, a parenteral pharmaceutical gene therapy composition comprising a non-immunogenic net polyanionic oligosaccharide associated with a particulate complex of an anionic nucleic acid material and a cationic macromolecule, optionally together with at... Agent: Ntnu Technology Transfer As
20120076852 - Drug carrier and drug carrier kit for inhibiting fibrosis: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative... Agent: Nitto Denko Corporation
20120076854 - Cellular compositions for use in therapy:
20120076855 - Oral testosterone composition: Preferably, a pharmaceutically acceptable preservative, such as benzyl alcohol, is included in the composition. The mixture of soybean oil and ethanol is present in the composition in an amount such that when the composition is orally ingested by the testosterone is absorbed and one or more of the symptoms of... Agent:
20120076856 - Orodispersible pharmaceutical composition of perindopril: The invention relates to a solid orodispersible pharmaceutical composition of perindopril, characterised in that it comprises perindopril or a pharmaceutically acceptable salt thereof and granules consisting of co-dried lactose and starch.... Agent: Les Laboratoires Servier
20120076857 - Forms of rifaximin and uses thereof: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.... Agent: Salix Pharmaceuticals, Ltd.
20120076858 - Orally disintegrating dosage forms containing taste-masked active ingredients: Orally disintegrating dosage forms, for the purpose of masking the taste, comprise active ingredients coated with a cationic polymer are described. The coating of polymers comprises N,N-diethylaminoethyl methacrylate (DEAEMA) polymerized therein. The taste-masked active ingredients are embedded into an orally disintegrating matrix.... Agent: Basf Se
20120076860 - Compositions, methods, and systems relating to controlled crystallization and/or nucleation of molecular species: The present invention generally relates to compositions, methods, and systems relating to controlled crystallization and/or nucleation of a molecular species. In some embodiments, the crystallization and/or nucleation of the molecular species may be controlled by tuning the surface chemistry and/or the morphology of a crystallization substrate. In some embodiments, the... Agent: Massachusetts Institute Of Technology
20120076859 - Targeted lung delivery of citrulline and/or another nitric oxide precursor and a method for treatment of pulmonary deficiency of nitric oxide in cystic fibrosis and other pulmonary diseases: A method of treatment of cystic fibrosis and other pulmonary diseases identified by nitric oxide deficiency, comprising administration of a nebulized solution of citrulline and/or another nitric oxide precursor as an inhalable aerosol or an inhalable dry powder for targeted delivery into conducting and central airways. Citrulline or another nitric... Agent: Activaero Gmbh
20120076861 - Materials and methods for the treatment of celiac disease: The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease.... Agent: Alba Therapeutics Corporation
20120076862 - Methods of enhancing drug delivery and effectiveness of therapeutic agents: The present invention in one aspect provides methods of enhancing uptake of a therapeutic agent in a target tissue as well as methods of treating a disease (such as cancer) or enhancing effectiveness of treatment with a therapeutic agent in an individual by co-administering a composition comprising nanoparticles comprising albumin... Agent:
20120076864 - Microcapsules containing microorganisms: The microcapsules provide a beneficial microflora on said surface by rupture of the capsules deposited onto said surface to release the microorganism onto said surface. This may reduce or obviate the need for chemical antimicrobial agents to clean said surface. For surfaces which are fabrics or textiles, rupture and release... Agent: Devan Chemicals Nv
20120076863 - Nanoparticulate stabilized anti-hypertensive compositions: The present invention is directed to anti-hypertensive compositions comprising a nanoparticulate temocapril, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate temocapril particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of hypertension and related... Agent: Elan Pharma International Ltd.
20120076865 - Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates... Agent: Jazz Pharmaceuticals, Inc.
20120076866 - Particulate pharmaceutical composition: The present invention provides a particulate pharmaceutical composition which has improved drug encapsulation stability and is suitable for a drug delivery system. The particulate pharmaceutical composition 1 contains: a plurality of block copolymer unit 2 arranged radially, each of which has a hydrophobic polymer-chain segment 2b, which is arranged radially... Agent:
20120076867 - Petroleum-free compositions for skin care and other applications, and methods of making same: A substantially non-aqueous, aerated composition is free of petroleum-based components and is suitable for skin applications, The composition primarily includes wax and oil, and can further include vitamin E oil and an essential oil. The composition can be a semi-solid at room temperature. A method of making the composition includes... Agent: Waxelene, Inc.
20120076868 - Cross-linked bioactive hydrogel matrices: The present invention is directed to a stabilized cross-linked hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component that are covalently linked, and at least one stabilizing or enhancing agent, wherein the first high molecular weight component and the second high molecular weight... Agent: Encelle, Inc.
20120076869 - Methods of treating dementia using omentum: Dementia is treated by administering a composition that includes an omentum tissue or an aqueous or organic extract of the omentum tissue to a mammal in need of treatment of dementia. The composition can be administered to the mammal via oral administration, parenteral administration, inhalation, topical administration, rectal administration, vaginal... Agent:
20120076870 - Bone substitute and method for the preparation thereof: The invention relates to a material that can be used as a bone substitute and to a method for the preparation thereof. The material comprises an organic phase (I) comprising striated collagen fibrils constituted of collagen I triple helices, said fibrils being organized over a large distance according to a... Agent:
20120076871 - Method for detecting, quantifying and mapping damage and/or repair of dna strands: Methods and products for detecting in vitro the presence of damage on DNA or the presence of a biological response to damage on DNA at the molecular level. Molecular Combing or other nucleic acid stretching methods are employed together with compounds reacting with DNA, probes binding DNA, or nucleic acid... Agent: Genomic Vision Sa
20120076872 - Modified green tea polyphenol formulations: Modified green tea polyphenols and methods of their use are provided. One aspect provides compounds and compositions containing green tea polyphenols with one on more ester-linked fatty acids.... Agent: Georgia Health Sciences University Research Institute, Inc.
20120076874 - Composition with improved bioavailability of saponin and method for improving the bioavailability of saponin (as amended): The present invention relates to a ginseng mixed composition with improved bioavailability of saponin. Further, the present invention relates to a method for improving saponin bioavailability of a subject comprising: administering to the subject an effective amount of at least one extract selected from a Schizandra chinensis extract and a... Agent:
20120076873 - Health food: The constitution of the health food is: consuming cereals including rices and wheats with or without husk, millets, pulses, tubers, leaf vegetables, fruit vegetables, rosette crops, root vegetables, citrus fruits, fruits, melons, seaweeds, and liverworts etc. as is; or consuming powders thereof, or by soaking in water so as to... Agent:
20120076875 - Herbal medicinal composition and extract thereof for inducing proliferation of cranial nerve cells and method of manufacturing the same: A herbal medicinal composition and an extract thereof for inducing proliferation of cranial nerve cells and a method of manufacturing the same are disclosed. The herbal medicinal composition includes Ginseng Radix and Aconiti Tuber.... Agent: Chen-yu Lee
20120076876 - Chia seed extract and related method of manufacture: Ethanolic chia (Salvia hispanica) seed extracts are provided in a system including one or more polyols and at least one hydrophobic compound that solubilize hydrophobic and slightly hydrophilic fractions of the extracts. The polyol can be pentylene glycol. The at least one hydrophobic compound can be a light oil or... Agent: Access Business Group International LLC
20120076878 - Compositions and methods for the prevention and treatment of brain diseases and conditions: Disclosed herein are compounds, extracts, and active fractions of the plant Geum japonicum and methods for preventing or treating brain diseases or conditions, such as ischemic stroke, Alzheimer's disease, vascular dementia, mild cognitive impairment (MCI), chronic cerebral ischemia and Parkinson's disease. The compounds provided herein can be formulated into pharmaceutical... Agent: Generex Pharmaceuticals, Inc.
20120076877 - Pharmaceutical compositions comprising extracts of sarcopoterium spinosum, components thereof, and uses thereof: Disclosed are pharmaceutical compositions comprising extracts of Sarcopoterium spinosum, components of the extracts and uses of the pharmaceutical compositions as well as methods of making the compositions.... Agent: Ariel-university Research And Development Company. Ltd.03/22/2012 > 154 patent applications in 87 patent subcategories. listing by industry category
20120070369 - Hif inhibitors and use thereof: The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.... Agent: The General Hospital Corporation
20120070368 - Methods of using c-met modulators: e
20120070370 - Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors: The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents,... Agent:
20120070371 - Low-density magnesium-aluminum-silicate (mas) microparticles for radiotherapy and/or radioimaging: This invention relates to low density radioactive magnesium-aluminum-silicate (MAS) microparticles that contain either samarium-yttrium, samarium, or lutetium as medical isotopes for radiotherapy and/or radioimaging.... Agent:
20120070372 - Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is... Agent: Stc.unm
20120070373 - Method and compound for treatment of cancer using phosphorous-32 labeled dna: This invention provides a combination of a gene and isotope therapy that is applied to a cancerous tissue to selectively kill that associated cancer cells with minimal negative effects on surrounding non-cancerous cells. Functionally, the specific DNA fragments with labeled isotope are able to bind the tumor cells DNA through... Agent:
20120070374 - Compounds for non-invasive measurement of aggregates of amyloid peptides: The invention relates to the provision of compounds, methods for producing them, and their use for imaging and quantification of aggregates of β-amyloid peptides in vivo. In a preferred aspect of the invention, a tracer is administered to humans and displays enrichment in body parts that are containing aggregates of... Agent:
20120070375 - Complex and contrast agent for photoimaging using the same: There is provided a gelatin-ICG complex that can suppress leakage of ICG included therein. The complex has a gelatin derivative including at least one of a phospholipid covalently bonded to a gelatin or a cholesterol covalently bonded to a gelatin, and indocyanine green.... Agent: Canon Kabushiki Kaisha
20120070377 - Compounds and biological materials and uses thereof: The invention provides compounds of Formula (I): wherein b, D, R1, R2, G, Ra and Rb have meanings given in the description, or pharmaceutically-acceptable salts or solvates, or pharmaceutically functional derivatives thereof. The invention further provides process for conjugating the compounds to carrier molecules and uses of such compounds and... Agent:
20120070376 - Yeast cell wall particles for receptor-targeted nanoparticle delivery: The present invention generally relates to yeast cell wall microparticles loaded with nanoparticles for receptor-targeted nanoparticle delivery. In particular, the present invention relates to trapping nanoparticles either on the surface or inside a yeast glucan particles, for example, yeast glucal particles. The present invention further relates to methods of making... Agent: University Of Massachusetts
20120070379 - Immunotherapy regimes dependent on apoe status: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.... Agent: Wyeth LLC
20120070378 - Lanthanide ion complexes and imaging method: A Ianthanide complex, method of forming and method of using the lanthanide complex as a near-infrared luminescent material are described. The complex includes at least one lanthanide ion and at least one polydentate ligand derived from a molecule having the general formula of Structure: Structure 2, where: E represents a... Agent: The University Of Akron
20120070383 - Polymeric nano-carriers with a linear dual response mechanism and uses thereof: The present invention features compositions in which nano-carriers are synthesized with polymers that respond to lower pH and/or ROS by being degraded. The compositions may be utilized to selectively deliver payloads within patients by responding to lower pH and/or ROS at localities within the patient. The present invention also features... Agent: The Regents Of The University Of California
20120070382 - Fluorescent conjugated polymers with a bodipy-based backbone and uses thereof: The present invention provides various fluorescent conjugated polymers with a BODIPY-based backbone. The invention also provides methods of using the polymers of the invention, such as for imaging and detection of cells, tumors, bacteria and viruses.... Agent: Michigan Technological University
20120070380 - Ingestible salt grabber: Disclosed herein include embodiments related to compositions, devices, computer systems, computer-implemented methods, and computer program products associated with an ingestible salt grabber.... Agent: Elwha LLC, A Limited Liability Company Of The State Of Delaware
20120070381 - Ophthalmologic composition having gelation ability: s
20120070385 - Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives: The present specification discloses tetrahydroindolone derivatives or analogues and methods for treating cognitive/attention deficit disorders using such tetrahydroindolone derivatives and analogues.... Agent: Spectrum Pharmaceuticals, Inc.
20120070384 - Topical antifungal composition: A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content less than... Agent: Stiefel Research Australia Pty Ltd
20120070387 - Dentifrice: t
20120070386 - Trehalulose-containing composition, its preparation and use: The present invention relates to a trehalulose-containing composition, its preparation and use.... Agent:
20120070392 - Composition for inhibiting erythema caused by ultraviolet radiation containing a dipeptide as active ingredient: The present invention relates to a composition for inhibiting erythema caused by ultraviolet radiation, wherein said composition contains a specific dipeptide, selected from 400 dipeptides, as an active ingredient. The composition of the present invention inhibit the production of prostaglandin E2(PEG2), thereby inhibiting erythema caused by ultraviolet radiation.... Agent:
20120070391 - Cosmetic composition comprising an aqueous dispersion of polysiloxane/polyurea and a silane, cosmetic treatment process and kit therefor: The present invention relates to a cosmetic composition comprising an aqueous dispersion of polysiloxane/polyurea copolymer and a silane, and to a cosmetic treatment process using said composition.... Agent: L'oreal
20120070389 - Methods for identifying treatments that treat and/or prevent uv irradiation inducing photoaging: Methods are provided for ascertaining and measuring RPTP-κ activity in response to insults such as UV irradiation and with respect to administration of a treatment and/or composition. Attenuation of EGFR activity by RPTP-κ affects aspects of photoaging, including damage to the skin, suppression of the immune system, DNA damage, and... Agent: The Regents Of The University Of Michigan
20120070390 - Topical drug delivery system with dual carriers: An over-the-counter (OTC) regulated therapeutic composition for self-medication use for application to wounds having a potential pathogen load, in which the composition comprises a tissue penetration enhancer comprising a Class I pharmaceutical incipient; a pharmaceutical antibiotic agent in a dosing suitable for use in an OTC listing; a hygroscopic carrier... Agent:
20120070393 - Antiperspirant stick composition: The present invention relates to an antiperspirant cosmetic composition for topical application to the skin comprising an effective amount of at least one antiperspirant active material, at least one gelling agent, at least one wax and at least one solvent for the at least one antiperspirant active material, wherein the... Agent: Coty Germany Gmbh
20120070395 - Novel amide derivative and whitening agent:
20120070396 - Activator including biosurfactant as active ingredient, mannosyl erythritol lipid, and production method thereof: The present invention includes as an active ingredient at least one biosurfactant, in particular mannosyl alditol lipid (such as MEL and MML) or triacylated mannosyl alditol lipid. This allows providing an activator and anti-aging agent that is excellent in activating and anti-aging effects on cells and that is safe enough... Agent: Toyo Boseki Kabushiki Kaisha
20120070397 - Maintaining feet dry to prevent freezing: A method of keeping the feet warm when engaging in activities in cold weather, comprising the step of applying antiperspirant to the feet. This is done prior to donning foot coverings such as socks. The foot coverings may comprise a wicking fabric or wool. The antiperspirant may be a liquid... Agent:
20120070398 - Hair cosmetic: m
20120070400 - Method for improving the mildness of cleansing compositions: A method for improving the mildness of a cleansing composition includes 0.1 to 15 wt. % of a combination of a lactate salt and a gluconate salt is provided in a cleansing composition comprising 4-55 wt. % of a surfactant and water, wherein the lactate salt makes up 10-90 wt.... Agent:
20120070401 - Composition and method for promoting wound healing: A composition for promoting wound healing comprises a bioadhesive polymer and a pharmaceutically acceptable liquid medium. Such a composition is applied to a wound to promote healing of the wound. The bioadhesive polymer can be selected from the group consisting of natural or synthetic hydrophilic polymers and hydrogels.... Agent:
20120070402 - Polymeric artificial tear system: The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and... Agent: Alcon Research, Ltd.
20120070403 - Use of g-csf for the extension of the therapeutic time-window of thrombolytic stroke therapy: The present invention relates to the use of G-CSF and derivatives thereof for extending the therapeutic window of subsequent thrombolytic treatment of acute stroke, and thereby, allowing the diagnostic examinations which are necessary prior to the thrombolytic treatment in order to avoid hemorrhagic and other severe adverse side effects of... Agent: Sygnis Bioscience Gmbh & Co. Kg
20120070404 - Increasing cancer patient survival time by administration of dithio-containing compounds: The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention... Agent: Bionumerik Pharmaceuticals, Inc.
20120070408 - Methods and compositions for treating lupus: The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes to alleviate lupus symptoms.... Agent: Genzyme Corporation
20120070406 - Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy: The present invention provides methods for reducing and/or evaluating the immunogenic potential of a therapeutic protein preparation. The present invention further provides pharmaceutical compositions of therapeutic proteins and methods of treatment with the same, the compositions having low immunogenic potential and/or improved efficacy. The invention achieves these goals by evaluating... Agent: Barofold, Inc.
20120070407 - Therapy for promoting cell growth: There is disclosed the use of a composition for promoting neuronal growth of neurons in tissues of the central or peripheral nervous system. There is also disclosed a method for inducing proliferation or differentiation of neuronal cells.... Agent:
20120070405 - Uses of modified elr-cxc chemokine g31p to treat cancer: Described herein is the use of a modified human chemokine, GS-CXCL8(3-72)K11R/G31P or G31P in the treatment of a number of cancers, including but by no means limited to prostate cancer, liver cancer and melanoma.... Agent:
20120070412 - Hcv inhibitor and therapeutic agent combinations: The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and... Agent: Ptc Therapeutics, Inc.
20120070410 - Imidazolothiazole compounds and methods of use thereof: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.... Agent:
20120070413 - Method of treating cancer with substituted amide derivatives: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention... Agent:
20120070411 - Substituted nucleotide analogs: Disclosed herein are phosphoroamidate nucleotide analogs, methods of synthesizing phosphoroamidate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphoroamidate nucleotide analogs.... Agent: Alios Biopharma, Inc.
20120070409 - Tetracyclic fused heterocyclic compound and use thereof as hcv polymerase inhibitor: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory... Agent: Japan Tobacco Inc.
20120070414 - Controlling disease vectors from insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi: The present invention utilizes extracts of the pre-sporulation (preconidial) mycelial stage of entomopathogenic fungi as insect and arthropod attractants and/or pathogens and can be employed to limit the zoonotic and plant diseases they transmit. The fungus can be cultivated on grain, wood, agricultural wastes or other cellulosic material and extracts... Agent:
20120070415 - Azido nucleosides and nucleotide analogs: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus,... Agent: Alios Biopharma, Inc.
20120070416 - Macrocyclic proline derived hcv serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Enanta Pharmaceuticals, Inc.
20120070417 - Anti-influenza formulations and methods: The invention relates to pharmaceutical compositions that contain a calcium salt as an active ingredient and also comprise another anti-influenza agent, and to methods for treating or preventing influenza virus infection.... Agent: Pulmatrix, Inc.
20120070419 - Method of altering the differentiative state of a cell and compositions thereof: The present invention provides a method of altering the differentiative state of cells utilizing innovative protein expression constructs encoding transcription factors. The methods and compositions described herein may be used to generate induced pluripotent stem (iPS) cells, as well as differentiate, transdifferentiate or dedifferentiate cells of various epigenetic status. The... Agent: International Stem Cell Corporation
20120070421 - Synergistic fungicidal mixtures: The present invention relates to fungicidal mixtures, comprising a compound of formula I and one fungicidal component II selected from groups A′) to C′) as defined in the description, and to compositions comprising these mixtures.... Agent: Basf Se
20120070418 - Stem cells for musculoskeletal tissue repair: The stem cells that can be propagated and maintained for extended periods of time in culture in the absence of a feeder layer, and can be used to repair tissue damage. These cells are derived from fetal tissues and are able to repair different types of damage in musculoskeletal system,... Agent: Celavie Biosciences, LLC
20120070420 - Compositions and methods for treating psychiatric and neurodegenerative disorders: Treatment methods are disclosed for psychiatric and neurodegenerative disorders by treatment of the patient with platelet-rich plasma (PRP). PRP is administered to areas of the brain that have been identified as associated with the psychiatric or neurodegenerative disorder to replenish the dysfunctional tissue.... Agent:
20120070422 - Method of treating ocular disorders: A method wherein subjects having or at risk for having hyperopia, presbyopia or astigmatism are administered a composition having an effective amount of ocular antioxidants, including specifically macular pigments, to prevent, treat, or delay the onset of age-related macular degeneration (AMD).... Agent: Kemin Industries, Inc.
20120070423 - Oral composition and method of forming and using same: An oral composition for the treatment of dry mouth symptoms and other conditions, a method of forming the oral composition, and a method of using the oral composition are disclosed. The oral composition includes a plurality of enzymes to prevent formation of and/or facilitate the break up of biofilm in... Agent:
20120070424 - Mutations on oas1 genes: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.... Agent:
20120070425 - Tissue kallikrein for the treatment of pancreatic beta-cell dysfunction and for beta-cell proliferation: The invention relates to methods of administering kallikrein, a variant, or active fragment thereof to stimulate proliferation of islet cells generally and β-cells specifically. The invention also includes compositions to stimulate proliferation in vivo and in vitro.... Agent: Diamedica, Inc.
20120070426 - Peptide-based passive immunization therapy for the treatment of atherosclerosis: The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method... Agent:
20120070427 - Vortex-induced silk fibroin gelation for encapsulation and delivery: The present invention provided for a novel process of forming silk fibroin gels, and controlling the rate of β-sheet formation and resulting hydrogelation kinetics, by vortex treatment of silk fibroin solution. In addition, the vortex treatment of the present invention provides a silk fibroin gel that may be reversibly shear-thinned,... Agent: Trustees Of Tufts College
20120070433 - Flavonoid hydrogel: There is provided methods for producing a hydrogel comprising conjugates of a hydrogel forming agent and a flavonoid including a method for producing a hydrogel that is capable of adhesion of cells and which comprises enzymatically cross-linked conjugates of a hydrogel forming agent and a flavonoid. There is also provided... Agent:
20120070429 - Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof: The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said... Agent: Macrogenics. Inc.
20120070430 - Identification of tumor-associated markers for diagnosis and therapy: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.... Agent:
20120070431 - Methods for treating chronic obstructive pulmonary disease: The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically effective amount of an anti-IgE moiety. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment... Agent:
20120070432 - Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine: Methods and compositions for treatment of exocrine pancreatic cancer in a human patient comprising administering a therapeutically effective amount of a DR5 agonist and gemcitabine. Methods and compositions for treating a patient by identifying the alleleic variant of FcγRIIIA.... Agent: Amgen Inc.
20120070428 - Treatment of vascularized pigment epithelial detachment with anti-vegf therapy: Methods for treating vascularized pigment epithelial detachment using anti-VEGF agents are disclosed.... Agent: Genentech, Inc.
20120070434 - Antibodies containing therapeutic tpo/epo mimetic peptides: The present disclosure features therapeutic antibodies (e.g., TPO mimetic antibodies) and therapeutically-active fragments thereof as well as methods for preparing and using the antibodies and fragments. For example, the therapeutic antibodies and their fragments are useful in a variety of diagnostic and/or therapeutic applications such as methods for increasing platelet... Agent: Alexion Pharmaceuticals, Inc.
20120070436 - Antigen-binding proteins: The present invention relates to antigen binding proteins comprising a receptor-Fc fusion which is linked to one or more epitope-binding domains, methods for making such proteins, and uses thereof.... Agent:
20120070435 - Chimeric antigens for eliciting an immune response: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising... Agent: Paladin Labs, Inc.
20120070437 - Method of identifying compounds that bind baff-r: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.... Agent: Biogen Idec Ma Inc.
20120070439 - Antigen-binding proteins: The invention relates to linkers suitable for use in antigen-binding proteins, certain antigen binding proteins and methods of making such proteins and uses thereof.... Agent:
20120070438 - Methods for treating melanoma: Methods of inhibiting melanoma tumor growth, methods of treating melanoma and metastatic melanoma, and methods of reducing the frequency of tumor initiating cells (or cancer stem cells) in melanoma tumors are described. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of... Agent: Oncomed Pharmaceuticals, Inc.
20120070440 - Therapeutic use of anti-cs1 antibodies: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including... Agent: Abbott Biotherapeutics Corp.
20120070441 - Extracellular yaluronidase from streptomyces koganeiensis: The invention relates to Streptomyces koganeiensis ATCC 31394 hyaluronidase having molecular weight of 21.6 kDalton, which has hyaluronidase activity and stability markedly higher than those of the hyaluronidase obtained from such microorganism to date. The invention further relates to a process for the isolation and purification of said hyaluronidase and... Agent: Keter Plastic Ltd.
20120070442 - Methods and compositions for treating cancer: Provided herein are methods for identifying a cancer patient responsive to treatment with an EGFR tyrosine kinase inhibitor. One method comprises obtaining a biopsy from the patient and measuring the number of copies of miR-128b in DNA extracted from the biopsy. A patient responsive to EGFR tyrosine kinase inhibitor treatment... Agent: The Regents Of The University Of Colorado, A Body Corporate
20120070445 - Brain-derived gonadotropins and cognition: A method of treating or preventing neurodegenerative disease in a subject, the method includes administering to the subject a therapeutically effective amount of at least one physiologically acceptable agent that modulates levels, production, and/or function of brain-derived hormones of the hypothalamic-pituitary-gonadal (HPG) axis or their receptors.... Agent:
20120070444 - In vivo screening models for treatment of isoqc-related disorders: A transgenic non-human animal for overexpressing isoQC, comprising cells containing a DNA transgene encoding human isoQC, characterized in that said human isoQC comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 75% sequence identity to the amino acid sequence of SEQ... Agent: Probiodrug Ag
20120070443 - Pde1 as a target therapeutic in heart disease: Disclosed are compositions and methods related to inhibition of PDE1.... Agent: University Of Utah Research Foundation
20120070447 - Methods of administering / dosing anti-rsv antibodies for prophylaxis and treatment: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of... Agent: Medimmune, LLC
20120070446 - Rsv specific binding molecule: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.... Agent: Aimm Therapeutics B.v.
20120070448 - Anti-il-3ra antibody for use in treatment of blood tumor: The present invention provides an antibody to human IL-3Rα chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3Rα chain but does not bind to C domain of the human IL-3Rα chain; a composition for preventing or treating a blood tumor in which a... Agent: Kyowa Hakko Kirin Co., Ltd
20120070449 - Methods of treating inflammation: A method of treating an inflammation in a subject in need thereof is disclosed. The method comprising administering to the subject an agent capable of down-regulating an activity or expression of CD151 in a lymphocyte, with the proviso that the agent is not CCL2, thereby treating the inflammation.... Agent: Yeda Research And Development Co. Ltd.
20120070450 - Leukemia stem cell markers: The invention provides a test method for predicting the initial onset or a recurrence of acute myeloid leukemia (AML) comprising (1) measuring the expression level of human leukemic stem cell (LSC) marker genes in a biological sample collected from a subject for a transcription product or translation product of the... Agent: Riken
20120070451 - Methods and compositions for modulating cardiac contractility: Provide is a Cavβ2 peptide or variant thereof, or synthetic molecules, or polynucleotides encoding said peptide or variant, for use in the modulation of cardiac inotropism. Also provided are compositions and methods of treatment comprising said Cavβ2 peptide, polynucleotide or variants thereof.... Agent: Consiglio Nazionale Delle Ricerche
20120070452 - Immunoadjuvant composition and use thereof: Disclosed is a composition comprising, as an active ingredient, at least one selected from the group consisting of a Zc3h12a gene inhibitor and a Zc3h12a protein inhibitor. This composition can be used as an immunoadjuvant.... Agent:
20120070453 - Methods for preparing and delivering adjuvant compositions: Methods are provided for preparing and delivering an adjuvant for vaccines including lecithin and a polymer. The polymer is preferably polyacrylic acid-based and the delivery method involves administering a vaccine, including an antigen and the adjuvant, to a mucosal surface.... Agent: Advanced Bioadjuvants, LLC
20120070454 - Dengue vaccine, pharmaceutical composition comprising the same, nucleotide sequence and antibody composition: The present invention relates to a dengue vaccine, a pharmaceutical composition comprising the same, a nucleotide sequence, and an antibody composition. The dengue vaccine of the present invention includes chimeric nonstructural protein 1, which comprises N-terminus of DV NS1 from amino-acid residues 1 to 270 and C-terminus of JEV NS1... Agent: National Cheng Kung University
20120070455 - Influenza vaccine: The present invention discloses isolated peptides encoding an antigen or fragments thereof from the N-terminus of hemagglutinin protein of influenza, methods for isolating such antigens and specific uses thereof. The peptide can be used as a vaccine to generate an antibody response that neutralizes influenza infectivtty against a variety of... Agent:
20120070456 - Polypeptide carrier protein: The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated... Agent:
20120070458 - Adjuvanting meningococcal factor h binding protein: Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge... Agent: Novartis Ag
20120070457 - Polypeptides from neisseria meningitidis: Polypeptides comprising Neisseria meningitidis amino acid sequences. Over 36000 meningococcal polypeptide sequences are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be usedin medicine for treating or preventing disease and/or infection caused by N. meningitidis, such as meningococcal meningitis.... Agent: Novartis Ag
20120070459 - Method for keeping a foot-and-mouth disease vaccine available for emergency vaccination: The present invention pertains to a method for keeping a foot-and-mouth disease vaccine available for emergency vaccination of animals against foot-and-mouth disease, the vaccine comprising a foot-and-mouth disease antigen formulated in a water-in-oil emulsion, the method comprising the steps of providing the formulated vaccine, freezing the vaccine, and storing the... Agent:
20120070460 - Dendritic cell modulatory molecule: The present invention provides a dendritic cell modulatory molecule which modulates, and preferable inhibits, the differentiation and maturation of mammalian dendritic cells. The invention also provides pharmaceutical compositions comprising the dendritic cell modulatory molecule and homologues and active fragments thereof, antibodies thereto and methods of treatment and screening methods which... Agent: Natural Environment Research Council
20120070462 - Targeted gene delivery to dendritic cells: Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions,... Agent: California Institute Of Technology
20120070461 - Use of myeloid cell biomarkers for the diagnosis of cancer: The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing... Agent: Immatics Biotechnologies Gmbh
20120070463 - Method of biotechnological production fo bovine hemoderivative and use of bovine hemoderivative: The method of biotechnological production of bovine hemoderivative is presented in the following overview providing a summary of individual technological operations in time sequence (Flow-Sheet).... Agent: Svus Pharma A.s.
20120070464 - Monoparamunity inducers based on attenuated rabbit myxomaviruses: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and... Agent:
20120070471 - Administration of enoxoparin sodium to patients 75 years and older with st-segment elevation myocardial infarction: Methods for treating ST-segment elevation myocardial infarction in a human patient 75 years of age or older. The methods comprise administering a dose of less than 1 mg per kg body weight, about 0.75 mg per kg of body weight, or 0.75 mg per kg of body weight of enoxaparin... Agent:
20120070473 - Apparatus and method for reducing the occurrence of post-surgical adhesions: A method for inhibiting formation of adhesions following abdominal surgery which involves application of an anti-static fatty acid ethoxylated amide (Cocamide DEA) in a matrix that is placed in the peritoneal cavity at the conclusion of an abdominal surgery and which releases this anti-adhesive chemical over a predetermined time in... Agent: Anhese LLC
20120070469 - Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents: Nanoparticulate assemblies of isolated β-casein are useful for encapsulation of bioactive therapeutic substances, particularly therapeutic agents with poor bioavailability. The nanoparticulate assemblies can be freeze-dried and re-suspended prior to administration.... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.
20120070472 - Chronotherapeutic compositions and methods of their use: n
20120070476 - Compositions and methods for inactivation of pathogens at genital tract surfaces: The present disclosure includes compositions and methods of inactivating pathogens of a genital tract of a female. The compositions include L-lactic acid substantially free of D-lactic acid. In particular, an intravaginal ring for sustained release of L-lactic acid out of a reservoir containing multi-gram quantities of L-lactic acid, with minimal... Agent:
20120070466 - Conjugated polymeric material and uses thereof: Disclosed are compositions comprising collagen covalently bound to particles, wherein covalent bonds are formed between reactive groups of the collagen and reactive groups of the particles, and wherein the particles have an average particle diameter ranging from 20 to 1000 nanometers. Also disclosed are various methods that utilize the compositions.... Agent: University Of Missouri, Office Of Ipa
20120070477 - Dry powder fibrin sealant: A fibrin sealant comprises a mixture of first microparticles that comprise fibrinogen, second microparticles that comprise thrombin, and additive material. The additive material may be particulate, and may be, for instance, a biocompatible, water-absorbent, material, a biocompatible, water-swellable material, a biocompatible, water-insoluble material, a polysaccharide or silica.... Agent: Profibrix B.v.
20120070470 - Hemostatic compositions, devices, and methods: Compositions that include a clay such as kaolin dispersed in a liquid such as water may be useful for promoting the clotting of blood. The compositions may be in a liquid, gel, paste, foam, or another form. Uses may include treating a traumatic injury such as in injury caused by... Agent: Z-medica Corporation
20120070467 - Ophthalmic drug delivery: The present invention includes and provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye,... Agent: Corinthian Ophthalmic, Inc.
20120070465 - Pharmaceutical composition for modified release: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.... Agent: Astellas Pharma Inc.
20120070474 - Polymer compound for biomedical use and biochip substrate using such a polymer compound: A biochip substrate capable of realizing the high detection accuracy by restricting a nonspecific adsorption or bonding of a substance to be detected, when used for a detection or analysis of protein, nucleic acids and the like. The biochip substrate is for fixing a biologically active substance on a surface... Agent: Sumitomo Bakelite Company, Ltd.
20120070468 - Removal of toxins from gastrointestinal fluids: b
20120070475 - Zero calorie polyphenol aqueous dispersions: A method for stably dispersing microparticulated water insoluble bioactive polyphenol in a beverage by combining the bioactive polyphenol dissolved in an alkaline solution with an aqueous solution of at least one dispersion stabilizer. A composition comprising dispersed microparticulated water insoluble bioactive polyphenol(s) and a dispersion stabilizer.... Agent: Pepsico, Inc
20120070478 - Color changing consumer products: The invention relates to personal care products containing multilayer films with decorative layers and may impart a noticeable color change. The invention is applicable in products including type toothpaste, soaps, and other products until diluted with water (or saliva).... Agent: Colgate-palmolive Company
20120070479 - Saline nose wipe and methods of manufacture and use: The present invention generally relates to a wet wipe or sheet that is suitable for contacting the skin and removing mucus from the skin. More specifically, the present invention relates to a wet wipe having an aqueous saline component suitable for dissolving and removing mucus in combination with the fabric... Agent: Little Busy Bodies, Inc.
20120070480 - Antimicrobial disposable absorbent articles: Disposable absorbent articles comprising an absorbent material and an antimicrobial composition are disclosed. The antimicrobial composition includes a carrier comprising fatty alcohol and a poly(alkyleneoxy) polymer, and an antimicrobial agent. The antimicrobial composition may be coated on to component substrates such as nonwovens and films, that are incorporated into disposable... Agent: 3m Innovative Properties Company
20120070481 - Stable aqueous solutions of silane quat ammonium compounds: Textiles coated with aqueous compositions of silane quaternary ammonium compounds and alkali metal bicarbonates are provided with deodorization properties and protection from allergens, irritants, molds, dust mites, bacteria, and fungi.... Agent: Church & Dwight Co., Inc.
20120070482 - Formulation comprising avermectin particles coated with a photo-protecting agent: A composition comprising a pesticide (A) selected from avermectin and a photo-protecting agent, wherein the mean diameter of the pesticide (A) particles is from 0.1 to 100 μm and where the amount of photo-protecting agent in the composition does not exceed 20% of the total weight of the pesticide (A)... Agent: Syngenta Crop Protection, LLC
20120070483 - Multi-functional biocompatible coatings for intravascular devices: A polymeric coating is adapted to substantially eliminate thrombus formation when in contact with blood. The polymeric coating includes a first polymeric layer and a second polymeric layer. Interposed between the first and second polymeric layers is a polymeric matrix layer doped with at least one of a nitric oxide... Agent:
20120070484 - Water-absorbing resin composition: A water-absorbent resin composition having an antimicrobial property, which suppresses the generation of dust of the antimicrobial agent. A water-absorbent resin composition comprising a water-absorbent resin and an antimicrobial agent comprising an inorganic compound carrying an antimicrobial metal, the water-absorbent resin composition being characterized in that the degree of generated... Agent:
20120070485 - method for producing a device applicable to biological tissues, particularly a patch for treating damaged tissues, and a device obtained by said method: The present invention relates to a device consisting of cross-linked nanofibrillary fibrin supported on and rooted to a microporous nonwoven fabric consisting of a biocompatible synthetic polymer material. An active ingredient is advantageously dispersed in the fibrin layer. The fibrin layer does not have a haemostatic function, but is suitable... Agent:
20120070487 - Alkylsaccharide compositions with nutraceuticals: The present invention provides nutraceutical compositions with enhanced oral bioavailability. The compositions of the present invention include one or more alkylsaccharides admixed with one or more nutraceutical.... Agent: Aegis Therapeutics LLC
20120070490 - Anti-trypanosomal peptides and uses thereof: The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid protozoan with hydrophobic signal sequence peptides and compositions including such hydrophobic signal sequence peptides.... Agent: University Of Georgia Research Foundation, Inc.
20120070491 - Casb7439 constructs: The present disclosure relates to compounds and methods for increasing the recombinant production of CASB7439 polypeptides, and for methods of utilizing the same.... Agent: Glaxosmithkline Biologicals S.a
20120070489 - Combination therapy for treatment of fiv infection: The present invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and... Agent:
20120070488 - Method of inducing neutralizing antibodies to human immunodeficiency virus: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.... Agent: Duke University
20120070486 - Methods and compositions related to prefoldin and its regulation: The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides methods for the delivery of a siNA (e.g., a siRNA) to a cell to modulate expression of a PFDN 1-6. These methods may be used to treat a disease, such... Agent:
20120070492 - Rhein or diacerein compositions: The invention relates to pharmaceutical compositions comprising rhein or diacerein or salts or esters or prodrugs thereof, optionally with one or more pharmaceutically acceptable excipients. The invention also relates to the methods for preparing such compositions.... Agent:
20120070493 - Targeted multi-epitope dosage forms for induction of an immune response to antigens: Provided herein are compositions and methods related to MHC II binding peptides. In some embodiments, the peptides are obtained or derived from a common source. In other embodiment, the peptides are obtained or derived from an infectious agent to which a subject has been repeatedly exposed.... Agent: Selecta Biosciences, Inc.
20120070494 - Treatment for attention-deficit hyperactivity disorder: A method for treating Attention Deficit/Hyperactivity Disorder (ADHD) in humans and the symptoms associated therewith, inattentiveness, and hyperactivity with impulsivity, using eltoprazine and related compounds is provided.... Agent: Psychogenics, Inc.
20120070495 - Oral formulations and lipophilic salts of methylnaltrexone: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.... Agent: Wyeth LLC
20120070496 - Antidepressant dosage form: A dosage form having sustained-release or controlled-release properties for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form over an extended period of time in a therapeutically responsive dose to produce antidepressant therapy.... Agent: Alza Corporation
20120070497 - Use of boswellic acids for the prophylaxis and/or treatment of damage to and/or inflammation of the islets of langerhans: Disclosed are methods and compositions related to the use of boswellic acids (such as acetyl-11-keto-β-boswellic acid, 11-keto-β-boswellic acid, β-boswellic acid, acetyl-β-boswellic acid, 9,11-dehydro-β-boswellic acid, acetyl-9,11-dehydro-β-boswellic acid, α-boswellic acid, acetyl-α-boswellic acid, 11-dehydro-α-boswellic acid, acetyl-9,11-dehydro-α-boswellic acid, lupeolic acid, acetyl lupeolic acid, 12-ursene-2-diketone, incensole, incensole acetate, a derivative, in particular an ester thereof,... Agent: Fraunhofer-gesellschaft Zur Forderung Der Angewandten Forschung E.v.
20120070498 - Submicron particles of antineoplastic agents: The present invention is concerned with the formation of submicron particles of an antineoplastic agent, particularly paclitaxel, by precipitating the antineoplastic agent in an aqueous medium to form a pre-suspension followed by homogenization. Surfactants with phospholipids conjugated with a water soluble or hydrophilic polymer such as PEG are used as... Agent: Baxter International Inc.
20120070499 - Delayed-release glucocorticoid treatment of rheumatoid disease: The present invention refers to the treatment of a rheumatic disease and/or osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.... Agent: Horizon Pharma Ag
20120070501 - Method and formulation for treating resistance to antihypertensives and related conditions: A method for the prevention or treatment of symptoms of hypertension in a patient who is resistant to antihypertensive effects of an antihypertensive compound administered in the absence of melatonin comprises administering to said patient melatonin in an amount effective to ameliorate or prevent symptoms of hypertension in said patient.... Agent: Neurim Pharmaceuticals (1991) Ltd.
20120070500 - Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of alzheimer's disease and associated methods: Disclosed is a composition immunologically targeted to Alzheimer's disease (AD), the composition containing amine functionalized nanoparticles of Cerium oxide coated with polyethylene glycol and bearing an antibody specific for an amyloid-beta antigen associated with AD. The invention also includes a medication manufactured with the targeted nanoceria particles and methods of... Agent:
20120070502 - Methods of treating cancer: The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an... Agent:
20120070503 - Nanoparticle-based targeted drug delivery for in vivo bone loss mitigation: The present invention is directed to nanoparticle-based targeted drug delivery system for treatment of bone-loss. An enantiomeric phenothiazine is formulated into an in-vivo nanoparticle delivery system which may contain bone-targeting functionality. The nanoparticle formulations and their associated influence on whole bone porosity may now also be evaluated utilizing nuclear magnetic... Agent: Southwest Research Institute
20120070505 - Functional amphipilic molecule or macromolecule formulations with multiple compartments: The invention relates to novel functional amphiphilic molecule or macromolecule formulations with multiple compartments for transporting or targeting at least one therapeutic agent, in particular an antitumor agent, as well as to a method for preparing such formulations and to the use thereof.... Agent: Universite Bordeaux Segalen
20120070504 - Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of... Agent: Curemark LLC
20120070506 - Animal treatment: The present invention relates to a composition for an animal within a particular weight range including at least one non-steroidal anti-inflammatory drug (NSAID) compound and at least one mussel extract characterised in that the therapeutic dose of NSAID compound in the composition is substantially less than the usual therapeutic dose.... Agent: Bomac Research Limited
20120070507 - Compositions and methods for the treatment of soft tissue injury: Provided herein are compositions and methods for the treatment of soft tissue injury, sports-related injury, physical overuse of muscles, ligaments or joints, and trauma, traumatic stress or sudden jolts on bones and tissues in an individual. Described herein are pharmaceutical compositions comprising a vasoconstrictor and, optionally, a topical analgesic and... Agent: Matrilinex LLC
20120070508 - Methods, compositions, and devices for managing chlorine dioxide release: Certain exemplary embodiments can provide a system, machine, device, manufacture, circuit, composition of matter, and/or user interface adapted for and/or resulting from, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise and/or relate to, a composition comprising molecular matrix-residing chlorine dioxide and/or one or more... Agent: Dharma Ip, LLC
20120070510 - Wound and mucous membrane disinfectant: Aqueous wound and mucous membrane disinfectant containing a) octenidine dihydrochloride, and b) one or more active ingredients selected from the group ethanol, 1-propanol, 2-propanol, undecylene amidopropyl trimonium methosulfate, 3-(4-chlorophenoxy)-1,2-propanediol and/or sodium hydroxymethylglycinate and c) glycerin and/or 1,2-diols having 3 to 10 carbon atoms, and d) optionally surfactants, emulsifiers, solubilisers, pH... Agent:
20120070511 - Mitochondrial inhibitors and uses thereof: Compositions which modulate mitochondrial functions treat diseases associated with cells that are hyperactively using their endoplasmic reticulum. Screening assays identify agents which modulate mitochondrial functions.... Agent: University Of Miami
20120070512 - Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives: The invention relates to substituted 6-(2-hydroxybenzylamino)purines of general formula I, to their activity as cyclin-dependent kinases 2, 5, 7 and 9 inhibitors and to their use as medicaments, particularly in the treatment of disorders involving cell proliferation or inflammation. The invention further includes pharmaceutical compositions containing the substituted 6-(2-hydroxybenzylamino)purines.... Agent:
20120070513 - Method and composition for treating diabetic ketoacidosis: Methods of treating diabetic ketoacidosis are disclosed. The methods utilize an endothelin antagonist to treat diabetic ketoacidosis in mammals, including humans.... Agent:
20120070514 - Aromatase inhibitor: A substance is disclosed that can inhibit the activity of aromatase (an enzyme capable of converting androgen into estrogen) to thereby effectively treat and/or prevent a sex hormone-dependent disease such as breast cancer occurring in a female person after menopause, as well as a climacteric disorder in a male person... Agent: Kracie Pharma, Ltd.
20120070515 - Composition comprising the extract of anemarrhena asphodeloides bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder: The present invention relates to a composition comprising an extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same, as an active ingredient. In particular, the extract and compounds have the excellent inhibitory effects on adipocyte differentiation, and thus can be used in a pharmaceutical composition and functional... Agent: Ewha University- Industry Collaboration Foundation
20120070516 - Mycotoxin binding food and feed additives and processing aids, fungistatic and bacteriostatic plant protecting agents and methods of utilizing the same: Method is proposed useful to render harmless mycotoxins that contaminate food, animal feed and assist infection of plant hosts by microbial parasites, comprising binding mycotoxins by a novel adsorbent, consisting partially or in full of plant lignocellulosic biomass or isolated biomass components, e.g., acid hydrolysis lignin, enzymatic hydrolysis lignin, coniferous... Agent: Cubena, Inc.
20120070517 - Pharmaceutical composition containing herbal extract for prevention or treatment of nephritis: The present invention relates to a novel use of herbal extracts in a pharmaceutical composition for prevention and treatment of nephritis and, more particularly, to a pharmaceutical composition and a health functional food for prevention and/or treatment of nephritis that contains at least one herbal extract selected from the group... Agent:
20120070518 - Methods and compositions for treating psoriasis: The present invention is directed to topical compositions and methods for topically treating psoriasis comprising meisoindigo as an active ingredient. The topical compositions preferably further comprise skin penetration enhancers, pharmaceutical surfactants and solubility enhancers, oil phase components, aqueous phase components, emulsifiers, moisturizers, antioxidants, vitamins, lubricants, herbal extracts, preservatives, and other... Agent: Natrogen Therapeutics International, Inc.
20120070519 - Method for extraction of fractions containing pharmacologically active ingredients with less cytotoxicity from one or more plants: A method of obtaining one or more fractions from one or more plants is disclosed. The method includes subjecting one or more parts of the one or more plants to hydro-alcoholic extraction in presence of a water-insoluble solvent to obtain one or more extracts. The method further includes subjecting the... Agent: Bio-ved Pharmaceuticals, Pvt. Ltd.
20120070520 - Composition containing a bean extract for improving blood circulation and increasing vascular health: The present invention relates to a composition containing a bean extract extracted by low-concentration, low-grade alcohol or fractions thereof. The composition exhibits excellent effects in improving blood circulation, improving obesity, and preventing diabetes, hyperlipidemia and the like, and exhibits the effects of alleviating or treating the symptoms of diabetes, hyperlipidemia,... Agent:
20120070521 - Method of extraction from withania somnifera and one or more fractions containing pharmacologically active ingredients obtained therefrom: A method of obtaining one or more fractions from a plant material of Withania somnifera (WS) is disclosed. The method includes subjecting the plant material to hydro-alcoholic extraction in presence of a water-insoluble solvent to obtain at least one extract. The method further includes subjecting the at least one extract... Agent: Bio-ved Pharmaceuticals, Pvt., Ltd.03/15/2012 > 190 patent applications in 100 patent subcategories. listing by industry category
20120063997 - Delivery system with scaffolds: An injectable, agent delivery system comprising a composition comprising: (i) an injectable scaffold material comprising discrete particles, which are capable of interacting to form a scaffold; and (ii) a carrier comprising an agent for delivery. The product can have a pharmaceutical use or use in cosmetic surgery; in particular it... Agent: Regentec Limited
20120063998 - Method for treating psoriatic arthritis by administering an anti-il-12 antibody: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriatic arthritis.... Agent:
20120063995 - Non-ad5 adenoviral vectors and methods and uses related thereto: Oncolytic human adenoviral vectors and cells and pharmaceutical compositions including the vectors. Also provided are methods for using the vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, methods of producing an adenoviral vector are provided.... Agent: Oncos Therapeutics Oy
20120063996 - Novel nimesulide compositions: The present invention provides nanoparticulate nimesulide compositions. The compositions preferably comprise nimesulide and at least one surface stabilizer adsorbed on or associated with the surface of the nimesulide particles. The nanoparticulate nimesulide particles preferably have an effective average particle size of less than about 2000 nm. The invention also provides... Agent: Elan Pharma International Ltd.
20120063994 - Rtef-1 variants and uses thereof: Disclosed are variant RTEF-1 polypeptides having an RTEF-1 amino acid sequence with one or more internal deletions, wherein the polypeptides reduce VEGF promoter activity. Some of the RTEF-1 polypeptides include an amino acid sequence that is at least 80% identical to the contiguous amino acids of 1) amino acids 24... Agent:
20120063993 - Therapeutic and diagnostic conjugates for use with multispecific antibodies: Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector molecule which may be conjugated to one or more of the haptens, the spacer/carrier,... Agent: Immunomedics, Inc.
20120064001 - Anti-vegf antibody compositions and methods: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols... Agent: Peregrine Pharmaceuticals, Inc.
20120064000 - Human monoclonal antibodies against hendra and nipah viruses: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for... Agent: The Government Of The United Sates Of America, As Represented By The Secretary, Department Of Health
20120063999 - Psca: prostate stem cell antigen and uses thereof: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.... Agent: The Regents Of The University Of California
20120064002 - Enantiomer-pure (4s,8s)- and (4r,8r)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3n,6n,9n-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents: e
20120064003 - Complex folate-nota-ga68:
20120064004 - Isotopologues of thalidomide: Provided herein are thalidomide, which is enriched with isotopes such as deuterium. Pharmaceutical compositions comprising the isotopes-enriched compounds, and methods of using such compounds are also provided.... Agent:
20120064005 - Radiolabeled pde10 inhibitors: The present invention is directed to radiolabeled pyrimidinone compounds of general structural formula I which are useful as radiotracers for quantitative imaging of PDE10 in mammals.... Agent:
20120064008 - Compositions for the treatment of metastatic cancer and methods of use thereof: An in vivo assay for assessing the metastatic potential of cancer cells has been developed. This is a functional assay that also allows for screening of compounds that are selective for metastatic cancer. Metastatic cancer is established in animals by intravenous injection of metastatic cancer cells before treatments are tested.... Agent:
20120064007 - Methods of using sustained release aminopyridine compositions: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of... Agent:
20120064006 - Systems and methods for using physiological information: Systems and methods using a database of physiological information for the design, development, testing and use of therapeutics. In one aspect, the physiological information can include at least one of: hemodynamic monitoring information, pulmonary arterial pressure, cardiac output, heart rate, respiratory rate, peripheral vascular resistance, total peripheral resistance or dicrotic... Agent:
20120064009 - Methods of leukemia cell detection: Methods are provided for, inter alia, determining the presence of leukemia cells in a subject, determining the change or potential change in the number of leukemia cells in the subject with time, determining whether a tissue in a subject contains a plurality of leukemia cells or a plurality progenitor leukemia... Agent: The Regents Of The University Of Colorado, A Body Corporate
20120064010 - Ccr3 and its ligands are therapeutic and diagnostic targets for neovascular age-related macular degeneration: The results presented herein demonstrate the specific expression of CCR3 in CNV endothelial cells in humans with AMD, and despite the expression of its ligands, eotaxin-1, -2, and -3, neither eosinophils nor mast cells are present in human CNV. The genetic or pharmacological targeting of CCR3 or eotaxins as disclosed... Agent: University Of Kentucky Research Foundation
20120064012 - Uniform fluorescent microspheres with hydrophobic surfaces: Fluorescent microspheres for the measurement of blood flow are provided. The microspheres are substantially uniform in diameter and have a hydrophobic surface, which allows them to circulate more freely throughout bloodstream, while reducing immunogenicity, particle aggregation and bioaccumulation. The hydrophobic surface on each microsphere is generally comprised of polymeric material... Agent: Life Technologies Corporation
20120064011 - Preparation for external application: Preparations for external application to human and animal skin, comprising: a) a composition in the form of a fluid nanophase system, comprising the components of a1) at least one water-insoluble substance with a water solubility of less than 4 gram per liter, a2) at least one amphiphilic substance (NP-MCA), which... Agent: Bubbles And Beyond Gmbh
20120064013 - Foamable topical composition: A foamable composition for topical application, the composition comprising a water in oil emulsion which is devoid of gelling agents.... Agent:
20120064014 - Azeotrope-like compositions comprising 1-chloro-3,3,3-trifluoropropene: An azeotrope-like mixture consisting essentially of chlorotrifluoropropene and at least one component selected from the group consisting of a C1-C3 alcohol, a C5-C6 hydrocarbon, a halogenated hydrocarbon, methylal, methyl acetone, water, nitromethane, and combinations thereof.... Agent: Honeywell International Inc.
20120064015 - Food additive composition as an agent for reducing the adhesion of dental biofilms in sweetened products: The present invention relates to a food additive composition to be added to sugar or sweetened products containing cariogenic free sugars or by-products thereof, enabling a reduction of the adhesion of dental biofilms and the appearance of caries while strengthening the tooth and the dental support tissue. The present invention... Agent:
20120064016 - Active gases and treatment methods: A method of making an active gas by generating a glow discharge, non-thermal plasma, in a gas mixture of a carrier gas and a more readily ionisable gas. The gas mixture is exposed to water vapour at or downstream from the generator to form the active gas. The gas mixture... Agent:
20120064017 - Borinic compositions: A stabilized oral care composition comprising a borinic acid derivative, e.g., a borinic ester.... Agent: Colgate-palmolive Company
20120064018 - Aqueous copolymer dispersion of polysiloxane/polyurea, cosmetic composition comprising the same, method for cosmetic treatment and method for preparation: The invention relates to an aqueous dispersion of polysiloxane/polyurea copolymer and a method for preparation thereof comprising the steps: solubilisation of the copolymer and silane in an organic phase, preparation of an aqueous phase comprising one or more surfactants, mixing the organic and aqueous phase followed by emulsification. The invention... Agent: L'oreal
20120064019 - Cosmetic composition for making-up and/or caring for keratin materials and make-up method: The invention relates to a composition containing the following components in a physiologically acceptable medium, namely: a) a siloxane resin comprising at least 80 mole % of units (i) (R3Si01/2)a and (ii) (SiO4/2)b, wherein R′ represents independently an alkyl group having between 1 and 8 carbon atoms, an aryl group,... Agent: L'oreal
20120064020 - Novel composition: The present invention relates to a composition comprising N2-(1-oxohexadecyl)-lysyl-valyl-lysine or a salt thereof, spent grain wax and/or conjugated linoleic acid. The compositions are particularly useful for the treatment or co-treatment of rosacea and its symptoms. Furthermore the invention relates to a stable W/O emulsion pre-mix comprising the composition according to... Agent:
20120064022 - Cyclosiloxane-substituted polysiloxane compounds, compositions containing the compounds and methods of use thereof: Provided herein are cyclosiloxane-substituted polysiloxane compounds, compositions that include the polysiloxane compounds, and methods for preparation and use of the polysiloxane compounds. Provided are mechanical lubricant compositions, hydraulic fluid compositions, anti-foam compositions, water repellant agent compositions, release agent compositions, personal care compositions, cosmetic compositions, household care compositions and drug delivery... Agent:
20120064023 - Agents for fibers containing keratin, containing at least one special cross-linked amphiphilic, anionic polymer and at least one further special non-cross-linked amphiphilic anionic polymer: Agents for treating fibers containing keratin containing in a cosmetically acceptable carrier (a) at least one cross-linked, amphiphilic, anionic polymer, comprising at least one structural unit of formula (I) and at least one structural unit of formula (II); and (b) at least one non-cross-linked, amphiphilic, anionic polymer, comprising at least... Agent:
20120064024 - Precipitated polymers: The present invention relates to precipitation polymers which comprise, in copolymerized form, 80 to 99.9% by weight of at least one nonionic water-soluble monomer a) and 0.1 to 20% by weight of a monomer b) carrying amide or urea groups. The invention further relates to the use of these polymers... Agent: Basf Se
20120064025 - Quinazolinone modulators of nuclear receptors: Compounds, pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided. In particular, quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors.... Agent: Exelixis, Inc.
20120064026 - Method for preventing and controlling biofouling on marine objects: A method for preventing and controlling the formation of biofouling on an object that is immersed or partially immersed in a water environment in which there is one or more organic or inorganic compounds capable of releasing gas, comprising the step of applying to the surface of the object a... Agent:
20120064027 - Absorbable adhesive paste: An absorbable adhesive paste contains absorbable solid carboxy-bearing microparticles dispersed in a continuous phase of an alkoxyalkyl cyanoacrylate. The paste may contain a soluble absorbable polymeric viscosity modifier and at least one bioactive agent to maximize the effective application as a cover for compromised tissues and wounds or as sealants,... Agent:
20120064029 - Compositions for treating nervous system conditions: Compositions for treating nervous system conditions. In at least one embodiment of a stem cell conditioned medium of the present disclosure, the stem cell comprises a cell culture supernatant containing at least one factor capable of exerting effective neuroprotection to treat a mammalian neural injury or insult, the cell culture... Agent:
20120064030 - Methods of treating nervous system conditions: Methods of treating nervous system conditions. In at least one embodiment of a method of treating a mammalian patient having a neuronal injury or insult of the present disclosure, the method comprises the step of administering a therapeutically-effective dose of a stem cell conditioned medium to a mammalian patient, the... Agent:
20120064028 - Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin: The present invention relates to a method to increase oligodendrocytes and oligodendrocyte precursor cells through administration of prolactin or a prolactin inducing agent.... Agent: Stem Cell Therapeutics Corp.
20120064031 - Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases: The present invention relates to cells capable of expressing IDO, nucleic acid constructs for expression of IDO, cells comprising said constructs and methods of utilizing said cells in the treatment of diseases. In particular the present invention relates to cells which expresses IDO in the absence of exposure to IFN-gamma,... Agent:
20120064036 - Methods of administration of thrombopoietin agonist compounds: The embodiments provide methods of administering a high dose or a loading dose of a TPO modulator to a subject. The embodiments further provide methods of treating thrombocytopenia and/or neutropenia in a subject. Additionally, the embodiments further provide methods of increasing platelet production and/or enhancing the number of peripheral blood... Agent:
20120064033 - Modulation of regulatory t cells by human il-18: The present invention relates to compositions and methods for modulating the presence and/or activity of regulatory T cells in a subject.... Agent: Trustees Of The University Of Pennsylvania
20120064032 - Novel hydroxamates as therapeutic agents: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also... Agent: Pharmacyclics, Inc.
20120064034 - Peptidomimetic protease inhibitors: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds... Agent: Vertex Pharmaceuticals Incorporated
20120064035 - Vaccine immunotherapy: A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A... Agent: Irx Therapeutics, Inc.
20120064037 - Methods for treating diseases and hcv using antibodies to aminophospholipids: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind... Agent: Board Of Regents, The University Of Texas System
20120064038 - Epidermal growth factor receptor (egfr) and methods of use in adenoviral-associated virus type 6 (aav6) transduction: Comparative gene analysis (CGA) was combined with pathway visualization software to identify a positive correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression. It was found that EGFR is necessary for vector internalization and functions as a co-receptor for AAV6. The identification and characterization of AAV6's requirement of... Agent: The United States Of America, As Represented By Th Secretary, Department Of Health And Human Service
20120064050 - Tissue engineering of lung: The present invention relates to compositions comprising a decellularized tissue. The present invention also provides an engineered three dimensional lung tissue exhibiting characteristics of a natural lung tissue. The engineered tissue is useful for the study of lung developmental biology and pathology as well as drug discovery.... Agent: Yale University
20120064039 - Use of guanylyl cyclase c agonists to suppress appetite: Compositions comprising a guanylyl cyclase C agonist formulated for sustained specific release of an amount effective to suppress appetite when administered orally to an individual are disclosed. Compositions comprising a guanylyl cyclase C agonist formulated for intravenous delivery in an amount effective to suppress appetite when administered intravenously to an... Agent: Thomas Jefferson University
20120064051 - Infant and young children feeding formula comprising probiotics for infants and young children: The present invention relates to the field of infant and young children nutrition. In particular, the present invention relates to infant and young children feeding formulas comprising probiotic micro-organisms to be administered to infants and young children older than 6 months. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such... Agent: Nestec S.a.
20120064052 - Hydrolysis resistant organomodified trisiloxane surfactants: are described wherein the substituents on the differing M and M′ groups, in conjunction with pendant polyalkylene oxide substituents on the D group render the surfactant resistant to hydrolysis under either basic or acidic conditions outside the pH range of 6.0 to 7.5. The compositions are useful in agricultural, household... Agent: Momentive Performance Materials Inc.
20120064045 - Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency: The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury-due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional... Agent:
20120064041 - Efficient generation of neurally-induced mesenchymal stem cells and applications thereof: The present invention provides methods and compositions for reprogramming mammalian mesenchymal stem cells, as well as to methods for using such cells, for example, to prevent or treat various injuries, diseases, and disorders in human and non-human animals.... Agent:
20120064046 - Maintenance and propagation of mesenchymal stem cells: Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated state in the absence of feeder cells and applications of the same.... Agent: The Board Of Trustees Of The University Of Arkansas
20120064044 - Methods of treating edema related to ischemia-reperfusion: Methods are described for preventing or reducing edema related to ischemia-reperfusion by treating the organ or tissue being transplanted with an aminoalkyl glucosaminide phosphate.... Agent:
20120064040 - Serum free culture medium and supplement: Provided herein is a chemically defined method of endothelial cell (EC) derivation from embryonic stem cells (ESC). These progenitor cells are capable of low-density lipoprotein uptake, an important function of EC, and also express EC specific markers. By using chemically defined culture conditions, the reproducibility of the derivation as well... Agent: The Regents Of The University Of California
20120064043 - Tissue engineering scaffolds and methods of use: Provided herein are methods of producing a meniscus scaffold to remove material and increase the pore size and porosity therein. In some embodiments, methods include seeding the tissue with allogeneic or autogeneic cells. Bioscaffolds produced by the processes described herein are also provided, as are methods of treating a subject... Agent:
20120064048 - Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Reprogramming factor, in particular, by targeting natural antisense polynucleotides of a Reprogramming factor. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with... Agent: Opko Curna, LLC
20120064047 - Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure: The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells in cardiac indications.... Agent: Regents Of The University Of Minnesota
20120064049 - Use of stem cells from hair root sheaths and keratinocyte precursor cells for the regeneration of aged skin: The present invention relates to the use of stem cells from hair root sheaths and/or keratinocyte precursor cells for the regeneration of aged but otherwise healthy and non-injured skin for the cosmetic purposes and for the prevention of skin diseases. In addition, the invention is directed to a cosmetic method... Agent: Skinrephair Ltd.
20120064042 - Xeno-free generation of tissue-specific progenitor cells: The invention relates to purified, tissue-specific progenitors, methods of making and using such tissue-specific progenitors.... Agent:
20120064053 - Baby lotion: The skin/body lotion composition of the present invention utilizes all natural plant derived components as a method for conditioning and moisturizing the skin. The invention provides good moisturizing and gives a smooth, soft touch feel upon conditioning of the skin, leaving no oily or greasy residue on the skin and... Agent:
20120064055 - Methods for treating lysosomal acid lipase deficiency in patients: The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency... Agent: Synageva Biopharma Corp.
20120064054 - Pharmaceutical compositions active in preventing, stabilizing and treating alzheimer's disease: The present invention relates to pharmaceutical compositions active in preventing, stabilizing and treating Alzheimer's disease and cognitive dysfunctions related thereto.... Agent:
20120064056 - Dichloracetate in combination with clinically high levels of cardioprotective or hemodynamic drugs: The present invention provides compositions and methods for using cardioprotective or hemodynamic drugs in combination with dichloroacetate enabling usage of cardioprotective or hemodynamic drugs at concentrations higher than used in normal clinical practice without increasing deleterious side effects normally associated with the cardioprotective or hemodynamic drug, thereby conferring added clinical... Agent: The Governors Of The University Of Alberta Tec Edmonton
20120064057 - Novel adamts-13 mutant: The present invention provides a method of enhancing an enzymatic activity of ADAMTS-13 and/or a method of reducing reactivity to an anti-ADAMTS-13 neutralizing antibody as well as a mutant of ADAMTS-13 prepared by the methods. The method of the present invention is characterized by substituting at least one charged amino... Agent: Juridical Foundation The Chemo-sero-therapeutic Research Institute
20120064058 - Compositions for protein-based dietary products: A human use dietary product composition to reduce fat body mass without substantially reducing lean body mass, in obese or overweight patients includes a protein component and an amino acid additional component, the additional component containing a determined amount of lysine and/or tryptophan such that on the whole lysine and... Agent: Italfarmacia Srl
20120064059 - Fusion proteins: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive... Agent: Syntaxin Ltd.
20120064061 - Adhesive composition comprising tannin, poly(ethylene glycol), and water, lower alcohol or mixture thereof: Provided is an adhesive composition disclosed herein includes tannin, poly(ethylene glycol) and water. The adhesive composition has little toxicity, allows adhesion even in the absence of a thermosetting curing agent, and is hardly soluble in water to show moisture resistance, unlike known tannin adhesives. Therefore, the adhesive composition may be... Agent: Korea Advanced Institute Of Science And Technology
20120064064 - Antigen-binding proteins: The present invention relates to antigen binding proteins comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises an epitope binding domain linked to the n-terminus of CH1-CH2-CH3, and the light chain comprises an epitope binding domain linked to the n-terminus of CL, wherein one... Agent:
20120064063 - Compositions of f(ab')2 antibody fragments: The present invention is directed to a pharmaceutical composition comprising F(ab′)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically acceptable carrier. It is also directed to a method for the production of a... Agent: Instituto Bioclon, S.a. De C.v.
20120064060 - Compound having s1p receptor binding potency and use thereof: (wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain; L represents a hydrogen atom or a substituent; X represents amino which may have a... Agent: Ono Pharmaceutical Co., Ltd.
20120064062 - Inhibitors of bacterial plasminogen activators: Organic compounds showing the ability to inhibit bacterial omptin proteases, specifically Yersinia pestis plasminogen activator (Pla) are disclosed. The disclosed Y. pestis plasminogen activator inhibitor compounds are useful for treating, preventing, or reducing the spread of infections by Y. pestis.... Agent:
20120064074 - Antigen binding domains: A process for the production of an antigen specific antigen binding domain using a transformed host containing an expressible DNA sequence encoding the antigen specific antigen binding domain, wherein the antigen specific antigen binding domain is derived from a variable region of the immunoglobulin isotype NAR found in fish.... Agent: University Of Maryland, Baltimore
20120064072 - Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor: A method of treating cancer comprising: (a) identifying a patient having cancer that initially responded to IRS1 agent therapy and that has resumed progression; (b) administering an effective regimen comprising the same or a different IRS1 agent and an IGF-1 R inhibitor administered together or sequentially.... Agent:
20120064073 - Il-17 homologous polypeptides and therapeutic uses thereof: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide... Agent:
20120064070 - Modulation of nkg2d: The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.... Agent: The Regents Of The University Of California
20120064066 - Monoclonal antibodies to hepatocyte growth factor: The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.... Agent: Galaxy Biotech, LLC
20120064065 - Safe and functional humanized antibodies: The present invention is related to safe and functional antibodies for the therapeutic and diagnostic use in the treatment of an amyloidosis, a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease.... Agent:
20120064067 - Therapeutic use of anti-cs1 antibodies: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including... Agent: Abbott Biotherapeutics Corp.
20120064068 - Therapeutic use of anti-cs1 antibodies: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including... Agent: Abbott Biotherapeutics Corp.
20120064069 - Therapeutic use of anti-cs1 antibodies: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including... Agent: Abbott Biotherapeutics Corp.
20120064071 - Treatment of cancer: Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.... Agent: Cerulean Pharma Inc.
20120064075 - Chimeric factor vii molecules with enhanced half life and methods of use: The present invention relates to novel proteins and methods of using chimeric Factor VIIa polypeptides.... Agent: The University Of North Carolina At Chapel Hill
20120064076 - Methods and composition to regulate iron metabolism: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in... Agent:
20120064077 - Stable and soluble antibodies inhibiting tnf alpha: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, and low immunogenicity. Said antibodies are designed for the diagnosis... Agent: Esbatech, An Alcon Biomedical Research Unit LLC.
20120064082 - Aminoacyl trna synthetases for modulating hematopoiesis: Hematopoietic-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof, as well as compositions comprising related agents such as antibodies and other binding agents. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of hematopoiesis.... Agent: Atyr Pharma, Inc.
20120064081 - Anti-kir3d antibodies: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.... Agent: Innate Pharma
20120064079 - Compositions and methods for preventing erythropoietin-associated hypertension: The inventors have discovered that both soluble erythropoietin-binding protein and antibodies against the erythropoietin-binding protein, when they are administered to a mammal along with erythropoietin (Epo), prevent or reduce the blood pressure increase normally caused by erythropoietin, while not affecting the hematocrit increase that is the purpose of Epo treatment.... Agent:
20120064080 - Human ly6-big molecules and methods of use: The present invention is directed to human Ly6-BIG molecules and their use in diagnostic, prognostic, and treatment methods for colon, lung and other cancers, in preventing the reoccurrence of such cancers, and in diagnostic, prognostic, and treatment methods for autoimmune disorders and AIDS.... Agent: Biogen Idec Ma Inc.
20120064078 - Novel tumor biomarket: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence or metastasis of cancer by detecting plasma Hsp90α having the amino acid sequence of SEQ ID No.1 as a tumor marker. In addition, the present invention also relates to a... Agent: Tsinghua University
20120064084 - Signal transduction protein tab2: A novel signal transducer TAB2 which acts as an adapter molecule of TRAF6 and TAK1 and mediates the activation of TAK1 in the signal transduction of IL-1 was isolated. TAB2 induced the activation of NF-κB and JNK by IL-1. The signal transduction by IL-1 was inhibited by inhibiting the signal... Agent:
20120064083 - Therapeutic use of anti-cs1 antibodies: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including... Agent: Abbott Biotherapeutics Corp.
20120064085 - Anti-influenza m2e antibody: Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza.... Agent: Los Alamos National Security, LLC
20120064086 - High concentration antibody and protein formulations: The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders... Agent: Genentech, Inc.
20120064089 - Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration: Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CXCL16 and/or the chemokine receptor CXCR6. Another method comprises the step of... Agent: Morehouse School Of Medicine
20120064091 - Dysfunction of the mitochondrial respiratory chain, methods for diagnosis, treatment and follow-up: The invention relates to a method, of assessing whether a subject is affected with or at risk for developing a dysfunction of the mitochondrial respiratory chain, the method comprising determining the concentration of fibroblast growth factor 21 (FGF21) in a biological sample from the subject, and comparing it to the... Agent: University Of Helsinki
20120064088 - Methods of treating aneurysm: The present invention is directed to a method for treating aneurysms in vascular tissue. The method includes administering a bisphosphonate compound to a subject in an amount which is effective against the formation or progression of aneurysm, or which is effective to induce regression of an established aneurysm. In alternative... Agent: Wisconsin Alumni Research Foundation
20120064087 - Methods to diagnose a required regulation of trophoblast invasion: Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-β3, receptors of cytokines of the TGfβ family, or HIF-1α.... Agent: Mount Sinai Hospital
20120064092 - Novel target for regulating multiple sclerosis: Methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). Methods are also provided for screening for agents that find use in treating demyelinating inflammatory disease in a subject.... Agent:
20120064090 - Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug: Provided are a pharmaceutical composition which enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, wherein the cancer has resistance to the molecular target drug, and a cancer therapeutic agent effective against a cancer having resistance to a molecular target drug, such as... Agent: Kringle Pharma Inc.
20120064093 - Antibody: The invention relates to antibodies to Aspergillus species and to methods of producing those antibodies. The invention also relates to the use of such antibodies in identifying the presence of the Aspergillus species and to methods of treating an infection with the Aspergillus species.... Agent:
20120064094 - Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders: The invention relates to serotonin 5-HT3 receptor antagonists or inhibitors of serotonin 5-HT3 receptor gene expression for use in the treatment of a lesional vestibular disorder.... Agent: Inserm (institut National De La Sante Et De La Recherche Medicale)
20120064096 - Btla antibodies and uses thereof: The invention relates to BTLA antibodies that block BTLA-HVEM interaction and uses thereof.... Agent: Universite De La Mediterranee
20120064095 - Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.... Agent:
20120064097 - Enhanced binding of pro-inflammatory cytokines by polysaccharide-antibody conjugates: We provide monoclonal antibodies against interleukin-1β and tumor necrosis factor-α that remain biologically active in vitro when conjugated to high molecular weight polysaccharides. We report enhanced binding of these cytokines when their monoclonal antibodies are conjugated to alginate compared to non-conjugated monoclonal antibodies. In cell assays, polysaccharide-antibody constructs of the... Agent:
20120064098 - Intracoronary device and method of use thereof: Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems.... Agent: Advanced Cardiovascular Systems, Inc.
20120064100 - Biomarkers and uses thereof: The present invention provides markers of regulatory T (Treg) cells, preferably, cell surface markers of Treg cells and uses of those markers or compounds that bind thereto to identify or isolate Treg cells or to diagnose/prognose/treat/prevent Treg-mediated conditions. The present invention also provides methods for identification and/or isolation of Treg... Agent:
20120064101 - Compounds and methods useful for detection and treatment of cancer: The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumours and HNPCC associated tumours. The compounds are useful for... Agent:
20120064099 - Compounds that inhibit nfkb and bace1 activity: The present invention relates to compounds with activity as BACE1 and NFκB modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment of diseases related to dysfunction of cell proliferation, the immune system and/or inflammation using such... Agent: The Trustees Of Columbia University In The City Of New York
20120064102 - Peptide inducing xage-1b-specific immune reaction and utilization of same: The object of the present invention is to clarify functions of XAGE-1b and to develop a vaccine therapy for cancer based on XAGE-1b. Humoral immunity or cellular immunity is induced against XAGE-1b in lung cancer, by use of a peptide comprising an amino acid sequence of any one of (a)... Agent: National University Corporation Okayama University
20120064104 - Combinations including pneumococcal serotype 14 saccharide: Meningococcal lipooligosaccharide and pneumococcal serotype 14 capsular saccharide share an antigen that can cross-react with human tissue. The invention provides various ways of minimising the production of autoreactive antibodies when these two antigens are co-administered.... Agent: Novartis Ag
20120064103 - Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates: An immunogenic composition comprising: (i) a conjugated pneumococcal capsular saccharide; and (ii) a meningococcal factor H binding protein (fHBP) antigen, and not including meningococcal outer membrane vesicles, is useful for immunising a subject against bacterial meningitis.... Agent: Novartis Ag
20120064105 - Engineered type iv pilin of clostridium difficile: The present invention relates to engineered Clostridium difficile type IV pilin (tfp) genes, type IV pilin proteins which can serve as a diagnostic marker for identification of patients infected with C. difficile, and vaccines comprising type IV pilin proteins, antigenic fragments and variants thereof for therapeutic interventions.... Agent: University Of Maryland, Baltimore
20120064106 - Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa: The invention provides compositions and fusion proteins comprising a flagellin adjuvant and a Pseudomonas aeruginosa antigen. The invention further provides pharmaceutical formulations and methods for inducing an immune response against P. aeruginosa (e.g., to prevent and/or treat P. aeruginosa infection).... Agent:
20120064107 - Compositions and methods for treatment of autoimmune and other disease: Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.... Agent: Cerulean Pharma Inc.
20120064108 - Glycoconjugate vaccines: Glycoconjugate vaccines and methods of preparing and using the same are described.... Agent: The Brigham And Women's Hospital, Inc.
20120064109 - Immunogenic composition and uses thereof: The present invention provides an immunogenic composition comprising an antigen and a dendritic cell targeting component. A charged group is covalently attached to a dendritic cell ligand and is electrostatically associated with the dendritic cell targeting component.... Agent: The University Of Melbourne
20120064110 - Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin: This invention relates to compositions and methods that can be used immunize a subject against influenza. Generally, the compositions and methods include peptides obtained or derived from human influenza A virus hemagglutinin.... Agent: Selecta Biosciences, Inc.
20120064111 - Attenuated vaccines for non-segmented negative sense rna viruses: The invention relates to an attenuated non-segmented negative-sense RNA virus characterized by at least one mutation in the L gene wherein the mutation reduces viral replication, the methods of manufacturing and methods of use.... Agent: President And Fellows Of Harvard College
20120064113 - Novel attenuated poliovirus: A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2aCD155... Agent: The Research Foundation Of State University Of New York
20120064112 - Recombinant newcastle disease viruses useful as vaccines or vaccine vectors: The present invention concerns an antigenomic RNA of Newcastle Disease virus (NDV) carrying one or more foreign genes inserted before NP gene, between P and M genes, and/or between HN and L genes. The invention is also directed toward a cDNA encoding a recombinant antigenomic RNA having one or more... Agent: The University Of Maryland, College Park
20120064114 - Use of e. coli surface antigen 3 sequences for the export of heterologous antigens: The present invention provides an export signal system based on E. coli CS3 antigen for directing the secretion of foreign antigens from host cells. In particular, the invention describes genetic constructs encoding fusion proteins that contain a CS3 export signal fused to at least one heterologous amino acid sequence. Attenuated... Agent: Emergent Product Development United Kingdom
20120064115 - Recombinant virus-like particles encoded by multi-gene vector: The invention describes novel virus-like particles for use as vaccines, diagnostic tools and R&D tools based on recombinant DNA and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected... Agent:
20120064116 - Influenza nucleic acid molecules and vaccines made therefrom: Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotypes using the vaccines that are provided.... Agent:
20120064117 - Tetravalent influenza vaccine and use thereof: Disclosed herein is the finding that baculovirus display of multiple influenza virus hemagglutinin (HA) proteins elicits broadly reactive immune responses against influenza. Thus provided herein are recombinant baculovirus vectors having a first, second, third and fourth nucleic acid sequence, each encoding an influenza hemagglutinin (HA) fusion protein. The first, second,... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education
20120064118 - Bacteria strains having a high anti-inflammatory activity: The present invention relates to probiotic bacteria strains having a high anti-inflammatory activity. The present invention relates to bacteria strains as strongly inducers of Interleukin-10 (IL-10) production. In particular, the present invention relates to the anti-inflammatory activity shown by said bacteria strains due to its enhancement of IL-10 production in... Agent: Probiotical S.p.a.
20120064119 - Neisserial vaccine compositions comprising a combination of antigens: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane... Agent: Glaxosmithkline Biologicals S.a.
20120064120 - Neisserial vaccine compositions comprising a combination of antigens: The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane... Agent: Glaxosmithkline Biologicals S.a.
20120064121 - Pyridine compounds for inflammation and immune-related uses: The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.... Agent: Synta Pharmaceuticals Corp.
20120064122 - Treatment of autoimmune inflammation using mir-155: The present disclosure relates to the finding that microRNA-155 plays a role in the development and activity of CD4+ T cells. CD4+ T cell development and function, particularly TH17 and TH1 T cell development, can be modulated by delivery of microRNA-155 (miR-155) or antisense miR-155 to target CD4+ cells or... Agent:
20120064125 - Agr-mediated inhibition of methicillin resistant staphylococcus aureus: The present invention involves the use of activators of bacterial Agrquoroum-sensing systems to prevent or reverse biofilm formation in methicillin resistant Staphylococcus aureus (MRSA), or to restore sensitivity of MRSA bio films to antibiotics.... Agent:
20120064132 - Antibacterial medical equipment and method for producing the same: An antibacterial medical equipment characterized in that inositol phosphate is bonded to a Ca compound of a medical equipment whose surface is at least coated with a layer of the Ca compound, or a medical equipment comprising the Ca compound. The antibacterial medical equipment as described above, wherein silver ions... Agent: Meiji University
20120064123 - Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye: The present invention is directed to a topical ophthalmic composition for a liquid comprised of clear colloidal polar nanolipids delivered in submicron sized particles (Nanopids™), aqueous colloidal lubricants, aqueous polymers, emulsifies, and a unique stabilizing buffer system, which undergoes a liquid-gel phase transition in the eye. Said composition is designed... Agent:
20120064127 - Composition for improving membrane composition and functioning of cells: the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin... Agent: N.v.nutricia
20120064126 - Dry powder formulations and methods for treating pulmonary diseases: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.... Agent: Pulmatrix, Inc.
20120064129 - Gastric retained gabapentin dosage form: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.... Agent: Depomed, Inc.
20120064124 - Macrolide dosage forms: Provided is a drug delivery composition comprising at least one polymer and at least one active agent; wherein the active agent is present in crystalline form on at least one region of an outer surface of the composition and wherein active agent surface content is adjusted to provide a selected... Agent: Micell Technologies, Inc.
20120064130 - Method for impregnation with supercritical co2: The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterised in that said method includes the following consecutive steps: a) mixing the active substance and the nonporous polymer pharmaceutical carrier, the pharmaceutical carrier being in a solid form and insoluble... Agent: Pierre Fabre Medicament
20120064133 - Multiparticulate controlled-release selective serotonin reuptake inhibitor formulations: Multiparticulate controlled-release selective serotonin reuptake inhibitor (SSRI) formulations for oral administration, which comprise subunits of a SSRI or a pharmaceutically acceptable salt thereof which are not coated with a rate-controlling polymer, are provided. Methods for preparation and use of these formulations are also provided.... Agent:
20120064128 - Nano-metallic alloy delivery system for treatment of infected cells and legions: A system for delivering nano-metallic alloys to infected cells in a patient is disclosed. The nano-metallic alloy may be formed from binary, triple, or quadruple elemental compositions complexed in predetermined percentages of monosodium phosphate monohydrate and disodium phosphate heptahydrate. The nano-metallic alloy may be capable of eliminating infectious microorganisms within... Agent: University Of North Carolina At Greensboro
20120064131 - Silver-based inorganic antimicrobial agent and method for preparing the same: Disclosed are a powder of a silver-based inorganic antimicrobial agent with superior dispersability or water permeability, composed of silver-supporting hexagonal zirconium phosphate, and an antimicrobial product and a water processing material using the silver-based inorganic antimicrobial agent powder. The silver-based inorganic antimicrobial agent containing hexagonal zirconium phosphate crystals, which has... Agent:
20120064136 - Anti-aging and wrinkle treatment methods using nanoemulsion compositions: The present invention relates to methods for treating, preventing, minimizing, and/or diminishing signs of aging in the skin comprising administering to the subject in need thereof a nanoemulsion composition.... Agent: Nanobio Corporation
20120064135 - Benzoyl peroxide composition, methods for making same, and pharmaceutical or cosmetic formulations comprising same, and uses thereof: The present invention relates to the preparation of compositions comprising benzoyl peroxide, with or without other additional active ingredients. The process involves introducing benzoyl peroxide, along with any other active ingredients present, into a fatty substance that contains and protects the ingredients that would otherwise be unstable when in contact... Agent: Norac Pharma
20120064134 - Color enhancement utilizing up converters and down converters: A light emitting composition including first color emitters and second color emitters. The first color emitters are configured to emit, upon exposure to an energy source, visible light at a target color in response to absorption of energy across a first band of wavelengths. The second color emitters are configured... Agent: Immunolight, LLC
20120064137 - Two-layer separate type hair cosmetic composition: l
20120064138 - Biocidal composition: The present invention relates to a biocidal composition comprising an inorganic compound and a polymer where the inorganic compound has been prepared using a controlled precipitation technique. The biocidal compositions overcome the settling and agglomeration problems of conventional inorganic biocidal compositions and offer enhanced activity, consistency, and stable long term... Agent: Harman Technology Limited
20120064139 - Antimicrobial sucralfate paste methods and compositions: Methods for the prevention and treatment of infection, preferably antibiotic resistant wound infection, using a paste formed by the reaction of sucralfate with an acid component are provided. Methods of preparing stable sucralfate compositions are disclosed. Compositions of and products containing the sucralfate paste are also described.... Agent:
20120064140 - Composite nanogranules from polymer/inorganic nanoparticles, preparation method thereof and use of the same: Composite nanogranules from polymer/inorganic nanoparticle, especially first composite nanogranules which are formed from first polymer and inorganic nanoparticles, second composite nanogranules which are obtained by forming second polymer on the first composite nanogranules, third composite nanogranules which is obtained by forming third polymer on the second composite nanogranules, and Nth... Agent: Wuxi Now Materials Corp.
20120064141 - Drug-coated balloon with location-specific plasma treatment: Method of coating an expandable member, e.g. balloon, is provided, the method comprising providing an expandable member having an outer surface. The method includes a plasma treatment with a supply of gas performed on at least a portion of the outer surface of the expandable member. A therapeutic agent is... Agent: Abbott Laboratories
20120064142 - Polymeric pharmaceutical dosage form in sustained release: This invention relates to a polymeric pharmaceutical dosage form for the delivery, in use, of at least one pharmaceutical composition in a rate-modulated and site-specific manner. The dosage form comprises a biodegradable, polymeric, scaffold incorporating loaded with at least one active pharmaceutical ingredient (API). The polymer or polymers making up... Agent: University Of The Witwatersrand, Johannesburg
20120064143 - Inhibition of mammalian target of rapamycin: Disclosed are microcapsules that include an inhibitor of the mammalian target of rapamycin (mTOR) within the microcapsules, and pharmaceutical compositions and kits that include the microcapsules. Also disclosed are methods for treating or preventing an age-related disease, condition, or disorder in a subject that involve administering to a subject a... Agent: The Board Of Regents Of The University Of Texas System
20120064144 - Method of treating eczema: The present invention relates to the treatment of eczema. More specifically, the invention relates to a new method of treating eczema through the epicutaneous route. In particular, the method of the invention comprises applying to a non eczematous area of the skin of the subject a skin patch device, comprising... Agent:
20120064145 - Wound dressing: The present invention discloses a wound dressing which may be a double-layer wound dressing, comprising a polymer material layer in combination with anti-infective antibiotics or anti-infective Chinese herb medicine at the upper layer of the wound dressing, and a porous carbon material layer capable of loading with skin-associated epithelial cells... Agent: China Medical University
20120064146 - Wound care device: A wound care device for local treatment of pain in a wound, said device comprising an active pain relieving composition, the device being constructed in such a manner that the pain killing agent is released to the wound in such a way that substantially no effective systemic plasma concentration of... Agent: Coloplast A/s
20120064147 - Agent for improving tissue penetration: The invention concerns a pharmaceutical preparation which improves penetration of active substances through the tissue membrane or barrier of the target organ.... Agent: Max-planck Gesellschaft Zur Foerderung Der Wissenshaften E.v.
20120064150 - Biocompatible materials containing stable complexes of tsg-6 and hyaluronan and method of using same: The present invention provides a biocompatible material in the form of a solid, a water insoluble cross-linked gel or a liposome, which contains a stable comples of TNF-stimulated gene 6 protein (TSG-6) and hyaluronan.... Agent: New York University Polytechnic Institute Of Nyu
20120064151 - Enhanced immune response in avian species: The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the avian species. The method is particularly effective for protecting a member of the avian species from infectious disease and treating animals inflicted with infectious disease.... Agent: Bayer Animal Health Gmbh
20120064149 - High-clarity aqueous concentrates of 4-hexylresorcinol: The present invention relates to hexylresorcinol/water concentrates that are high in clarity, easily handled, and readily blended with other ingredients to form skin care compositions.... Agent:
20120064148 - Ph-responsive liposome: The present invention uses pH-responsive liposomes comprising, as constituent lipids thereof, a cationic amphiphilic molecule and at least one of an anionic amphiphilic molecule and a twitterionic amphiphilic molecule, wherein the liposomes, when dispersed in an aqueous medium, have a positive zeta potential in an acidic environment where the dispersion... Agent: Bionanosheeter Co., Ltd.
20120064153 - Compositions and methods for treating centrally mediated nausea and vomiting: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.... Agent: Helsinn Healthcare Sa
20120064154 - Solid drug for oral use: o
20120064155 - Oral pharmaceutical composition for use in respiratory diseases: A modified-release oral pharmaceutical composition in capsules with microspheres contains loratadine, phenylephrine and pharmaceutically acceptable excipients. The composition has immediate bioavailability, with plasmatic concentration values within the therapeutic window with a uniform, continuous release. A method for the production of the composition and a method for treatment as a nasal... Agent: Laboratorios Senosiain S.a. De C.v.
20120064156 - Pharmaceutical compositions for the coordinated delivery of nsaids: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe... Agent:
20120064158 - Dissolution properties of drug products containing olmesartan medoxomil: A pharmaceutical tablet containing olmesartan medoxomil and amlodipine besylate, which has improved dissolvability. Said composition contains (A) olmesartan medoxomil and (B) amlodipine besylate as active ingredients and (C) a calcium-containing additive. A method of improving the dissolution properties of a pharmaceutical composition containing olmesartan medoxomil and amlodipine besylate by using... Agent: Daiichi Sankyo Company, Limited
20120064159 - Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen: Multilayer tablets of a non-steroidal anti-inflammatory drug (NSAID) and/or acetaminophen for oral administration containing an immediate release layer or layers containing a NSAID and/or acetaminophen and/or a second therapeutic agent and an extended release layer containing a NSAID and/or acetaminophen are provided. Multilayer tablets containing an additional immediate and/or extended... Agent: Aptapharma, Inc.
20120064157 - Pharmaceutical composition and administrations thereof: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders and mini-tablets and methods for treating cystic fibrosis employing the pharmaceutical composition.... Agent: Vertex Pharmaceuticals Incorporated
20120064160 - Fibrate-statin combinations with reduced fed-fasted effects: This invention discloses an orally administered pharmaceutical composition for the treatment of elevated levels of cholesterol and related conditions comprising a statin and fenofibrate in the form of microparticles of solid fenofibrate that are stabilized by phospholipid as a surface active substance, wherein a therapeutically effective amount of the composition... Agent: Jagotec Ag
20120064162 - Dry-coated orally-disintegrating tablet: The purpose of the present invention is to provide a press-coated orally-disintegrating tablet characterized by containing an inner core which has an excellent disintegratability in oral cavity and a suitable hardness as a whole tablet. The present invention relates to a press-coated orally-disintegrating tablet with an outer layer surrounding an... Agent: Dainippon Sumitomo Pharma Co., Ltd.
20120064161 - Modified release niacin pharmaceutical formulations: Pharmaceutical formulations comprising niacin in a matrix comprising a hydrophobic polymer that modifies release of niacin.... Agent: Dr. Reddy's Laboratories Ltd.
20120064163 - Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof: Disclosed are mammalian tumor and/or cancer cell conditioned substrate preparations having tumor inhibiting activity. In some embodiments, the mammalian tumor and/or cancer cell conditioned substrate preparations are essentially free of cellular components. These preparations comprise a conditioned heterologous acellular collagenous tissue preparation, and may be prepared using a mammalian extracellular... Agent:
20120064164 - Extended release pharmaceutical compositions: The present invention provides extended release pharmaceutical compositions structured for once a day administration comprising skeletal muscle relaxant such as cyclobenzaprine or its pharmaceutically acceptable salt thereof that extends the release of the drug under in-vitro conditions for at least 8 to 12 hours. The invention also provides process for... Agent: Inventia Healthcare Private Limited
20120064165 - Treatment of tissue adhesion: Dry powder compositions are useful in the treatment or prevention of tissue adhesions during or after surgery or during wound therapy. The dry powder compositions may contain trehalose. The dry powder compositions may be fibrin sealant compositions comprising fibrinogen and/or thrombin.... Agent: Profibrix B.v.
20120064166 - Formulation comprising drospirenone for subcutaneous or intramuscular administration: The present invention relates to a composition comprising Drospirenone dispersed in a liquid or semi-solid lipophilic vehicle. The present invention further relates to the use of such compositions as contraceptives and for treatment of diseases, disorders and symptoms associated with deficient endogenous levels of estrogen in women.... Agent: Bayer Pharma Aktienesellschaft
20120064167 - Modified-release pharmaceutical drug composition: The present invention provides compositions and methods for a modified-release pharmaceutical drug composition having a first charged active agent and a second charged active agent at least partially surrounded by a rate controlling membrane. The first charged active agent and the second charged active agent interact to form a modified... Agent: Coating Place, Inc.
20120064168 - Methods of treatment using a gastric retained gabepentin dosage: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.... Agent: Depomed, Inc.
20120064169 - Multiple antigen delivery system using hepatitis e virus-like particle: This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.... Agent: National Institute Of Infectious Disease
20120064170 - Gallium-doped phosphocalcic compounds: The present invention relates to a gallium-doped phosphocalcic compound of formula (I): Ca(10.5-1.5x)Gax(PO4)7, wherein 0<x<1 and the salts, hydrates and mixtures thereof. The invention further relates to a solid state process in solution for the manufacture of such compounds and the use thereof for the preparation of a biomaterial, in... Agent: Graftys
20120064171 - Pesticide composition: Stable non-toxic pesticide composition having fungicidal and insecticidal properties including a pesticide that is nontoxic to mammals; one or more disinfectants; a vegetable oil; and one or more stabilizing agents. In one example, one or more stabilizing agents are selected and are present in an amount in combination with the... Agent: Bedo Holding Ag
20120064172 - Bone filling material comprising sintered titanium dioxide and dextrin and method for reconstructing bone defects using the same: A bone filling material comprising sintered titanium dioxide and dextrin and a method for reconstructing bone defects which comprises filling the bone defects in an animal with the bone filling material. The bone filling material of the invention has excellent cell compatibility, biocompatibility and shape-imparting property.... Agent: Aichi Gakuin
20120064173 - Compositions and methods for treating signs of skin aging: The invention relates to methods and compositions for treating skin aging, said compositions comprising at least one tropoelastin promoter and at least one tropoelastin crosslinker.... Agent:
20120064174 - Method for stimulating hair growth: e
20120064176 - Composition for preventing and treating fatty liver: A composition for preventing and treating fatty liver is disclosed. The composition includes a lactoferrin and a trivalent chromium compound. The trivalent chromium compound of the present invention is selected from the group consisting of chromium (III) chloride hexahydrate, chromium (III) chloride, chromium (III) acetate, chromium (III) sulfate, chromium picolinate,... Agent: National Chung Hsing University
20120064177 - Method of preparing an intranasal composition and intranasal compositions obtainable thereby: The present invention relates to a method of preparing an intranasal composition including from about 0.0010-0.0040% by weight capsaicin, from about 0.50-0.90% by weight hydroxypropyl methylcellulose, from about 0.010-0.080% by weight n-alkyl dimethyl benzyl ammonium chloride (Quat), and various moisturizing and irrigation agents, wherein the method includes dissolving the above... Agent:
20120064178 - Cell-8 solution: Cell-8 Solution is an intravenous solution introduced into the veins of the patient. Cell-8 Solution provides the cells of the body with highly absorbed minerals as well as new RNA information which changes the relationship of the body to the cancer in question. Treatment with Cell-8 Solution will prevent the... Agent:
20120064179 - Bicarbonate solution for bioavailable magnesium and uses thereof: The invention relates to a method of prevention or treatment of a condition such as magnesium deficiency or deficit or abnormality, creatine or creatine phosphate (phosphocreatine) deficiency or abnormality, parathyroid hormone (PTH) excess or abnormality, sodium deficiency or abnormality, potassium deficiency or abnormality, antidiuretic hormone excess or abnormality or a... Agent: Unique Global Possibilities Medical Pty Limited
20120064180 - Use of no and no donors for terminating dormancy in invertebrates: The present invention relates to a method for terminating dormancy in an invertebrate, wherein said invertebrate is brought in contact with nitric oxide and/or a nitric oxide donor. The method can be used in pest management of unfavourable species, in eliminating dormant stages of aquatic invertebrates in ballast water in... Agent: Universiteit Gent
20120064181 - P2x3 receptor antagonists for treatment of pain: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.... Agent:
20120064182 - Cosmetic or dermatological preparation comprising collagen, chitosan, glycosylaminoglycan and cell growth promoting peptide and/or cellular complex: A cosmetic or dermatological preparation that is obtainable by combining collagen and/or a derivative thereof, chitosan and/or a derivative thereof, glycosylaminoglycan and/or a derivative thereof with a peptide which is capable of promoting skin cell growth and/or with a composition which comprises glycoproteins 1 and 2 and ginseng and horsetail... Agent: Beiersdorf Ag03/08/2012 > 164 patent applications in 106 patent subcategories. listing by industry category
20120058047 - Method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection: The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer... Agent: Gtc Biotherapeutics, Inc.
20120058048 - Directed radiotherapy: The present invention relates enhanced targeting of drug delivery vehicles to vascular endothelial cells... Agent:
20120058049 - Cromolyn derivatives and related methods of imaging and treatment: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula (I), or formula (II); wherein X is OH, C1-C6 alkoxyl, 18F, or 19F; Y and Z... Agent:
20120058051 - Anti-human ror1 antibodies: The invention relates to antibodies having specificity for human ROR1, compositions thereof, and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with aberrant ROR1 expression.... Agent: The Usa, As Represented By The Secretary, Department Of Health And Human Services
20120058050 - Loaded latex optical molecular imaging probes containing lipophilic large stokes shift dyes: The present invention relates to a loaded particle comprising at least one fluorescent dye, and in particular, a fluorescent dye with a large Stokes shift. The invention further relates to a method for producing an loaded latex particle, loaded with a fluorescent dye having a large stokes shift. In addition,... Agent:
20120058053 - Carbon nanohorn mri contrast agents: A contrast agent characterized in that each of carbon nanohorns forming a carbon nanohorn aggregate has an opening at the side wall or tip, wherein a metal M (at least one metal selected from among paramagnetic metals, ferromagnetic metals, and superparamagnetic metals) or a compound of the metal M is... Agent:
20120058054 - Gadolinium complex, method for preparing same, and mri contrast agent comprising same: Disclosed are a gadolinium complex formed by coordination of gadolinium to the diethylenetriaminepentaacetic acid dianhydride (DTPA) moiety of a pullulan-DTPA conjugate formed by an ester bond between pullulan and DTPA, a preparation method thereof, an MRI contrast composition comprising the complex, and a method of providing information for diagnosis of... Agent: Catholic University Industry Academic Cooperation Foundation
20120058052 - Method for avian sex determination: The invention relates to a method and apparatus for pre-hatch avian embryo sex determination. In particular, the invention relates to a non-invasive method and apparatus for in-ovo determining the sex of avian species while in the egg and allowing to sort the eggs into groups consisting primarily of either male... Agent: Prinzen B.v.
20120058055 - Gastrorententive oral high dose zinc preparations: A method of providing zinc to a subject in need of treatment includes administering to the subject an effective amount of a sustained-release zinc composition.... Agent:
20120058057 - Anti-dandruff agents: The present invention relates to special ammonium carboxylates, their synthesis and application, particularly as anti-dandruff agents.... Agent: Merck Patent Gmbh
20120058058 - Compounds derived from muscodor fungi: The present invention relates to novel compounds and compositions and the use of them for the control of fungal and bacterial pathogens, insect pests, acari, nematodes and other invertebrate pests including, but not limited to post-harvest and soil diseases, building mold remediation, and seed and grain sanitation.... Agent: Agraquest, Inc.
20120058056 - Treatment of cutaneous hemangioma: This invention concerns a method of treating hemangiomas with a beta blocker by applying the beta blocker onto the hemangiomas directly. The invention also concerns a combination therapy by using a beta blocker along with a corticosteroid or an alpha adrenergic receptor agonist for the treatment of hemangiomas.... Agent: University Of Medicine And Dentistry Of New Jersey
20120058059 - Single phase whitening dentifrice: The invention provides a single phase whitening dentifrice that includes (i) a whitening agent selected from the group consisting of hydrogen peroxide, a bound peroxide and a solid peroxide (ii) an abrasive and (iii) a substantially anhydrous orally acceptable carrier, for example, polyethylene glycol. The bound peroxide may be hydrogen... Agent: Colgate-palmolive Company
20120058060 - Cationic/cationogenic comb copolymer compositions and personal care products containing the same: in which Y is a moiety forming part of a copolymer backbone, Z is a moiety that exhibits association with other Z moieties or with other moieties within the ultimate formulation in which the copolymer will be employed, and b is a bond or moiety that links the Z moiety... Agent: Air Products And Chemicals, Inc.
20120058061 - Cosmetic basic composition and its use: The present invention relates to a cosmetic basic composition comprising hydroxypropylmethylcellulose (HPMC) modified with C15-C20 alkyl ether groups as thickener, Oleosomes and water, wherein the Oleosomes comprise at least one cosmetically active substance. The invention also relates to the use of the cosmetic basic composition in products of decorative cosmetics,... Agent: Coty Germany Gmbh
20120058063 - Process for treating and/or forming a non-newtonian fluid using microchannel process technology: The disclosed invention relates to a process, comprising: conducting unit operations in at least two process zones in a process microchannel to treat and/or form a non-Newtonian fluid, a different unit operation being conducted in each process zone; and applying an effective amount of shear stress to the non-Newtonian fluid... Agent:
20120058062 - Two component interactive emulsion product: The present invention describes, in one aspect, the use of two oppositely charged surfactants as the primary emulsifiers in two separated parts of a product. The emulsifiers are chosen such that when the two parts of the emulsion product are mixed, the emulsifiers react to form water insoluble compounds that... Agent: Carson Product Development, Inc.
20120058065 - Oil-based skin treatment composition: e
20120058064 - Use of charged surfactants for reducing textile staining by antiperspirants: The invention comprises the use of one or more charged surfactants in preparations having an antiperspirant effect for reducing staining in or on clothing and improving improvement the ability of stains to be washed out of the clothing.... Agent: Beiersdorf Ag
20120058066 - Self-assembling peptide and peptide gel with high strength: Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a1b1c1b2a2b3db4a3b5c2b6a4 where: a1 to a4 each represent a basic amino acid residue; b1 to b6 each represent an uncharged... Agent: Menicon Co., Ltd.
20120058069 - Cationic benzoxazine (co)polymers: Cationic benzoxazine (co)polymers wherein at least 5% of all nitrogen atoms are in the form of quaternary nitrogen atoms, and to a method for producing said polymers. The invention also relates to a washing and cleaning agent, a textile treatment agent or a cosmetic agent containing at least one cationic... Agent:
20120058070 - Method for producing a hair shine cosmetic, and hair shine cosmetic product: A hair shine cosmetic product and a method for producing same are disclosed. The product is composed of sunflower glycerides, water, sunflower seed extract, a plant mixture, preservatives, citric acid and a fragrance, besides silica or Antil 200 (hydrogenated and polyethoxylated glyceryl palmate with 200 ethylene glycol units, combined with... Agent:
20120058071 - Hair care product containing acetylpyridinium salts: Cosmetic hair treatment agent comprising, in a cosmetically acceptable carrier, at least one surface-active agent chosen from cationic and/or zwitterionic surfactants, and at least one acetylpyridinium derivative of formula (I) for improving the general condition of the hair, for reducing hair damage in the interior of the hair, and for... Agent:
20120058068 - Compositions for repairing and restoring keratin-containing fibers: Disclosed are compositions that can be used as an adjunct to regular shampooing and conditioning products, wherein the disclosed compositions provide a means for repairing and restoring keratin-containing fibers to their original condition.... Agent:
20120058067 - Compositions for treating keratin-containing fibers and maintaining dyed fiber color integrity: Disclosed are compositions, inter alia, shampoos, conditioners, and restoratives that are effective in preventing further damage to keratin-containing fibers damaged by exposure to oxidative dyeing catalysts, mechanical damage, exposure to UV and visible radiation, and the like.... Agent:
20120058072 - Compositions for removal of odors: The present invention provides, in one embodiment, a composition for removing odors. The composition includes, in one embodiment, a salt having at least one of a halogen and an alkaline in an effective amount sufficient to remove odors from the materials when applied thereto. The salt, in an embodiment, may... Agent:
20120058073 - 2-oxaspiro[5.5]undec-8-ene derivatives useful in fragrance compositions: Disclosed are substituted 2-oxaspiro[5.5]undec-8-ene derivatives of formula (I) and their use as odorants. This disclosure relates furthermore to a method of their production and flavour and fragrance compositions comprising them.... Agent:
20120058074 - Deodorizing compositions: The present invention relates to odor-inhibiting compositions comprising water-absorbing polymer particles and at least one oxidase.... Agent: Basf Se
20120058075 - Novel methods for cleaning a surface: A method of killing and removing bacteria, mold, mildew or fungus from a surface or keratin substrate includes contacting the surface with an aqueous solution containing a multi carboxylic alpha hydroxy acid, a mono carboxylic organic acid and optionally Aloe. The aqueous solution has a pH of less than 2.... Agent:
20120058076 - Aesthetic treatment of scars and aging skin: Beneficial topical compositions for treating scar or aging skin are provided. In one embodiment, the compositions include Bulbine frutescens, Centella asiatica and a phenol derived from olives, such as oleuropein. The composition may be used in the treatment of scars formed during surgery. The composition may also be used cosmeceutically... Agent:
20120058077 - Biostatic polymer: Methods and compositions effective for at least a week for prevention of microbial colony growth on a surface, for example an inanimate surface, where the surface is covered with a dry or substantially dry film formed from a composition comprising a polyvinyl alcohol and a quaternary ammonium compound. The film... Agent: Novapharm Research (australia) Pty Ltd
20120058079 - 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.... Agent: Incyte Corporation, A Delaware Corporation
20120058078 - Assay for the detection of factors that modulate the expression of ingap: A reporter construct contains mammalian INGAP 5′-regulatory region or a fragment thereof, a minimal promoter element from mammalian INGAP or a heterologous promoter, and a reporter gene. The reporter construct can be used to screen for agents which alone or in combination up-regulate or down-regulate reporter gene expression. Alternatively, the... Agent: Gmp Endotherapeutics, Inc.
20120058080 - 7-nitro-2-(3-nitro phenyl)-4h-3,1-benzoxazin-4-one or derivatives thereof for treating or preventing antiviral infections: Surprising antiviral activity of 7-Nitro-2-(3-nitro phenyl)-4H-3,1-benzoxazin-4-one (Compound 1) was reported in the treatment or prevention of viral infections, particularly in combination with other antiviral agents such as interferon and/or ribavarin.... Agent:
20120058081 - Ex-vivo treatment of peripheral blood leukocytes with ifn-lambda: The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-λ). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-λ and returned... Agent: Medical Diagnostic Laboratories, LLC
20120058082 - Methods and compositions for treatment: The invention provides methods for improving the efficacy and reducing side effects of anti-CD52 antibody treatment. The methods can be used to treat patients who are in need of immunoregulation such as lymphocyte depletion and patients who have cancer. Also included are compositions useful for these methods.... Agent: Genzyme Corporation
20120058083 - Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta: The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, chronic demyelinating neuropathies, e.g., CIDP. The methods involve the administration of IFN-β therapeutics.... Agent: Biogen Idec Ma Inc.
20120058085 - Deuterium modified benzimidazoles: This invention relates to derivatives of 1-(p-chlorobenzyl)-2-(1-pyrrolidinylmethyl)benzimidazole according to Formula I wherein at least one Y is deuterium described herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that... Agent:
20120058084 - Interferon alpha carrier prodrugs: The present invention relates to a pharmaceutical composition comprising a water-soluble polymeric carrier linked prodrug of interferon alpha, wherein the prodrug is capable of releasing free interferon alpha, wherein the release half life under physiological conditions is at least 4 days. The invention further relates to prodrugs for said pharmaceutical... Agent: Ascendis Pharma As
20120058086 - Compositions, kits, and methods for promoting ischemic and diabetic wound healing: Compositions, kits and methods for promoting diabetic wound healing are based on the discovery that SDF-1α specifically upregulates expression of E-selectin in mature endothelial cells (EC), leading to an increase in EC-endothelial progenitor cell (EPC) adhesion and EPC homing. Methods for promoting healing of a wound in a diabetic subject... Agent:
20120058090 - Alimentary protein-based scaffolds (aps) for wound healing, regenerative medicine and drug discovery: The invention provides engineered biomaterials derived from plant products. The engineered biomaterials are useful for biomedical applications. The engineered biomaterials are able to support the growth of animal cells.... Agent: Drexel University
20120058091 - Diagnostic and therapeutic treatments related to mitochondrial disorders: The invention is based in part on the discovery that chromosomal disorders such as Down Syndrome can be diagnosed by assessing maternal mitochondrial status. Thus the invention relates to diagnostic and therapeutic methods and related products for chromosomal disorders such as Downs Syndrome, for example, for identifying a risk of... Agent: The Regents Of The University Of Colorado
20120058093 - Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders: Cells present in adipose tissue are used to treat patients, including patients with PVD and related diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a... Agent: Cytori Therapeutics, Inc.
20120058092 - Process for the preparation of a composition of genetically modified hematopoietic progenitor cells: Described are compositions and methods relating to gene therapy, particularly as applied to hematopoietic progenitor (HP) cells, to transduced cells and methods of obtaining them, and to methods of using them to provide prolonged engraftment of modified hematopoietic cells in human subjects. The invention particularly relates to ex vivo gene... Agent: Johnson & Johnson Research Pty, Limited
20120058087 - Diagnosis of endometritis: The present invention relates to methods for diagnosing and treatment of a dormant infection of at least one pathogen. The invention further relates to a composition comprising an anti-dormancy factor as well as to said composition for use in a method of diagnosis or treatment and also to a method... Agent: Kobenhavns Universitet
20120058094 - Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota: The present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (HPMC) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve... Agent: New York University
20120058095 - Oily suspension containing probiotic bacteria for paediatric uses: The present invention refers to an oily suspension containing probiotic bacteria, particularly suitable for paediatric use.... Agent: Probiotical S.p.a.
20120058088 - Resveratrol-containing compositions and methods of use: A resveratrol-containing composition capable of providing a therapeutic benefit to a subject such as modulation of a biological activity, improving cell transplantation therapy, or improving macular degeneration or dystrophy treatments. The compositions comprise trans-resveratrol, a metal chelator, and one or more additional antioxidants such as phenolic antioxidants or vitamin D.... Agent: Resveratrol Partners, LLC
20120058089 - Treatment of organ injuries and burns using placental stem cells: The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush... Agent:
20120058096 - Compositions and methods for generating interleukin-35-induced regulatory t cells: Compositions and methods are provided for generating T cells having a regulatory phenotype from conventional T (Tconv) cells. Such compositions and methods include culturing isolated, naïve Tconv cells with an effective amount of interleukin-35 (IL-35) until the cells have the regulatory phenotype. Also provided are methods to treat subject having... Agent: St. Jude Children's Research Hospital
20120058097 - Compositions including a sodium channel blocker and a b vitamin molecule and methods of use thereof: The invention generally relates to compositions including a sodium channel blocker and a B vitamin molecule and methods of use thereof. In certain embodiments, the invention provides compositions that include a sodium channel blocker and a B vitamin molecule. In other embodiments, the invention provides methods for treating a subject... Agent: Ms Therapeutics Limited
20120058098 - Non-cytotoxic protein conjugates: The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a dynorphin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein... Agent: Syntaxin Ltd.
20120058100 - Modulation of drug release rate from electrospun fibers: Disclosed are co-electrospun polymeric fibers comprising polymers comprising pharmaceutically active agents and/or biologically active agents and capable of release at a combined release rate. Also disclosed are processes for preparing polymeric fibers capable of release at a combined release rate. Also disclosed are processes of modulating delivery rate of pharmaceutically... Agent:
20120058101 - Treatment of human or animal body surface infection: A method of treatment of a human or animal body surface infection, particularly a fungal infection, comprises applying an aqueous liquid to the infected body surface, e.g. nail region, followed by applying a dressing comprising a source of hydrogen peroxide. Also provided is a combination of the liquid and dressing... Agent:
20120058099 - Use of hypoxanthine for promotion of neuronal outgrowth: Disclosed herein is a method of promoting neuronal outgrowth in a neuron. The method comprises contacting the neuron with an effective amount of hypoxanthine, to thereby promote neuronal outgrowth of the neuron. The hypoxanthine may be contacted in the absence of xanthine oxidase and/or in the absence of exogenous nerve... Agent: Children's Medical Center Corporation
20120058102 - Pharmacologically induced transgene ablation system: The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in safety mechanism for ablating the therapeutic gene product, either permanently or temporarily, in response to a pharmacological agent—preferably an oral formulation, e.g., a... Agent: The Trustees Of The University Of Pennsylvania
20120058103 - Composition of individual proteolytic enzymes: The invention relates to bioengineering, in particular to producing a composition of individual enzymes exhibiting the extended range of proteolytic activity, thereby enabling the composition to hydrolyse protein substrates up to individual amino acids. The composition contains at least two proteases, the molecular mass of which ranges from 23 to... Agent: Joint-stock Company 'high Tech'
20120058104 - Use of a fermented soy extract as a prebiotic composition: The present invention relates to use of a fermented soy extract as a prebiotic composition to protect beneficial bacteria in the gastrointestinal tract of an animal. Particularly, the fermented soy extract of the invention exhibits the prebiotic activity even under an antibiotic treatment. Also disclosed is combined use of an... Agent: Microbio Co., Ltd.
20120058105 - Method of treatment of vascular complications: The present invention provides methods for the prevention or treatment of one or more vascular complication(s) in a subject at risk of developing diabetes mellitus, impaired glucose tolerance and/or hyperglycemia or a subject suffering from diabetes mellitus, impaired glucose tolerance and/or hyperglycemia, wherein an amount of a composition effective to... Agent:
20120058106 - Novel cancer-associated antigen: The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits.... Agent: Viventia Biotechnologies Inc.
20120058107 - Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors: The present invention relates to pyrrolo[3,2-c]pyridine-4-one 2-indolinone compounds of Formula (I) and their pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8 X, Y and have the meaning cited in the specification. Also disclosed are the pharmaceutical compositions containing the foregoing compounds, methods for the... Agent: Shanghai Hengrui Pharmaceutical Co., Ltd.
20120058108 - Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes: The present invention relates to the fields of genetics and oncology and provides methods for detecting tumors as well as methods for treating patients and predicting the prognosis to a patient. Specifically, the present invention relates to a method of demonstrating the malignant character of a tumor or cell subpopulation... Agent:
20120058110 - method for predicting the responsiveness to an anti-tnf alpha antibody treatment: The present invention relates to a method for predicting the responsiveness of a patient to an anti-TNFα antibody treatment.... Agent: Inserm (institut National De La Sante Et De La Recherche Medicale)
20120058112 - Antibodies: The combination of an IGF-1R antagonist such as a humanized antibody and an anti-proliferative drug is described. In a preferred embodiment, the present invention describes the combination of an IGF-1R antibody and an anti-proliferative drug belonging to the EGFR-inhibitor class, which is preferably erlotinib. The combination according to the present... Agent:
20120058113 - Cancer treatment method: A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.... Agent:
20120058109 - Reelin rescues cognitive function: Disclosed are methods of influencing, and enhancing, cognitive function by increasing, and/or preventing interference with, Reelin levels as well as Reelin signaling. Cognitive function is improved, in a subject in need thereof, by administering a therapeutically effective amount of Reelin, a Reelin-specific modulator or an agonist of a lipoprotein receptor... Agent: University Of South Florida
20120058111 - Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them: The present invention is directed to a sialylated isolated antibody specific for an antigen selected from autoimmune antigens, allergens, MHC molecules or Rhesus factor D antigen, comprising an Fc-portion of IgG type, and exhibiting a sialic acid residue at the Fc-portion for use in treatment and/or prophylaxis of autoimmune disease,... Agent:
20120058115 - method for promoting bone growth using activin-actriia antagonists: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.... Agent: Acceleron Pharma Inc.
20120058114 - Erbb2 antibodies comprising modular recognition domains: Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also... Agent: The Scripps Research Institute
20120058116 - Fgfr1c antibody combinations: The invention relates to combinations of FGFR1c antagonists with agonist peptides and provide dual targeting proteins which bind to FEFR1c comprising an antigen binding protein which is capable of binding to FGFR1c and which is linked to one or more agonist peptides, methods of making such constructs and uses thereof,... Agent:
20120058117 - Neuropilin-1 inhibitors: The present invention relates to molecules interfering with the function of neuropilin-1 in the context of angiogenesis and the treatment of cancer. Molecules, polypeptides, antibodies, compositions and methods are provided that are useful for reducing, inhibiting or treating angiogenesis, the invasion of blood vessels into tumors, and/or the invasion or... Agent: Tufts University
20120058118 - A-beta binding polypeptides: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including... Agent: Boehringer Ingelheim International Gmbh
20120058119 - Human tumor necrosis factor tr21 and methods based thereon: The present invention relates to TR21 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR21 protein. TR21 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21... Agent: Human Genome Sciences, Inc.
20120058120 - Targets for growth factor signalling and methods of therapy: Methods of screening or designing therapeutic agents effective for the treatment of a transglutaminase-associated disease, disorder and/or condition are provided which include determining whether a candidate agent can modulate an interaction between a transglutaminase and an insulin-like growth factor and/or a member of the IGF family of receptors. Also provided... Agent:
20120058121 - Methods and compositions for treating lupus: The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount sufficient to treat the lupus; preferably by modulating cytokine expression. Preferably the... Agent: Natrogen Therapeutics International, Inc.
20120058122 - Antibodies directed to her-3 and uses thereof: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases... Agent:
20120058123 - N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating... Agent: Panmira Pharmaceuticals, LLC.
20120058124 - Influenza virus-neutralizing antibody and screening method therefor: Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody.... Agent: Fujita Health University
20120058128 - Anti- integrin antibodies, compositions, methods and uses: The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.... Agent:
20120058126 - Anti-vegfr-3 antibody compositions: The present invention provides anti-VEGFR-3 monoclonal antibodies, pharmaceutical compositions containing said antibodies and uses of said antibodies in the treatment of disease.... Agent: Imclone LLC
20120058125 - Methods relating to peripheral administration of nogo receptor polypeptides: This invention relates to methods of treating diseases involving accumulation of Aβ plaques, including Alzheimer's Disease by the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of increasing the plasma to brain ratio of Aβ peptide and enhancing Aβ peptide clearance via peripheral administration of soluble... Agent: Yale University
20120058127 - Par2 agonists for use in the treatment or prevention of influenza virus type a infections: The present invention provides methods and compositions (such as pharmaceutical compositions) for treating or preventing influenza virus type A infections. More particularly, the invention relates to a PAR2 agonist for use in the treatment or prevention of an influenza virus type A infection.... Agent:
20120058130 - Compositions and methods for diagnosing, treating, and preventing prostate conditions: Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN).... Agent: Phigenix, Inc.
20120058131 - Pta089 protein: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer, for monitoring the effectiveness of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer,... Agent: Oxford Biotherapeutics Ltd
20120058133 - Inhibition of trna synthetases and therapeutic applications thereof: The present invention provides novel methods for modulating Th 17-mediated immune responses using aminoacyl tRNA synthetase inhibitors. Inhibition of aminoacyl tRNA synthetase inhibitors activates an amino acid starvation response (AAR) and can produce beneficial therapeutic effects. In some embodiments, aminoacyl tRNA synthetase inhibitors are used to treat disorders such as... Agent: President And Fellows Of Harvard College
20120058134 - Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant: For the purpose of providing a method of safely and inexpensively producing a fermented plant extract containing an immunopotentiator at a high concentration, the method for fermentation and culture of the present invention ferments a plant component such as wheat flour using Pantoea agglomerans which is a gram negative bacterium... Agent: Soma, Gen-ichiro
20120058132 - Treatment of glycogen storage disease type ii: Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II.... Agent: Duke University
20120058135 - Identification and characterization of racemases, definition of protein signatures, and a test for detecting d-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase: This invention relates to the identification and characterization of racemases and definition of protein signatures of these racemases. More particularly, this invention relates to the identification of nucleic acid molecules encoding a peptide consisting of a motif characteristic of the protein signatures, and to the peptides consisting of these motifs... Agent: Institut Pasteur
20120058136 - Non-splicing variants of gp350/220: Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use... Agent: Medimmune, LLC
20120058137 - Efficient transport into white blood cells: The present invention relates to the use of specific transporter cargo conjugate molecules for the transport of a substance of interest (cargo molecule) into white blood cells. Said transporter cargo conjugate molecules may be used for the treatment, prophylaxis, attenuation and/or amelioration of a disease and/or disorder involving white blood... Agent: Xigen, S.a.
20120058138 - Novel adenovirus vectors: An adenoviral vector comprising a promoter further comprising a fragment of the 5′ untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumour antigen for use as a medicament.... Agent:
20120058139 - Novel multimodular assembly useful for intracellular delivery: A stabilized multimodular assembly for intracellular delivery comprising a complex of at least one cationic transfection agent and of at least one negatively charged macromolecule, wherein the complex has a theoretical charge ratio ranging from about 0 to about 4, and an efficient amount of at least one amphiphilic block... Agent: Institut National De La Sante Et De La Recherche Medicale (inserm)
20120058140 - Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities: A topical composition according to the present invention for use in a skin care regimen that provides matrix metalloprotease (MMP) inhibiting activity, tissue inhibitor of metalloprotease (TIMP) inducing activity, and immediate and delayed antioxidative activity. Preferably, the topical composition comprises at least one MMP inhibitor, a TIMP inducing agent, Tremella... Agent: Bath & Body Works Brand Management, Inc.
20120058141 - Chimeric newcastle disease viruses and uses thereof: Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer.... Agent:
20120058142 - Vaccine for protection against shigella sonnei disease: Compositions and methods for protecting a susceptable host against an infection of Shigella sonnei are disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.... Agent: Government Of The United States Of America, As Represented By The The Secretary
20120058143 - Staphylococcus aureus proteins and nucleic acids: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.... Agent: Novartis Vaccines & Diagnostics Srl
20120058144 - Lipids and compositions for the delivery of therapeutics: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures XIV or XVII.... Agent: Alnylam Pharmaceuticals, Inc.
20120058145 - Method for producing virus from cell culture involving homogenization: A method of purifying a virus, or a viral antigen thereof, from a culture of infected cells comprising at least the steps of: (a) collecting the virus-containing cell culture medium, and (b) purifying the virus, wherein at least one homogenization step is implemented during the purification to obtain a virus... Agent:
20120058146 - Immunogens from uropathogenic escherichia coli: Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic E. coli strains. The genes are from uropathogenic strains but are absent from non-pathogenic strains, and their encoded proteins have cellular locations which render them accessible to the immune system.... Agent: Novartis Vaccines And Diagnostics Srl
20120058147 - Geographically region specific allergy immunotherapy for companion animals: Implementations and techniques for providing geographically region specific allergy immunotherapy for companion animals are generally disclosed.... Agent:
20120058148 - Certain aminoalkyl glucosaminide phosphate compounds and their use: Compounds that are adjuvants and immunoeffectors are described and claimed. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed.... Agent: Corixa Corporation
20120058149 - Treatment of infection: The invention relates to compositions including a substance useful as an adjuvant for potentiating an immune response, and methods of using the composition in individuals with infections of tissue within or adjacent to a transformation zone, such as the transformation zone of the cervix or anal canal.... Agent:
20120058151 - nanoparticulate compositions of poorly soluble compounds: The present invention relates to a method for the production of a nanoparticulate pharmaceutical composition. The method comprises the steps of a) suspending in water a poorly soluble active ingredient without the presence of a detergent, b) mechanically treating said suspension to obtain particles comprising the active ingredient with an... Agent: Capsulution Pharma Ag
20120058156 - Activated leukocyte composition and uses for wound healing: Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds.... Agent: Macrocure Ltd.
20120058161 - Alkylated semi synthetic glycosaminoglycosan ethers, and methods for making and using thereof: Described herein are alkylated and semi-synthetic glycosaminoglycosan ethers, referred to herein as “SAGEs.” The synthesis of sulfated and alkylated SAGEs is also described. The compounds described herein are useful in a number of applications including use for ocular or ophthalmic treatment.... Agent: University Of Utah Research Foundation
20120058152 - Bone regeneration materials based on combinations of monetite and other bioactive calcium and silicon compounds: The present invention incorporates new materials for bone regeneration, methods for their manufacture, and application in traumatology surgery, maxillo facial surgery, dental surgery, orthognatic surgery, endodontics, ophthalmology, neurosurgery and/or osteoporotic processes, and other indications where bone regeneration is required. In particular, the present invention incorporates synthetic materials with a 20%... Agent: Azurebio, S.l.
20120058150 - Methods for delivering compositions by electrospraying a medical device: Methods are provided for administering a phospholipid composition to a subject, comprising coating a medical device with at least one layer of a phospholipid composition, wherein the coating is achieved by electrospraying the device with the composition, and wherein the composition is carrying or can carry at least one therapeutic... Agent: Colorado State University Research Foundation
20120058157 - Methods of treating cardiovascular disorders associated with atherosclerosis: Layered phyllosilicates are useful for adsorbing and/or binding to cholesterol in the gastrointestinal (GI) tract and, thereby, reducing blood cholesterol in a patient. Accordingly, provided herein is a method of reducing hypercholesteremia in a mammal comprising administering to said mammal a protonated and at least partially exfoliated layered phyllosilicate material... Agent: Amcol International Corporation
20120058160 - Particulate materials: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having... Agent:
20120058155 - Slow-degrading polymers for undelayed and sustained drug delivery: The invention provides polymers and methods for their use. Certain embodiments of the invention provide slow degrading microspheres for undelayed and sustained drug delivery.... Agent: Rutgers, The State University Of New Jersey
20120058162 - Stable, spray dryed, immunogenic, viral compositions: Viruses, and particularly genetically engineered, replication deficient viruses such as adenoviruses, poxviruses, MVA viruses, and baculoviruses which encode one or more antigens of interest, such as TB, malarial, and HIV antigens, are spray dried with a mannitol-cyclodextrin-trehalose-dextran (MCTD) to form a powder where the viability of the viruses are maintained... Agent:
20120058158 - Sublingual pharmaceutical composition comprising a neutral oil: The invention provides pharmaceutical compositions for the sublingual delivery of medicaments comprising a neutral oil and a medicament soluble in said oil, providing that said medicament is not nitroglycerine. The invention also provides delivery devices adapted for sublingual delivery of such compositions.... Agent: Londonpharma Ltd.
20120058154 - Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus m2e: This invention relates to compositions and methods that can be used immunize a subject against influenza. Generally, the compositions and methods include peptides obtained or derived from human influenza A virus M2 protein.... Agent: Selecta Biosciences, Inc.
20120058153 - Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin: This invention relates to compositions and methods that can be used immunize a subject against influenza. Generally, the compositions and methods include polypeptides obtained or derived from human influenza A virus hemagglutinin.... Agent: Selecta Biosciences, Inc.
20120058159 - Treatment of animal litter with ferric sulfate granules: Methods of treating animal litter and/or bedding material for control of volatile ammonia and soluble phosphorous include applying granular partially hydrated ferric sulfate to the litter. The partially hydrated ferric sulfate ranges from gray to tan in color and is spread onto the litter at a rate effective to reduce... Agent:
20120058164 - Cleaning or cosmetic compositions comprising natural zeolites: The invention describes compositions which are useful as cleansers of the skin. The compositions described comprise zeolitic ingredients which are in general softer than known products. The natural zeolitic ingredients are inherently soft. The softness is due to a number of factors including but not limited to younger zeolitic rock... Agent: Zeosoft Limited
20120058166 - Filaments comprising a non-perfume active agent nonwoven webs and methods for making same: Filaments that contain a filament-forming material and an additive, nonwoven webs, and methods for making such filaments are provided.... Agent:
20120058167 - Methods for treating scars and aging skin: Beneficial topical compositions for treating scar or aging skin are provided. In one embodiment, the compositions include Bulbine frutescens, Centella asiatica and a phenol derived from olives, such as oleuropein. The composition may be used in the treatment of scars formed during surgery. The composition may also be used cosmeceutically... Agent:
20120058165 - Opacifying lotion: A lotion for opacifying a wet wipe. A wet wipe may comprise a lotion, the lotion comprising an opacifying agent. The lotion or the substrate may further comprise a retention aid. The substrate may comprise an opacifying agent the same as or different than the opacifying agent of the lotion.... Agent:
20120058163 - Water-dispersible and multicomponent fibers from sulfopolyesters: Disclosed are water-dispersible fibers derived from sulfopolyesters having a Tg of at least 25° C. The fibers may contain a single sulfopolyester or a blend of a sulfopolyester with a water-dispersible or water-nondispersible polymer. Also disclosed are multicomponent fibers comprising a water dispersible sulfopolyester having a Tg of at least... Agent: Eastman Chemical Company
20120058168 - Animal attractant: Disclosed herein are compositions and methods useful for attracting animals to a site determined by the user of the compositions and method disclosed herein. Disclosed are compositions that contain an absorbent material and an animal attractant. The animal attractant may be in the form of a liquid and may have... Agent:
20120058169 - Silver iodate compounds having antimicrobial properties: The present invention is compositions, methods of use, methods of treating, and articles of manufacture that include at least one silver iodate for imparting antimicrobial properties, particularly as it relates to the manufacture, use, and properties of medical devices. The invention also includes obtaining and using one or more silver... Agent:
20120058170 - Drug delivery by carbon nanotube arrays: The invention generally relates to carbon nanotube based drug delivery methods, devices, and compositions. More particularly, the invention relates to controlled drug delivery using anchored carbon nanotube arrays.... Agent: Califomia Institute Of Technology
20120058171 - Zoo-technical drug delivery device: The present invention relates to a veterinary zoo-technical drug delivery system (device) for the simultaneous release of two or more active substances, which system releases the active substances in a substantially constant ratio over a prolonged period of time. The drug delivery system can be in different forms, such as... Agent:
20120058172 - Plant extracts for use in brain modulation: e
20120058173 - Selective starch feeding protocol: The present invention includes a method for improving milk production in a ruminant. An amount of ruminally digestible starch in relation to the dry matter of a feed is manipulated to include a first selected ratio of ruminally digestible starch in relation to the dry matter of the feed which... Agent: Purina Mills, LLC
20120058174 - Fabrication of interconnected model vasculature: Methods of fabricating a substantially interconnected model vasculature, as well as compositions formed from such methods are provided. In some embodiments, the methods may comprise forming a non-woven fiber network comprising a plurality of fibers and a void space; backfilling the void space of the fiber network; and removing the... Agent:
20120058175 - Transdermal preparation: Provided is a transdermal preparation, which is capable of long-term (1-day to 7-day) release of a basic drug from a preparation, continuously and at a consistent concentration; shows little reduction over time in the drug content, even if multiple drugs are contained in the preparation; and is produced by a... Agent:
20120058176 - Controlled release delivery system for nasal applications and method of treatment: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma... Agent:
20120058178 - Liposome composition: The present invention provides a novel liposome composition containing eribulin or its pharmacologically permissible salt, and its method of manufacture.... Agent: Eisai R&d Management Co., Ltd.
20120058177 - Nanoparticle-based tumor-targeted drug delivery: The present invention provides an aqueous tumor-targeting liposome nanoparticle composition comprising an aqueous dispersion of liposome nanoparticles. The nanoparticles preferably encapsulate an anti-cancer chemotherapeutic agent, which can be added to a pre-formed liposome composition or can be incorporated in the liposomes during the formation of the liposomes. The liposome nanoparticles... Agent: The Scripps Research Institute
20120058179 - Apparatus and process for encapsulating microparticles with liquid in soft gel capsules: The invention provides an apparatus for producing soft gel capsules having encapsulated therein microparticles, nanoparticles and fluids, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies; (d) a liquid fill system (medicine pump system); (e) a wedge for heating gelatine ribbons and... Agent:
20120058180 - Liver-specific nanocapsules and methods of using: This disclosure describes liver-specific nanocapsules for specifically targeting liver cells. This disclosure also provides methods of using such liver-specific nanocapsules to deliver one or more cargo moieties to the liver cells.... Agent:
20120058181 - Prebiotic suppositories: A composition for vaginal insertion is in the form of a softgel, a two-part gelatin capsule, a tablet, or a suppository. The composition is designed to promote the growth of native vaginal flora, but does not promote the growth of Gardenerella vaginalis and Candida albicans. The composition includes a prebiotic... Agent: Wisconsin Pharmacal Company, LLC
20120058182 - Method and composition for administering an nmda receptor antagonist to a subject: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.... Agent: Adamas Pharmaceuticals, Inc.
20120058183 - Retigabine tablets, preferably having modified release: The invention relates to tablets, especially tablets with modified release, containing (a) retigabine and a combination of (b) water-soluble excipient and (c) non-water-soluble excipient; and a process for producing them.... Agent: Ratiopharm Gmbh
20120058184 - Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males: The instant application provides methods and compositions for the treatment of male subjects having ulcerative colitis.... Agent: Salix Pharmaceuticals, Ltd.
20120058185 - Stable pharmaceutical compositions of olanzapine and process for their preparation: The present invention provides a stable pharmaceutical composition of Olanzapine or its pharmaceutically acceptable salt comprising coated tablet formulations of Olanzapine or its pharmaceutically acceptable salt, wherein the coating consists essentially of pectin or copovidone, and a process of making the same.... Agent:
20120058186 - Therapeutic or prophylactic agent for dyskinesia: The present invention relates to a stable orally disintegrating coated tablet containing a drug, wherein the tablet is coated with a coating layer containing a water-soluble substance and a polyvinyl alcohol resin of not less than 5% by weight based on the weight of the coating layer, the water-soluble substance... Agent: Toray Industries, Inc.
20120058187 - Water-in-oil type emulsion for treating a disease of the eye: A composition is described herein for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved... Agent: Novagali Pharma Sa
20120058188 - Lipid encapsulated interfering rna: The present invention provides compositions and methods for silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell.... Agent: Protiva Biotherapeutics, Inc.
20120058191 - Carbon-bearing nsp3 nanoparticle and its synthesis route: The invention relates to nanotechnology. The carbon-bearing nanoparticle consists of a cubical carbon monocrystal nucleus, the size of which is equal to or less than 4 nm, and a monocrystalline carbon shell having an SP3 structure and a thickness ranging from 0.19 to 0.2 nm. The method for producing carbon-bearing... Agent:
20120058190 - Food containing prolactin: A nutritional Composition for a subject, comprising prolactin identical or similar or analogous to prolactin found in a natural food source, and at least one protective layer, wherein release of said prolactin from the composition in said subject is the result of an environmental event.... Agent: Technion-research & Development Foundation Ltd
20120058189 - Process for making a crystalline zilpaterol salt: This invention generally relates to processes for making a crystalline zilpaterol salt, particularly zilpaterol hydrochloride. This invention also relates to methods of treatment using a crystalline zilpaterol salt prepared in accordance with this invention to increase the rate of weight gain, improve feed efficiency, and/or increase carcass leanness in livestock,... Agent:
20120058193 - Injectable smart gel and method for fabricating the same: An injectable smart gel and a method for fabricating the same are disclosed. A basic structural stabilizer/polymeric electrolyte and a diluting solution are added to a modified chitosan to regulate the chitosan solution to have a pH value closing to that of the human body and form a flowable chitosan... Agent:
20120058192 - Sunscreen compositions: Sunscreen compositions containing a discontinuous oil phase dispersed in a continuous water phase, at least 10% by weight of an organic UV-filter, a water-insoluble, C2-C8, liquid silicone, a branched fatty acid ester of a polyprotic carboxylic acid; and at least 2% by weight of a mineral particulate having a starch... Agent:
20120058194 - Pharmaceutical formulations comprising substituted benzimidazole derivatives: Stabilized substituted benzimidazole modified release pharmaceutical formulations with at least two drug-containing fractions, wherein the release from a first fraction precedes the release from a second fraction, pharmaceutical excipients, processes for preparing the stable formulations, packaging therefor, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive... Agent:
20120058195 - Microencapsulation of bioactive substances and methods of making the same: The present invention relates to microparticles and methods of making such microparticles that protect a bioactive substance from heat, humidity and oxidation. A microparticle comprising a bioactive substance, an agglomerating agent, an emulsifier and solid fats is disclosed. A method to produce a microparticle comprising an agglomerated bioactive substance enrobed... Agent:
20120058196 - Pharmaceutical compositions of dextran polymer derivatives and a carrier material: Pharmaceutical compositions are provided comprising (a) nanoparticles of an active agent and a dextran polymer derivative, and (b) a carrier material.... Agent: Bend Research Inc.
20120058197 - Compositions comprising water with deuterium for the prevention or treatment of allergic diseases and a process for the preparation thereof: The invention relates to pharmaceutical and food compositions for the prevention or treatment of allergic diseases and a process for the preparation thereof. The process of the invention comprises mixing water having 0.01-135 ppm deuterium content (preferably prepared by known electrolysis or distillation) with usual additives, and formulating this mixture... Agent:
20120058198 - Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis: The invention relates to methods for treating bacterial infection of the respiratory tract, including pneumonias, such as ventilator-associated pneumonia, and to methods for treating ventilator-associated tracheobronchitis, comprising administering an effective amount of a salt formulation as an aerosol to the respiratory tract of an individual in need thereof. The formulations... Agent: Pulmatrix, Inc.
20120058199 - Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin: The present invention provides the use of surface active proteins, especially class I and class II hydrophobins, in topically applied pharmaceutical formulations. The invention is particularly directed to topically applied pharmaceutical products for enhancing the penetration to achieve a transungual delivery of a prophylactically and/or therapeutically effective amount of an... Agent: Basf Se
20120058200 - Process for the preparation of lanthanum carbonate dihydrate: Present invention relates to a process for the preparation and pharmaceutical usage of dihydrate form of lanthanum carbonate. Present process produces lanthanum carbonate dihydrate (La2(CO3)3.2H2O) free of lanthanum hydroxycarbonate and is stable at ambient condition. Lanthanum carbonate dihydrate exhibit improved performance over standard lanthanum carbonate tetrahydrate in phosphate binding studies.... Agent: Natco Pharma Limited
20120058201 - Method of predicting a predisposition to qt prolongation: The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having... Agent: Vanda Pharmaceuticals, Inc.
20120058202 - Means and method for ovarian cancer prognosis: There is provided a method for determining whether a mammalian subject having an ovarian cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an... Agent:
20120058203 - Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2,3-d]pyrimidines: where R4 is selected from the group consisting of substituted or unsubstituted aryls or heteroaryls, arylalkyls, heteroarylalkyls, and hydrogen. The compound may inhibit mitosis in cells that have developed multidrug resistance due to P-glycoprotein and MRP1, and facilitate the reversal of P-glycoprotein mediated resistance.... Agent:
20120058204 - Use of over expression of cystathionine gamma lyase as a prognostic, diagnostic and therapeutic target for cancer: The present invention relates to a method of identifying an expression level of cystathionine gamma lyase (CTH) in a sample from a subject. The present invention further discloses a method of diagnosing a subject with cancer having risk of resistance to a platinum-based drug. The present invention also discloses a... Agent: Abnova Corporation
20120058205 - Compositions and treatment regimes for reducing inflammation, end-organ injury, and/or systemic endotoxemia: The invention relates to pharmaceutical compositions and treatment regimes useful in treating one or more of the following conditions: inflammation, kidney disease, eye disease, end-organ injury, systemic endotoxemia, and/or vitamin D resistance. The compositions and treatment regimes are also useful in reducing elevated CRP levels and/or elevated pro-inflammatory cytokines.... Agent:
20120058206 - Antiallergic marine biopolymers: The present invention relates to pharmaceutical compositions for administration to the respiratory tract, the gastrointestinal tract or the eyes. In particular, the invention relates to liquid formulations and dry powder compositions comprising carrageenan, and in particular iota and kappa carrageenan, and one or more therapeutic agents. These sprays, powders, and... Agent: Marinomed Biotechnologie Gmbh
20120058207 - Anti-diabetic nutraceutical composition from palm leaf extract: A comestible composition with anti-diabetic property which is effective in lowering the blood glucose and help reduce oxidative stress in diabetics and have anti-diabetic properties that protect against diabetic complications, retarding diabetes related organ degeneration and effective to hinder or prevent ailments or conditions resulting from, or exacerbated by, a... Agent: Universiti Putra Malaysia
20120058208 - Synergistic composition for enhancing bioavailability of curcumin: The present disclosure relates to a composition to enhance the bioavailability of curcumin. In one embodiment, a composition comprising plant extracts of curcumin, vanilla and ginger, wherein the extracts of ginger and vanilla are rich in gingerol and vanillin respectively, is provided. In other embodiments, curcumin, and one or more... Agent: Synthite Industries Ltd.
20120058209 - Magnolia extract containing compositions: Disclosed is a composition and method for its use that includes Magnolia bark extract, vitis vinifera extract, tocopherol or tocopherol acetate, and hydrogenated lecithin, lecithin, or dextrin.... Agent: Mary Kay Inc.
20120058210 - Extract of fraxinus excelsior seeds and therapeutic applications therefor: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior... Agent: Naturex, S.a.
20120058211 - Defined dose therapeutic phage: The invention provides therapeutic, defined-dose anti-bacterial phage preparations, methods to make such preparations, methods to treat bacterial infections using such preparations and methods to diagnose bacterial infections using such preparations.... Agent: Gangagen, Inc.03/01/2012 > 140 patent applications in 96 patent subcategories. listing by industry category
20120052004 - Carbon nanotube based magnetic resonance image contrast agents: A contrast agent composition comprising at least one carbon nanotube and a metal catalyst. A method for obtaining a magnetic resonance image, the method comprising: administering to a subject a contrast agent composition, wherein a contrast agent composition comprises at least one carbon nanotube and a metal catalyst; and obtaining... Agent:
20120052005 - Combination therapy to improve drug efficiency: Compositions and methods for increasing drug bioavailability and/or preventing multi-drug resistance through inhibition of ABCG2 by xanthine compounds are disclosed.... Agent: University Of Medicine And Dentistry Of New Jersey
20120052003 - Microorganisms for preventing and treating neoplasms accompanying cellular therapy: Provided are methods for using cellular compositions in combination with oncolytic viruses. The methods include administering oncolytic viruses for the inhibition and treatment of tumors caused by administration of cellular therapies, such as stem cell therapies. The methods also include contacting cellular compositions with oncolytic viruses for the removal of... Agent:
20120052006 - Gold/lanthanide nanoparticle conjugates and uses thereof: The present disclosure is directed generally to gold/lanthanide nanoparticle conjugates, such as gold/gadolinium nanoparticle conjugates, nanoparticle conjugates including polymers, nanoparticle conjugates conjugated to targeting agents and therapeutic agents, and their use in targeting, treating, and/or imaging disease states in a patient.... Agent: Colorado School Of Mines
20120052007 - Peripheral blood sparc binding antibodies and uses thereof: The invention provides SPARC binding antibodies that have high affinity to SPARC, particularly plasma SPARC, and methods of using such antibodies in treating conditions including cancer.... Agent: Abraxis Bioscience, LLC
20120052008 - Nanostructures comprising radioisotopes and/or metals: Nanostructures comprising radioisotopes and/or metals are provided. More particularly, in some embodiments, nanostructures comprising radioisotopes and/or metals, methods of their synthesis, and their use in cancer imaging and therapy are provided.... Agent:
20120052009 - Imaging probes, methods of making imaging probes, and methods of imaging: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to methods of detecting the over-expression of epidermal growth factor receptor (EGFR) in a subject or sample, methods of diagnosing the presence of one or more... Agent: The Board Of Trustees Of The Leland Stanford Junior University
20120052010 - Imaging tumor perfusion, oxidative metabolism using dynamic ace pet in patients with head and neck cancer during radiotherapy: The present invention provides methods of using optimal PET tracers for diagnosing head and neck cancer. Non-invasive methods for assessing tumor perfusion and oxidative metabolism for in vivo imaging with PET tracers that are suitable for uses in radiation therapy (RT) in head and neck cancer and evaluation of salivary... Agent: Ge Healthcare Limited
20120052011 - Composition and a method for producing contrast agent using the composition: A composition including a hydrophilic dye having a sulfonate group and a hydrophobic solvent, wherein the composition includes at least one of a nicotinic acid derivative and a tiamine derivative, can form densely accumulated particles and the like since the composition includes a hydrophilic dye that is likely to dissolve... Agent: Canon Kabushiki Kaisha
20120052012 - Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions: The present disclosure relates to a chitosan solution neutralized with amino-sugar carbonate buffering solution or amino-sugar phosphate buffering solution or phosphorylated aminosugar buffering solution. The resulting thermogelling chitosan composition is highly biocompatible, isotonic and has the ability to rapidly turn into gel upon heating to the body temperature. It provides... Agent: Oligo Medic Inc.
20120052013 - Methods of measuring activities of daily living: A method of assessing the health of a companion animal. The method can include providing a first group of companion animals, the first group comprising a first plurality of companion animals; subjecting each of the first plurality of companion animals to a performance assessment; evaluating a performance of each companion... Agent:
20120052015 - End-capped polymers: Polymers that can include an end-cap selected from Formula (I) and/or Formula (II) and a recurring unit of the Formulae (III), and/or (IV). The polymers can include various substituents such as drug, targeting agents, stabilizing agents, imaging agent and polydentate ligands. Such polymer can be useful for variety of drug,... Agent: Nitto Denko Corporation
20120052014 - Ferritin biosensor and methods of using the same: Disclosed herein are methods of diagnosing, monitoring and treating iron disorders using assays of serum ferritin. Some embodiments relate to detection and management of iron and iron-containing proteins in the body. For instance, the level of ferritin may be determined by contacting a sample with one or more magnetic nanoparticles;... Agent:
20120052016 - Reconstitutable microsphere compositions useful as ultrasonic contrast agents: Methods and suspensions are provided that are useful for preparing readily reconstitutable, dry compositions of micro- or nanospheres. The dry compositions find use in diagnostic applications such as ultrasonic imaging. The suspension includes as key ingredients one or both of t-butyl alcohol and/or an amorphous sugar (or mixture of amorphous... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education
20120052017 - Method for producing contrast agent for optical imaging: A contrast agent for optical imaging is produced by preparing a composition containing a hydrophilic dye having a sulfonate group, a hydrophobic solvent, a lipid having a positively charged site, and a polymerizable monomer or a prepolymer, dispersing the composition into water, and polymerizing the polymerizable monomer or the prepolymer.... Agent: Canon Kabushiki Kaisha
20120052018 - Smmr (small molecule metabolite reporters) for use as in vivo glucose biosensors: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.... Agent: Masimo Laboratories, Inc.
20120052019 - Certain chemical entities, compositions, and methods: Chemical entities which are triterpenoid derivatives, pharmaceutical compositions and methods of treatment of inflammatory, neurodegenerative, neoplastic and autoimmune diseases are described.... Agent:
20120052020 - Polymer combination from at least two different n-vinylpyrrolidone/n-vinylcaprolactam copolymers for cosmetic hair shine products: Products for treating keratin-containing fibers containing, in a cosmetically acceptable carrier, (i) 1.0% by weight to 2.8% by weight of at least one copolymer (a) having at least one structural unit of formula (I) and at least one structural unit of formula (II) and at least one structural unit of... Agent:
20120052022 - Composition for oral health treatment and related methods of use: The present invention provides compositions and related methods for oral health treatment of a subject. Compositions of the invention include an anti-oxidant enzyme, an anti-inflammatory agent, and a pharmaceutically acceptable buffer. In certain embodiments, the compositions are administered to the subjection in conjunction with teeth whitening, oral surgery, oral pathology... Agent:
20120052021 - Inhibition of undesired sensory effects by the compound camphor: A smokeless tobacco product or medicinal nicotine product includes nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 ppm to about 1300 ppm. Also disclosed are methods of making such products.... Agent: Philip Morris Usa Inc.
20120052023 - Controlled release active agent carrier: The present invention relates to carriers for the controlled release of active agents, comprising surface reacted natural or synthetic calcium carbonate, one or more active agents, wherein said one or more active agent is associated with said surface-reacted calcium carbonate, and wherein said surface-reacted natural or synthetic calcium carbonate is... Agent:
20120052024 - Novel composition: Electrospun polymer fibres comprising an amorphous calcium compound, oral care compositions comprising such fibres and their use in remineralising dental hard tissues and/or blocking dentinal tubules are described. Such compositions are of use in strengthening dental enamel of teeth thereby providing protection from acidic challenges. Such compositions are of use... Agent:
20120052025 - Borinic compositions: A stabilized topical composition comprising a borinic acid derivative, e.g., a borinic ester.... Agent: Colgate-palmolive Company
20120052026 - Oral compositions containing biphenol antibacterial compounds: Antiplaque oral compositions are provided that contain an orally acceptable carrier and an antibacterial effective amount of the compound of formula (I). In various embodiments, the compositions contain from about 0.001% to about 10% by weight of the compound of formula (I).... Agent: Colgate-palmolive Company
20120052027 - Benefit agent containing delivery particle: The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts... Agent: Appleton Papers Inc.
20120052028 - Cinnamic acid ascorbates: The invention relates to specific cinnamic acid ascorbates and to the use thereof as UV filters which bond to the skin, and to a process for the preparation thereof, and to preparations comprising these compounds.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung
20120052029 - Methods and substances for strengthening and conditioning human fingernails and toe nails: A method and a substance for strengthening fingernails and toe nails of a human being. The method comprises the steps of providing a substance comprising a natural oil composition, a bioactive glass composition and a solvent; applying the substance topically to an outer surface of the fingernail or toe nail;... Agent:
20120052030 - Cosmetic composition combining a silicone polyamide, a silicone resin and at least 51% dyestuff: The present invention relates to a cosmetic makeup or care composition comprising, in a physiologically acceptable medium, at least one fatty phase comprising: at least one silicone polyamide, at least one silicone resin, and at least 51% of dyestuff chosen from pigments, nacres and reflective particles, and mixtures thereof.... Agent: L'oreal
20120052031 - Malodor counteracting compositions and method for their use to counteract sweat malodor: The invention relates to a malodor counteractancy or counteracting (MOC) method that resorts to the use of specific malodor counteracting (MOC) mixtures of MOC ingredients. More particularly, the invention relates to new MOC compositions capable of neutralizing or masking in an efficient manner sweat malodor and which can be used... Agent:
20120052032 - Hair treatment composition: Disclosed is a pretreatment agent which can achieve a chemical treatment such as the formation of permanent waves or hair-dye uniformly only by pre-treating hair with the pretreatment agent, and which can impart smooth and soft touch to hair as if a hair treatment is applied to the hair after... Agent:
20120052036 - Filaments comprising an active agent nonwoven webs and methods for making same: Filaments that contain a filament-forming material and an additive, nonwoven webs, and methods for making such filaments are provided.... Agent:
20120052035 - Two phase depilatory composition: An improvement on the prior art dual phase chemical depilatory composition. The present invention is a dual phase present composition comprising: (1) a polymer; (2) depilatory active ingredients; (3) complexing agent; and (4) polyol.... Agent:
20120052037 - Web material and method for making same: A web material containing one or more active agents and methods for making same are provided.... Agent:
20120052038 - Organosilicones: The present application relates to organosilicones and compositions such as consumer products comprising such organosilicones, as well as processes for making and using such organosilicones and such compositions. Such compositions comprising such organosilicones are easier to formulate, and provide more economical and superior care benefits when compared to current silicone... Agent:
20120052039 - Organosilicones: The present application relates to organosilicones and compositions such as consumer products comprising such organosilicones, as well as processes for making and using such organosilicones and such compositions. Such compositions comprising such organosilicones are easier to formulate, and provide more economical and superior care benefits when compared to current silicone... Agent:
20120052033 - Hair cosmetic: Disclosed is a hair cosmetic which can achieve fixing of hair (hairstyle) by sticking and also has an excellent arranging ability (also including a restyling ability), and moreover imparts a good sense of use. Specifically disclosed is a hair cosmetic comprising a novel adhesive setting resin which is obtained by... Agent: Shiseido Company Ltd.
20120052034 - Hair treatment composition with naturally - derived peptide identical to human hair: A hair treatment composition containing at least one peptide identical to human hair, where preferably the peptide is synthesized from naturally-derived amino acids and can serve as a natural alternative to the commonly used human or animal derived (wool) keratin peptides.... Agent: Zotos International, Inc.
20120052041 - Polymeric nanoparticles with enhanced drug-loading and methods of use thereof: The invention is directed to modified polymers with increased drug-loading including compounds of formula (I): wherein Z is a poly(lactic-co-glycolic acid) (PLGA) polymer having molecular weight from 1-15 kDa and where the ratio of lactide to glycolide in the PLGA polymer is from 1:10 to 10:1; formula (II) R1 are... Agent: The Brigham And Women's Hospital, Inc.
20120052042 - Amphiphilic compounds and self-assembling compositions made therefrom: The present disclosure relates to amphiphilic compounds, self assembling compositions formed from the amphiphilic compounds and methods of making such compositions.... Agent:
20120052040 - Polymer compositions and methods for their use: Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.... Agent: Angiotech International Ag
20120052043 - Chemokine-chaperone fusion proteins: A fusion protein comprising at least one chemokine or a derivative or fragment thereof and at least one peptide derived from a chaperone. The fusion protein can be provided in a pharmaceutical preparation for the treatment of inflammatory conditions or cancer.... Agent:
20120052044 - Uses of mammalian cytokine; related reagents: Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.... Agent: Schering Corporation
20120052045 - Compositions and methods for modulating ischemic injury: The invention is directed to methods of modulating ischemic injury in tissues and organs. The invention is further directed to methods of increasing time to ischemic injury in tissues and organs. Such methods utilize compositions comprising cells capable of modulating inflammatory responses, referred to herein as Inflammatory Response Modulating Cells... Agent:
20120052046 - Phosphoramidate derivatives of guanosine nucleoside compunds for treatment of viral infections: Phosphoramidate compounds derived from guanine bases having enhanced therapeutic potency are provided, and these compounds in particular have enhanced potency with respect to treatment of viral infections, such as hepatitis C virus. Pharmaceutical compositions, methods of preparing the compounds, and methods of using the compounds and compositions to treat viral... Agent:
20120052047 - Use of probiotic strain gm-080 in treating cardiac inflammation and apoptosis: A use of probiotic strain GM-080 in treating cardiac inflammation and apoptosis is disclosed. The probiotic strain GM-080 such as Lactobacillus paracasei strain GM-080 (accession No. CCTCC M 204012) is utilized to produce a composition for treating cardiac inflammation and apoptosis in an effective dose.... Agent: Genmont Biotech Incorporation
20120052050 - Use of specific lactic bacteria for the preparation of immunomodulating compositions: The invention concerns the use of two lactobacteria for the preparation of immunomodulating compositions, in particular for the treatment and/or prevention of allergies and immunodeficiencies, and specifically use of the following two strains Lactobacillus salivarlus I 1794 and Lactobacillus paracasei I 1688, alone or in combination, in the treatments indicated... Agent: Proge Farm S.r.l.
20120052048 - Antibacterial phage, phage peptides and methods of use thereof: The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel... Agent: Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa
20120052049 - Systemic, allogenic stem cell therapies for treatment of diseases in animals: A method for treating preselected diseases comprising the steps of providing a therapeutic dose of a mesenchymal stem cell composition, the mesenchymal stem cell composition comprising mesenchymal stem cells harvested from at least one tissue selected from the group consisting of placental tissue, bone marrow, dental tissue, testicle tissue, and... Agent: Renovocyte, LLC
20120052051 - Method of treating diabetes - related vascular complications: The method of treating diabetes-related vascular complications includes the treatment of diabetic patients with α-lipoic acid (LA) in order to mitigate the negative impact of diabetes-related vascular dysfunctions upon vascular homeostasis. The treatment method includes the step of administering to the patient an initial dosage of α-lipoic acid believed to... Agent: Kuwait University
20120052052 - Control of biofilm formation: The invention relates to control of biofilm development. Specifically, some embodiments of the present invention relate to control of bacterial biofilm formation through addition or breakdown of signal(s) that induce biofilm formation. More specifically, some embodiments of the present invention relate to control (e.g., promotion, prevention) of biofilm development by... Agent: The Regents Of The University Of Michigan
20120052053 - Compositions and methods for the treatment of altered alpha-synuclein function: Compositions and methods are provided for treating a disorder characterized by α-synuclein dysfunction and/or altered lipid metabolism.... Agent:
20120052054 - Method for preventing skin elasticity loss by suppressing increase of subcutaneous fat: A cosmetic method for preventing an aggravation of skin condition accompanied with elasticity loss such as sag and a wrinkle is developed. The invention provides the method for preventing an elastic property loss specifically including the step of suppressing the increase in subcutaneous fat. In the step of the present... Agent: Shiseido Company, Ltd.
20120052055 - Method of treating thrombocytopenia: Invented is a method of treating thrombocytopenia in a human, in need thereof which comprises the in vivo administration of a therapeutically effective amount of a peptide or a non-peptide TPO receptor agonist and an anti-clotting agent or agents, and optional further active ingredients, to such human.... Agent: Glaxosmithkline LLC
20120052056 - Composition for improving blood circulation containing fermented tea, and pharmaceutical and health-food compositions comprising the same: The present invention relates a composition containing, as an active ingredient, a post-fermented tea extract obtained by inoculating green tea with yeast as a fermentation strain and fermenting the inoculated green tea for a predetermined time. The composition has an excellent preference while it reduces the serum and liver cholesterol... Agent:
20120052057 - method for selecting responders to blockade of integrin receptors: The present invention relates to a method for identifying responders to a blockade of integrin receptors, as well as to a method for determining responsiveness to a treatment involving with said blockade in a patient in need of such treatment. Furthermore, the present invention relates to a kit for use... Agent:
20120052058 - Methods of managing the blood coagulation and pharmaceutical compositions related thereto: The disclosure relates to methods of managing blood coagulation and pharmaceutical compositions related thereto. In certain embodiments, the disclosure relates to methods of managing the coagulation of blood in a patient undergoing surgery comprising administering combinations of a direct thrombin inhibitor and a coagulation factor inhibitor. In some embodiments, the... Agent: Emory University
20120052059 - Regulatory b cells and their use: Isolated regulatory B cells are disclosed, and compositions including these isolated regulatory B cells. The isolated regulatory B cells are mammalian and express T cell immunoglobulin mucin-1 (TIM-1). In some embodiments the regulatory B cells produce IL-10. Methods for treating a subject with an immune-mediated disorder are disclosed. These methods... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education
20120052064 - Anti-hgf antibody combinational cancer therapies: The present invention relates to the treatment of cancer (tumor) by administering to a patient in need of such treatment a first agent that inhibits Hepatocyte Growth Factor (HGF) in combination with a second agent that inhibits a signaling pathway other than the one stimulated by HGF.... Agent:
20120052063 - Automated detection of breast cancer lesions in tissue: The present disclosure relates to methods of analyzing breast tumor samples, for example as a means to determine whether the tumor is cancerous or benign. For example, it is shown herein that analysis of a Fourier transform infrared (FT-IR) spectroscopic image allows for automated detection of breast cancer or benign... Agent: The Board Of Trustees Of The University Of Illinois
20120052060 - Human antibody molecules for il-13: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.... Agent: Medimmune Limited
20120052062 - Methods for treatment of non-small cell lung cancer: The present invention provides methods of treating non-small cell lung cancer by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound in combination with a therapeutically effective amount of an epidermal growth factor tyrosine kinase inhibitor... Agent: Arqule, Inc.
20120052065 - Methods of treatment using ctla4 mutant molecules: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33... Agent: Bristol-myers Squibb Company
20120052061 - Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors: Described herein are compositions and methods for using these compositions in the treatment of cancer, tumors, and tumor-related disorders in a subject.... Agent: Tragara Pharmaceuticals Inc.
20120052067 - Activin-actrii antagonists and uses for increasing red blood cell levels: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.... Agent: Acceleron Pharma Inc.
20120052068 - Autophilic antibodies and method of making the same: Antibodies having noncovalent, autophilic properties are disclosed. The autophilic antibodies are derived from antibodies conjugated with an autophilic peptide. Such autophilic antibodies can promote apoptosis of target cells and enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Compositions containing the antibodies, and... Agent: Innexus Biotechnology International Limited
20120052069 - Fgf21 mutants and uses thereof: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.... Agent: Amgen Inc
20120052066 - Markers and methods for assessing and treating lupus patients susceptible to photoprovocation: A method for predicting or detecting susceptibility to lupus of an individual subjected to photoprovocation obtains biological samples from the individual before and after exposure to photoprovocation and compares the levels of at least a portion of members of a 45-member panel or subset thereof to determine whether the individual... Agent:
20120052070 - Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both: Methods of using binding molecules and fragments thereof that bind to the protein target Dickkopf-1 (DKK1), Dickkopf-4 (DKK4) or both (wherein specificity to DKK1 or DKK4 or both is herein denoted as “DKK1/4”) are provided.... Agent: Novartis Ag
20120052072 - High affinity human antibodies to human il-4 receptor: The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.... Agent: Regeneron Pharmaceuticals, Inc.
20120052071 - Tumor markers and methods of use thereof: The invention provides newly identified proteins as markers for the detection of tumors, or as targets for their treatment, particularly of tumors affecting lung, colon, breast, ovary; affinity ligands capable of selectively interacting with the newly identified markers; methods of screening a tissue sample for malignancy, for determining the presence... Agent: Externautics S.p.a.,
20120052073 - Antibodies directed to angiopoietin-2 and uses thereof: Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the... Agent: Medlmmune Limited
20120052074 - Human monoclonal antibodies to activin receptor-like kinase-1: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like, kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and... Agent: Amgen Fremont Inc.
20120052075 - Modulation of the vps10p-domain receptor family for the treatment of mental and behavioural disorders: The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of mental and behavioural disorders. The modulation is carried... Agent:
20120052076 - Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors: The present invention teaches anti-Trop-2 monoclonal antibodies with high affinity and able to recognize different regions of the Trop-2 molecule, and uses thereof in the treatment and diagnosis of tumors, such as for example endometrium, breast, head and neck, colon-rectum, stomach, lung, ovary, prostate, pancreas, kidney, cervix and bladder (urothelial)... Agent:
20120052077 - Therapeutic modulation of vaginal epithelium boundary lubrication: The present invention relates to the management of vaginal health. In particular, the present invention relates to pharmaceutical compositions, and methods of use thereof, for treating diseases associated with compromised boundary lubrication at the vaginal epithelium.... Agent:
20120052078 - Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38: The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods of using the same for the treatment of diseases associated with CD38 expression, including hematological malignancies such as multiple myeloma.... Agent: Morphosys Ag
20120052079 - Compositions, kits, and methods for predicting anti-cancer response to anthracyclines: The present invention is based, in part, on the discovery that amplification of human chromosome 8q22-23 regions and over-expression of 8q22-23 genes (e.g., LAPTM4B and YWHAZ) is associated with and predictive of resistance to anthracycline-type chemotherapy. Accordingly, the invention relates to compositions, kits, and methods for predicting the response of... Agent: Dana-farber Cancer Institute, Inc.
20120052081 - Compositions for use in the treatment of chronic obstructive pulmonary diseases and asthma: The present invention provides compounds and methods for treating or preventing pulmonary diseases include COPD and asthma. In particular, the present invention provides for compounds comprising type V collagen, or tolerizing fragments thereof, for the treatment of COPD and asthma.... Agent: Indiana University Research And Technology Corporation
20120052080 - Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines: Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education
20120052082 - Cross-protective influenza vaccine: A cross-protective influenza virus vaccine has been designed based on the incorporation of the genetically engineered, highly conserved M2 influenza viral protein optionally in combination with an adjuvant such as a bacterial flagellin protein incorporated into the membrane of a virosome or virus-like particles. Immunogenicity and the breadth of cross... Agent: Zetra Biologicals, LLC
20120052083 - Mutant cyaa polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell: The invention is more particularly directed to polypeptides derived from an adenylate cyclase protein (CyaA) either under the form of a toxin or of a toxoid, which are mutant polypeptides. Said mutant polypeptides are capable of retaining the binding activity of native CyaA to a target cell and preferably of... Agent: Institut Pasteur
20120052084 - Staphylococcus aureus proteins and nucleic acids: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.... Agent: Novartis Vaccines & Diagnostics Srl
20120052085 - Vaccines against tularemia: The disclosure relates generally to an antigenic composition useful for immunization against tularemia. The disclosure is a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach to producing vaccines against tularemia.... Agent: The Regents Of The University Of California
20120052086 - Vaccine composition for prophylaxis and/or therapy of alzheimer's disease: A vaccine composition for prophylaxis and/or therapy of Alzheimer's disease, which comprises a fusion protein prepared by inserting a single or tandemly repeated multiple copies of amyloid β antigenic peptide having 5 to 15 continuous amino acid residues derived from the N-terminus of amyloid β peptide into a wild type... Agent: Hokko Chemical Industry Co., Ltd.
20120052088 - Pneumococcal vaccine and uses thereof: The present invention relates to new pneumococcal vaccines. The invention also relates to vaccination of subjects, in particular immunocompromised subjects, against pneumococcal infections using said novel pneumococcal vaccines.... Agent: Coley Pharmaceutical Group, Inc.
20120052087 - Siderophore conjugate immunogenic compositions and vaccines: An immunogenic composition comprising a siderophore covalently linked to a pharmaceutically acceptable carrier molecule wherein the antigenicity of the siderophore moiety is sufficient to stimulate an immuno-logic response to the siderophore when the composition is circulating in the bloodstream of a human or non-human animal and vaccine.... Agent: University Of Florida Research Foundation, Inc.
20120052089 - Newcastle disease virus vectored herpesvirus vaccines: The present invention encompasses recombinant Newcastle Disease Virus-Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals against disease.... Agent:
20120052090 - Peptidic antigen that induces antibody recognizing three-dimensional structure of hiv and method for synthesizing same: An object of the present invention is to provide an HIV antibody-inducing peptide antigen that can be used without problems for HIV, which is highly prone to mutation, and is effective in developing an antibody or a vaccine having excellent specificity and binding activity even for the three-dimensional structure of... Agent: National University Corporation Tokyo Medical And Dental University
20120052091 - Potomac horse fever isolates: The present invention discloses novel isolates of Neorickettsia risticii, compositions comprising such isolates, vaccines and methods for using such vaccines against Potomac Horse Fever.... Agent:
20120052092 - Vaccine compositions comprising a mutated factor h binding protein: The present invention relates to an immunogenic composition comprising at least one modified factor H binding protein, wherein the composition is capable of eliciting an immune response, when administered to a human or non-human animal; and associated compositions, uses and kits.... Agent: Imperial Innovations Limited
20120052093 - Compositions and methods for preventing and treating uterine disease: The present invention relates to methods and compositions for preventing and treating uterine disease, and in particular to vaccines and bacteriophage compositions for treating or preventing puerperal metritis, clinical endometritis and/or subclinical endometritis.... Agent: Cornell University
20120052094 - Agonists of neurotrophin receptors and their use as medicaments: e
20120052098 - Liquid ganaxolone formulations and methods for the making and use thereof: In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.... Agent: Marinus Pharmaceuticals
20120052099 - Pharmaceutical composition containing arbidol in the form of phospholipid nanoparticles: The invention relates to the fields of medicine and pharmacology and concerns a storage-stable composition made up of nanoparticles which are based on vegetable phospholipids and contain the antiviral drug Arbidol. The aim of the present invention is to develop a non-fatty phospholipid composition of Arbidol in which the micellar... Agent:
20120052097 - Therapeutic peptide-polymer conjugates, particles, compositions, and related methods: Described herein are conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, which can be used, for example, in the treatment of a disorder such as cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder),... Agent: Cerulean Pharma Inc.
20120052095 - Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof: Nanoemulsified topical formulation comprising curcumin, tetrahydroxycurcumin (BDMC) and curcuminoid either alone or in combinations in an amount of 0.001% to 50% together with one or more pharmaceutically, nutraceutically or dietically acceptable excipient(s) or inactive ingredients, useful for the treatment of inflammation, various skin and oral disorders, mucosal disorders and other... Agent: Laila Pharmaceuticals Pvt. Ltd.
20120052103 - Cosmetic composition containing white ginseng powder: The present invention relates to a cosmetic composition containing white ginseng powder. Applying a cosmetics containing white ginseng powder to the skin of a user stimulates blood circulation and exhibits superior skin scrubbing effect.... Agent:
20120052100 - Cosmetic for eyelashes: To provide a cosmetic for eyelashes, which is excellent in the effect of imparting a feeling of voluminousness to eyelashes and exerts high base transparency without damage to the color inherent in the cosmetic base. Means of attaining the object A cosmetic for eyelashes which comprises (a) a silicone resin... Agent: Shiseido Company, Ltd.
20120052102 - Method for producing cosmetics: A method is provided for producing a cosmetic or pharmaceutical product, wherein a plurality of components are processed to form the product and at least one component in a liquid state is atomized, shock-cooled and converted into a granulate. The granulate is processed with further components to form the product.... Agent: Linde Aktiengesellschaft
20120052101 - Thin film strips: A method of forming a thin film strip and thin film strips formed thereby where the method comprises coating a liner substrate with a wet slurry of film forming ingredients and other components and drying the wet slurry in a drying apparatus to form a film, measuring the moisture content... Agent:
20120052104 - Polypeptides and antibacterial or antiseptic use of same: A novel polypeptide, and an antibacterial agent, antifungal agent and/or antiseptic containing as an effective ingredient the polypeptide are disclosed. The polypeptide of this invention has an amino acid sequence shown in SEQ ID NOs:1 to 12 and 13 to 31. This antibacterial agent, antifungal agent and/or antiseptic is useful... Agent: Anges Mg, Inc.
20120052105 - Nanostructural composition of biocide and process of obtaining nanostructural biocide nanocomposition: This invention concerns biocides possessing fungicidal and bactericidal properties which can be used in construction, medicine and other various areas of technics. A nanostructural composition of biocide is realized from nanoparticles of bentonite powders intercalated by ions of Zn2+ and ions of Ag+ and/or ions of Cu2+. The biocides according... Agent:
20120052106 - Antimicrobial wipes and solution: A surface of an object may be treated using an antimicrobial wipe presoaked in an antimicrobial treatment solution. Alternatively, the antimicrobial treatment solution may be sprayed directly on the surface. The antimicrobial treatment solution may be made of isopropyl alcohol and an unreacted organofunctional silane antimicrobial substance that is substantially... Agent:
20120052107 - Hydrophobic polysaccharides with pendent groups having terminal reactive functionalities and medical uses thereof: Hydrophobic α(1→4)glucopyranose polymers useful for the preparation of implantable or injectable medical articles are described. The hydrophobic α(1→4)glucopyranose polymer includes pendent groups having hydrocarbon groups and terminal amine or hydroxyl groups. Biodegradable matrices can be formed from these polymers, and the matrices can be used for the preparation of implantable... Agent:
20120052108 - Macrocyclic lactone drug delivery system: Disclosed is a drug delivery system from which a macrocyclic lactone can be released with a desirable zero order release profile. The system is based on the use of thermoplastic polymers, and particularly of polyethylene vinyl acetate copolymers (EVA). The drug delivery system of the invention comprises a solid non-porous... Agent:
20120052109 - Control of parasites: The invention concerns a composition for the treatment of varroa mite infestations in honeybee colonies, comprising a base layer and an active layer, wherein the active layer comprises an effective amount of an acaricidal compound.... Agent: Vita (europe) Limited
20120052110 - Methods and compositions for promoting wound healing: Provided herein are compositions and methods that inhibit expression of Adam12 gene products, such as ADAM12 mRNA and/or ADAM12 polypeptides, as a therapeutic approach for the treatment of, or promotion of healing of, wounds.... Agent: Hospital For Special Surgery
20120052111 - Adhesive laminates for rapid wound occlusion: Provided herein are protective laminate devices comprising a biocompatible non-adherent substance and a fast-setting adhesive and methods of use. Also provided is a dispenser for an adhesive tape. The protective laminate devices and methods may be used for wound closure.... Agent:
20120052112 - Risperidone-containing transdermal preparation and adhesive patch using same: A transdermal preparation is provided that contains risperidone and/or a pharmaceutically acceptable salt thereof as a drug, and the amount of the drug is 1 to 20 parts by mass based on 100 parts by mass of the total mass of the preparation. The skin permeation rate of the preparation... Agent: Hisamitsu Pharmaceutical Co., Inc.
20120052113 - Transdermal preparation: The present invention relates to a transdermal preparation having a backing and an adhesive layer laminated on the backing, wherein the adhesive layer contains 4E indolone and a physiologically active compound.... Agent: Hisamitsu Pharmaceutical Co., Inc.
20120052114 - Apparatus and methods for making nanosomes loaded with nucleic acid: Embodiments of the present invention are directed to an apparatus and methods for making nucleic acid loaded nanosomes. One embodiment of the present invention directed to an apparatus comprises a first containment means for containing a mixture of an aqueous solution of nucleic acid and a phospholipid solution with a... Agent:
20120052116 - Immunogenic epitopes of ngep antigen: The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid encoding the peptide, a vector comprising the... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services
20120052115 - Nanocarrier therapy for treating invasive tumors: Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis. The liposomes include cholesterol and chemically pure phospholipids that are essentially neutral and... Agent: Georgia Tech Research Corporation
20120052118 - Apparatus and process for encapsulating capsules or other solid dosage forms within capsules: The present invention provides an apparatus and process for making softgel capsules having incorporated therein other solid dosage forms selected from the group consisting of pellets, smaller capsules, smaller tablets, sustained release solid dosage forms, immediate release solid dosage forms, extended release solid dosage forms and zero order release solid... Agent:
20120052119 - Nanoencapsulated delta-9-tetrahydrocannabinol: Embodiments of the present invention are directed to articles of manufacture and methods of making such articles having utility for the delivery of cannabinoids as a therapeutic. One embodiment of the present invention directed to the article of manufacture comprises a lyophilized particle or sphere having a diameter of about... Agent:
20120052120 - Nanotechnology formulation of poorly soluble compounds: Embodiments of the present invention are directed to articles of manufacture, spheres having a diameter of 50 to 500 nanometers which contain poorly soluble drugs and methods of making such spheres. Embodiments of the present invention have particular application for the following drug candidates and closely related poorly soluble derivatives... Agent:
20120052117 - Soft capsule of butylphthalide and a process for preparing the same: The present invention discloses a novel soft capsule of butylphthalide and a process for preparing the same. The soft capsule of butylphthalide is composed of a capsule wall material and a drug-containing oil, wherein the drug-containing oil is essentially composed of butylphthalide and a vegetable oil as the diluent in... Agent:
20120052121 - New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative: Pharmaceutical composition containing a combination of a non steroidal anti inflammatory drug and a colchicoside derivative, the active ingredients being present in the free state or in the form of a salt.... Agent: Sanofi
20120052122 - Treatment of chronic obstructive pulmonary disease with phosphodiesterase-4 inhibitor: Disclosed is a method of treatment of chronic obstructive pulmonary disease associated with chronic bronchitis in a patient at risk of exacerbations. The method includes administering to a patient with a history of chronic obstructive pulmonary disease associated with chronic bronchitis and at risk of exacerbations, a maintenance dose of... Agent: Nycomed Gmbh
20120052123 - Silyl ether-modified hydrophilic polymers and uses for medical articles: Silane-functionalized hydrophilic polymers and polymeric matrices are described. Hydrophilic matrices can be formed from the polymers, and can be used in association with the preparation of implantable and injectable medical devices. Exemplary devices include those having a durable lubricious coating formed from the hydrophilic polymers.... Agent:
20120052124 - Silk fibroin systems for antibiotic delivery: The present invention provides for silk fibroin-based compositions comprising one or more antibiotic agents for prevention or treatment of microbial contamination, methods of making antibiotic-containing silk scaffold, methods of stabilizing antibiotics in silk scaffolds, and methods for preventing or treating microbial contamination using the antibiotic-containing compositions. Various methods may be... Agent: Trustees Of Tufts College
20120052125 - Cholesteryl sulfate-containing composition as a haemostatic: The present invention relates to a composition comprising a wound dressing device and cholesteryl sulfate and especially to a composition containing cholesteryl sulfate and at least one carrier material for use as a haemostatic agent, as well as to a method for its preparation and use.... Agent: Dr. Suwelack Skin & Health Care Ag
20120052126 - Nanoemulsions containing antioxidants and other health-promoting compounds: Nanoemulsions contain particles that comprise an outer shell layer containing at least one oil and a core portion containing at least one antioxidant and, optionally, other health-promoting compounds, wherein the nanoemulsions are relatively stable for prolonged periods without significant change in physical properties and are suitable for administering to humans... Agent:
20120052127 - Expanded polystyrene particles having skin layer with superior moldability, method for preparing the same and expanded polystyrene molded article using the same: Disclosed are an expanded polystyrene particle having a skin layer with superior moldability, a method for preparing the same, and an expanded polystyrene molded article using the same. Provided is an expanded polystyrene particle provided on the surface thereof with a skin layer with superior moldability wherein the skin layer... Agent: Polma Co., Ltd.
20120052128 - Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions: The present invention provides oral dosage compositions, and methods of making thereof, which contain an edible oil, preferably containing an omega-3 fatty acid, and admixed therein one or more water soluble vitamins and/or minerals, for example vitamins B6, B9, and/or B12. The present invention also provides a method of making... Agent: Pbm Pharmaceuticals, Inc.
20120052130 - Gpr 119 modulators: Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPFM 19 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.... Agent: Pfizer Inc.
20120052129 - Motor function improver: The present invention relates to a motor function improving method, including administering or taking a fat globule membrane component.... Agent: Kao Corporation
20120052131 - Compositions and methods for treatment and prevention of osteoarthritis: The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and rheumatology. The invention provides pharmaceutical compositions for the treatment and/or prevention of osteoarthritis in mammals, particularly humans, comprising sodium bicarbonate and calcium gluconate, and optionally comprising one or more additional components. The invention also provides methods of treating... Agent:
20120052132 - Compositions and methods for treatment of body weight conditions: A nutritional supplement composition having therapeutically effective amounts of milk minerals including calcium, a protein source including kappa-casein fragment 106-169, and enzyme-inhibiting peptides is provided for the treatment of body weight conditions. The nutritional supplement composition is administered in amounts effective for limiting weight gain and/or enhancing weight loss, as... Agent: University Of Tennessee Research Foundation
20120052134 - Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents: The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds... Agent: Ecolab Usa Inc.
20120052133 - Synergy of strong acids and peroxy compounds: Disclosed is a method for improving decontamination in meat, poultry, fish, fruit and vegetable processing using a combination of acid(s) and peroxy compound(s). The method comprises a “stacked” approach, sequentially adding the acid(s) and peroxy compound(s) to an aqueous stream to provide a point-of-use low-pH antimicrobial composition that is highly... Agent:
20120052135 - Phosphate adsorbent: Subject of the present invention are compositions comprising a mixture of calcium, magnesium and iron salts for use as a pharmaceutical preparation for adsorbing phosphate, especially for use as pharmaceutical preparations for the treatment of hyperphosphataemia, chronic kidney deficiency as well as for the treatment of haemodialysis patients.... Agent: Vifor (international) Ag
20120052136 - Novel heamoglobin and uses thereof: The present invention relates to isolated haemoglobin from worms belonging to the Nereididae family and its use in cell culture medium, in preservation solutions and as artificial oxygen carrier for transfusion.... Agent: Hemarina
20120052138 - Composition comprising green tea extract: The present invention relates to a composition containing a green tea extract as an active ingredient. The composition is effective in treating or preventing obesity and the like and can be beneficially employed in various ways in fields such as foodstuffs and medicine.... Agent:
20120052137 - Weight loss formulation: A weight loss product comprises a mixture of Alchemilla vulgaris, Olea europaea, Cuminum cyminum, and Mentha longiflora (in the weight proportion 12:10:5:4), to which additional ingredients have been added to increase weight loss efficacy. The additional ingredients may include, but are not limited to, Gamma-oryzanol, Caffeine, Cirsimarin, Fucoxanthin, Guggulsterones, Evodiamine,... Agent: Northern Innovations And Formulations Corp.
20120052139 - Fragrance composition having good sleep-inducing effect: Disclosed herein is a fragrance composition which contains natural oils, including rose oil and sandalwood oil, and has a good sleep-inducing effect. More specifically, disclosed is a fragrance composition which contains rose oil, sandalwood oil, neroli oil and ylang-ylang oil and creates a comfortable sleeping environment using the good sleep-inducing... Agent:
20120052141 - Novel use of compounds for treating and alleviating cellulite: The present invention is directed inter alia to the use of at least one compound selected from the group consisting of (−)-epigallocatechin gallate, resveratrol, eicosapentaenoic acid, docosahexaenoic acid, rose hip extract/concentrate, hydroxytyrosol, lycopene, lutein, β-cryptoxanthin, zeaxanthin and derivatives thereof, for the treatment of cellulite, for the prevention of the development... Agent: DsmIPAssets B.v.
20120052142 - Biologically active compositions from schisandra chinensis for treating colorectal cancer: A biologically active composition to treat colorectal cancer includes an extract of the plant Schisandra chinensis and a suitable pharmaceutical formulation. The extract can be at least one of gomisin A, angeloylgomisin H, deoxyschisandrin and gomisin N, showing activities against human tumor cell line HT-29 in the range of about... Agent: Dr. Chang Naturals, LLCPrevious industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus
RSS FEED for 20130516:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.
FreshPatents.com Support - Terms & Conditions
Results in 3.8631 seconds